Polymorphic forms of (e)-l-((10S)-4-((4-([l,2,4]triazolo[l,5-a]pyridin- 7-yloxy)-2-fluoro-5-methylphenyl)amino)-7,8,10,ll-tetrahydro- 9h-6,10-methanopyrimido[4',5':5,6]pyrido[3,2-b][l,4,7]oxadiazonin-9- YL)-4-(dimethylamino)but-2-en-l-one

WO2024229019A1PCT designated stage expired Publication Date: 2024-11-07ENLIVEN INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/027040
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-01
Filing Date
2024-04-30
Publication Date
2024-11-07

Smart Images

  • Figure US2024027040_07112024_PF_FP_ABST
    Figure US2024027040_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates generally to crystalline forms and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said crystalline forms and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.
Need to check novelty before this filing date? Find Prior Art

Description

POLYMORPHIC FORMS OF (E)-1-((10S)-4-((4-([1,2,4]TRIAZOLO[1,5-A]PYRIDIN- 7-YLOXY)-2-FLUORO-5-METHYLPHENYL)AMINO)-7,8,10,11-TETRAHYDRO- 9H-6,10-METHANOPYRIMIDO[4',5':5,6]PYRIDO[3,2-B][1,4,7]OXADIAZONIN-9- YL)-4-(DIMETHYLAMINO)BUT-2-EN-1-ONE CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No.63 / 463,294, filed on May 1, 2023, the entire content of which is incorporated herein by reference for all purposes. FIELD OF THE INVENTION

[0002] The present disclosure relates generally to crystalline forms and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said crystalline forms and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head and neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer. BACKGROUND

[0003] ErbB2 (or HER2) is a member of the ErbB receptor tyrosine kinase family consisting of four related receptors, including ErbB1 (also known as epidermal growth factor receptor, or EGFR), ErbB3 and ErbB4. Although there are no known ligands that bind to monomeric ErbB2, it can dimerize with other ErbB receptors, particularly ErbB3, and regulate downstream signaling cascades including, but not limited to, the MAPK and PI3K pathways, that promote cell proliferation and survival. Aberrant overexpression of ErbB2 or certain genetic alterations (including point mutations that lead to certain amino acid substitutions or small in-frame insertions in Exon 20 that lead to the deletion and / or insertion of certain small stretches of amino acids) are known to confer elevated or constitutive tyrosine kinase activation to the receptor. Accordingly, the overexpression or mutation of ErbB2 is highly associated with aggressive forms of solid cancers, including breast, ovarian, stomach, and lung cancer (NSCLC).

[0004] Currently, there are few approved treatments for cancers associated with ErbB2 overexpression, including tyrosine kinase inhibitors (TKIs) such as tucatinib. Although these TKIs can be effective at ameliorating cancers associated with ErbB2 overexpression, theirtherapeutic utility is often limited by inadequate selectivity for ErbB2 over EGFR, and consequently are dose-limited by toxicity concerns related to EGFR inhibition (especially gastrointestinal and skin-related toxicities). These toxicities necessitate restrictive dosing regimens, leading to suboptimal target engagement and thus limited therapeutic benefit. Moreover, while current TKIs provide therapeutic benefit for cancers driven by ErbB2 overexpression, they may have limited efficacy in patients harboring specific genetic alterations, such as EGFR or ERBB2 exon 20 insertions, specific point mutations or genetic alterations associated with ErbB family ligands, such as NRG1 gene fusions.

[0005] For example, in a small proportion of lung cancer patients, certain especially pernicious mutations in EGFR and ErbB2 known as EGFR exon 20 insertions / ErbB2 insertions are markedly less sensitive to first and second generation reversible TKIs. An added challenge to the development of viable therapies for these specific ErbB Exon 20 mutants (20ins or E20I) is the fact these alterations are heterogeneous, encompassing a diversity of amino acid insertions / deletions. In addition to E20I mutations, a number of other genetic alterations of the receptor, specifically point mutations leading to single amino acid substitutions, have been associated with the development of a variety of cancers, including lung cancer. Although the resistance mechanisms associated with each of these mutations are not fully understood, it is believed that the mutations may share a commonality in promoting ligand-independent activation of the kinases. Further investigation of the underlying mechanisms and development of TKIs tailored to these mutants are needed.

[0006] Other aggressive, refractory cancers exhibiting ErbB2 overexpression have been observed to harbor NRG1 gene re-arrangements resulting in novel fusion proteins. NRG1 gene fusions may induce overproduction of neuregulin-1, the cognate ligand for ErbB3. The simultaneous overexpression of ErbB2 and overproduction of neuregulin-1 may lead to excess activation of ErbB2-ErbB3 heterodimers and resultant hyperplasia.

[0007] Accordingly, there remains a need for new therapeutics for the treatment of cancers driven by dysregulated ErbB2 receptor kinase activity, not only with improved safety and selectivity for ErbB2 over EGFR, but also for addressing mutation-associated sub- variants of ErbB2 (e.g., E20I mutations and NRG1 gene fusions) with enhanced potency.SUMMARY OF THE INVENTION

[0008] In one aspect, provided herein is a crystalline form of a salt of (E)-l-((10S)-4-((4- ([l,2,4]triazolo[l,5-a]pyridin-7-yloxy)-2-fluoro-5-methylphenyl)amino)-7,8,10,l 1- tetrahydro-9H-6, 10-methanopyrimido[4', 5' : 5,6]pyrido[3 ,2-b] [ 1 ,4,7]oxadiazonin-9-yl)-4- (dimethylamino)but-2-en-l-one, as detailed herein.

[0009] In some aspects, the crystalline form is a crystalline form of a HBr, HC1, sulfate, esylate, tosylate, mesylate, napsylate, besylate, maleate, aspartate, phosphate, glutamate, malonate, fumarate, tartarate, citrate, glucuronate, glycolate, malate, lactate, benzoate, succinate, or acetate salt. In some aspects, the crystalline form is a crystalline form of a HBr, HC1, sulfate, tosylate, mesylate, napsylate, besylate, aspartate, maleate, esylate, malonate, glucuronate, glycolate, lactate, benzoate, succinate, or acetate salt.

[0010] In another aspect, provided herein is a method of preparing a crystalline form of a salt of (E)-l-((10S)-4-((4-([l,2,4]triazolo[l,5-a]pyridin-7-yloxy)-2-fluoro-5- methylphenyl)amino)-7,8,10,l l-tetrahydro-9H-6,10-methanopyrimido[4',5':5,6]pyrido[3,2- b][l,4,7]oxadiazonin-9-yl)-4-(dimethylamino)but-2-en-l-one, as detailed herein.

[0011] In another aspect, provided herein is a pharmaceutical composition comprising a crystalline form of a salt of (E)-l-((10S)-4-((4-([l,2,4]triazolo[l,5-a]pyridin-7-yloxy)-2- fluoro-5-methylphenyl)amino)-7, 8, 10,11 -tetrahydro-9H-6, 10- methanopyrimido[4',5':5,6]pyrido[3,2-b][l,4,7]oxadiazonin-9-yl)-4-(dimethylamino)but-2- en-l-one, as detailed herein.

[0012] In another aspect, provided herein is a kit comprising a crystalline form of a salt of (E)-l-((10S)-4-((4-([l,2,4]triazolo[l,5-a]pyridin-7-yloxy)-2-fluoro-5-methylphenyl)amino)- 7,8,10,11 -tetrahydro-9H-6, 10-methanopyrimido[4', 5' : 5,6]pyrido[3 ,2-b] [ 1 ,4,7]oxadiazonin-9- yl)-4-(dimethylamino)but-2-en-l-one, as detailed herein.

[0013] In one aspect, provided herein is a method of inhibiting kinase activity of a human receptor tyrosine kinase ErbB2 or a mutant form of human ErbB2 comprising contacting the ErbB2 or the mutant form with a therapeutically effective amount of a cyrtalline form described herein, or a therapeutically effective amount of a pharmaceutical composition described herein. In some embodiments of the present aspect, the mutant form of human ErbB2 comprises a mutation in Exon 20. In further embodiments of the present aspect, themutant form of human ErbB2 comprises one or more mutations that introduce amino acid deletions and / or insertions selected from the group consisting of: A775_A776insYVMA, G778_P780insGSP, G776delinsVC, P780_Y781insGSP, M774delinsWLV, A775_G776insSVMA, A775_G776insI, G776delinsLC, G778_S779InsCPG, and V777_G778insGSP. In other embodiments of the present aspect, the mutant form of human ErbB2 comprises a disease-associated point mutation in ErbB2. In still further embodiments of the present aspect, the mutant form of human ErbB2 comprises one or more point mutations in ErbB2 that introduce amino acid substitutions selected from the group consisting of P122L, R217C, I263T, A293T, S305C, S310F / Y, H470Q, I655V, V659E, G660D, R678Q / C, L755R / S / P, I767M, D769H / N / Y, V777L / M, V842I, R868W, H878Y, E930K / D, E1021Q, F1030C, VI 1281, N1219S, and A1232fs. In other embodiments, the mutant form of human ErbB2 comprises one or more point mutations in ErbB2 that introduce (a) an amino acid substitution selected from the group consisting of are P122L, R217C, I263T, A293T, S305C, S310F / Y, H470Q, I655V, V659E, G660D, R678Q / C, L755R / S / P, I767M, D769H / N / Y, V777L / M, V842I, R868W, H878Y, E930K / D, E1021Q, F1030C, VI 1281, and N1219S; or a frameshift at A1232.

[0014] In yet another aspect, provided herein is a method of treating a patient having a cancer, comprising administering to the patient a therapeutically effective amount of a crystalline form described herein, or a therapeutically effective amount of a pharmaceutical composition described herein. In some embodiments of the present aspect, the cancer comprises cells or tissue having increased ErbB2 kinase activity. In some embodiments of the present aspect, the cancer comprises cells or tissue having increased ErbB2 kinase activity as compared to a control. In certain embodiments, the cancer comprises cells or tissue having increased ErbB2 kinase activity as compared to ErbB2 kinase activity in control cell or in control tissue. In further embodiments of the present aspect, the cancer comprises cells or tissue having one or more mutations in Exon 20 of the ErbB2. In certain embodiments, the cancer comprises cells or tissue having one or more mutations in Exon 20 of the ErbB2 that introduce amino acid deletions and / or insertions selected from the group consisting of A775_A776insYVMA, G778_P780insGSP, G776delinsVC, P780_Y781insGSP, M774delinsWLV, A775_G776insSVMA, A775_G776insI, G776delinsLC, G778_S779InsCPG, and V777_G778insGSP. In other embodiments, the cancer comprises cells or tissue having one or more disease-associated point mutations in ErbB2. In certain other embodiments, the cancer comprises cells or tissue having one or more point mutationsthat introduce amino acid substitutions selected from the group consisting of are P122L, R217C, I263T, A293T, S305C, S310F / Y, H470Q, I655V, V659E, G660D, R678Q / C, L755R / S / P, I767M, D769H / N / Y, V777L / M, V842I, R868W, H878Y, E930K / D, E1021Q, F1030C, VI 1281, N1219S, and A1232fs. In certain embodiments, the cancer comprises cells or tissue having one or more point mutations that introduce (a) an amino acid substitution selected from the group consisting of are P122L, R217C, I263T, A293T, S305C, S310F / Y, H470Q, I655V, V659E, G660D, R678Q / C, L755R / S / P, I767M, D769H / N / Y, V777L / M, V842I, R868W, H878Y, E930K / D, E1021Q, F1030C, VI 1281, and N1219S; or a frameshift at A1232.

[0015] In some embodiments of the present aspect, which may be combined with any of the preceding embodiments, the cancer is lung, glioma, skin, head and neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer. In certain embodiments, the cancer is non-small cell lung cancer. In still other embodiments, which may be combined with any of the preceding embodiments, the patient has received at least one, at least two, or at least three prior therapies for the cancer. In certain embodiments, one or more of the prior therapies selected from the group consisting of lapatinib, neratinib, afatinib, pyrotinib, poziotinib, TAK-788, and tucatinib. In some embodiments, the method further comprises administering one or more additional anti-cancer agents.BRIEF DESCRIPTION OF THE DRAWINGS

[0016] FIG. 1A depicts an experimental X-ray powder diffraction (XRPD) pattern of a crystalline form of an HBr salt of (E)-l-((10S)-4-((4-([l,2,4]triazolo[l,5-a]pyridin-7-yloxy)- 2-fluoro-5-methylphenyl)amino)-7, 8, 10,11 -tetrahydro-9H-6, 10- methanopyrimido[4',5':5,6]pyrido[3,2-b][l,4,7]oxadiazonin-9-yl)-4-(dimethylamino)but-2- en-l-one (Compound A), HBr Form I.

[0017] FIG. IB depicts a simultaneous thermogravimetric analysis (TGA) / differential scanning calorimetry (DSC) thermogram for HBr Form I.

[0018] FIG. 2 depicts an experimental XRPD pattern of a crystalline form of an HBr salt of Compound A, HBr Form II.

[0019] FIG. 3A depicts an experimental XRPD pattern of a crystalline form of an HBr salt of Compound A, HBr Form III.

[0020] FIG. 3B depicts a simultaneous TGA / DSC thermogram for HBr Form III.

[0021] FIG. 3C depicts a differential scanning calorimetry (DSC) thermogram for HBr Form III on first heat.

[0022] FIG. 3D depicts (a) a dynamic vapor sorption (DVS) isotherm pattern and (b) a DVS kinetic pattern for HBr Form III.

[0023] FIG. 4A depicts an experimental XRPD pattern of a crystalline form of an HC1 salt of Compound A, HC1 Form I.

[0024] FIG. 4B depicts simultaneous TGA / DSC thermograms for HC1 Form I.

[0025] FIG. 4C depicts a DSC thermogram for HC1 Form I on first heat.

[0026] FIG. 4D depicts (a) a DVS isotherm pattern and (b) a DVS kinetic pattern for HC1Form I.

[0027] FIG. 5 depicts an experimental XRPD pattern of a crystalline form of a HC1 salt of Compound A, HC1 Form II.

[0028] FIG. 6A depicts an experimental XRPD pattern of a crystalline form of a sulfate salt of Compound A, Sulfate Form I.

[0029] FIG. 6B depicts a simultaneous TGA / DSC thermogram for Sulfate Form I.

[0030] FIG. 7A depicts an experimental XRPD pattern of a crystalline form of a Sulfate salt of Compound A, Sulfate Form II.

[0031] FIG. 7B depicts a simultaneous TGA / DSC thermogram for Sulfate Form II.

[0032] FIG. 8 depicts an experimental XRPD pattern of a crystalline form of a sulfate salt of Compound A, Sulfate Form III.

[0033] FIG. 9A depicts an experimental XRPD pattern of a crystalline form of a tosylate salt of Compound A, Tosylate Form I.

[0034] FIG. 9B depicts simultaneous TGA / DSC thermogram for Tosylate Form I.

[0035] FIG. 9C depicts a DSC thermogram for Tosylate Form I on first heat.

[0036] FIG. 9D depicts (a) a DVS isotherm pattern and (b) a DVS kinetic pattern forTosylate Form I.

[0037] FIG. 9E depicts an experimental Polarized Loght Microscopy (PLM) micrograph (a) under plane polarized and (b) cross polarized light of Tosylate Form I.

[0038] FIG. 10 depicts an experimental XRPD pattern of a crystalline form of a mesylate salt of Compound A, Mesylate Form I.

[0039] FIG. 11A depicts an experimental XRPD pattern of a crystalline form of a mesylate salt of Compound A, Mesylate Form II.

[0040] FIG. 11B depicts a simultaneous TGA / DSC thermogram for Mesylate Form II.

[0041] FIG. 12A depicts an experimental XRPD pattern of a crystalline form of a napsylate salt of Compound A, Napsylate Form I.

[0042] FIG. 12B depicts a simultaneous TGA / DSC thermogram for Napsylate Form I.

[0043] FIG. 13 depicts an experimental XRPD pattern of a crystalline form of a napsylate salt of Compound A, Napsylate Form II.

[0044] FIG. 14 depicts an experimental XRPD pattern of a crystalline form of a napsylate salt of Compound A, Napsylate Form III.

[0045] FIG. 15A depicts an experimental XRPD pattern of a crystalline form of a besylate salt of Compound A, Besylate Form I.

[0046] FIG. 15B depicts a simultaneous TGA / DSC thermogram for Besylate Form I (prepared on a 20 mg scale).

[0047] FIG. 15C depicts a simultaneous TGA / DSC thermogram for Besylate Form I (prepared on a 500 mg scale).

[0048] FIG. 15D depicts a DSC thermogram for Besylate Form I on first heat.

[0049] FIG. 15E depicts (a) a DVS isotherm pattern and (b) a DVS kinetic pattern for Besylate Form I.

[0050] FIG. 15F depicts an experimental PLM micrograph (a) under plane polarized and (b) cross polarized light of Besylate Form I.

[0051] FIG. 15G depicts an exemplary molecular structure of Besylate Form I.

[0052] FIG. 15H depicts a simulated XRPD pattern of Besylate Form I.

[0053] FIG. 16A depicts an experimental XRPD pattern of a crystalline form of a besylate salt of Compound A, Besylate Form II.

[0054] FIG. 16B depicts a simultaneous TGA / DSC thermogram for Besylate Form II.

[0055] FIG. 17 depicts an experimental XRPD pattern of a crystalline form of an aspartate salt of Compound A, Aspartate Form I.

[0056] FIG. 18A depicts an experimental XRPD of a crystalline form of an aspartate salt of Compound A, Aspartate Form II.

[0057] FIG. 18B depicts a simultaneous TGA / DSC thermogram for Aspartate Form II.

[0058] FIG. 19A depicts an experimental XRPD pattern of a crystalline form of a maleate salt of Compound A, Maleate Form I.

[0059] FIG. 19B depicts a simultaneous TGA / DSC thermogram for Maleate Form I.

[0060] FIG. 19C depicts a DSC thermogram for Maleate Form I on (a) first heat and (b) first cool.

[0061] FIG. 19D depicts (a) a DVS isotherm pattern and (b) a DVS kinetic pattern for Maleate Form I.

[0062] FIG. 20A depicts an experimental XRPD pattern of a crystalline form of a maleate salt of Compound A, Maleate Form II.

[0063] FIG. 20B depicts a simultaneous TGA / DSC thermogram for Maleate Form II.

[0064] FIG. 21A depicts an experimental XRPD pattern of a crystalline form of an esylate salt of Compound A, Esylate Form I.

[0065] FIG. 21B depicts a simultaneous TGA / DSC thermogram for Esylate Form I.

[0066] FIG. 22A depicts an experimental XRPD pattern of a crystalline form of an esylate salt of Compound A, Esylate Form II.

[0067] FIG. 22B depicts a simultaneous TGA / DSC thermogram for Esylate Form II.

[0068] FIG. 23A depicts an experimental XRPD pattern of a crystalline form of a mal onate salt of Compound A, Mai onate Form I.

[0069] FIG. 23B depicts a simultaneous TGA / DSC thermogram for Malonate Form I.

[0070] FIG. 24A depicts an experimental XRPD pattern of a crystalline form of a malonate salt of Compound A, Malonate Form II.

[0071] FIG. 24B depicts a simultaneous TGA / DSC thermogram for Malonate Form II.

[0072] FIG. 25 depicts an experimental XRPD pattern of a crystalline form of a glucuronate salt of Compound A, Glucuronate Form I.

[0073] FIG. 26A depicts an experimental XRPD pattern of a crystalline form of a glucuronate salt of Compound A, Glucuronate Form II.

[0074] FIG. 26B depicts a simultaneous TGA / DSC thermogram for Glucuronate Form II.

[0075] FIG. 27 depicts an experimental XRPD of a crystalline form of a glucuronate salt of Compound A, Glucuronate Form III.

[0076] FIG. 28A depicts an experimental XRPD pattern of a crystalline form of a glycolate salt of Compound A, Glycolate Form I.

[0077] FIG. 28B depicts a simultaneous TGA / DSC thermogram for Glycolate Form I.

[0078] FIG. 29A depicts an experimental XRPD pattern of a crystalline form of a lactate salt of Compound A, Lactate Form I.

[0079] FIG. 29B depicts a simultaneous TGA / DSC thermogram for Lactate Form I.

[0080] FIG. 30A depicts an experimental XRPD pattern of a crystalline form of a lactate salt of Compound A, Lactate Form II.

[0081] FIG. 30B depicts a simultaneous TGA / DSC thermogram for Lactate Form II.

[0082] FIG. 31A depicts an experimental XRPD pattern of a crystalline form of a benzoate salt of Compound A, Benzoate Form I.

[0083] FIG. 31B depicts a simultaneous TGA / DSC thermogram for Benzoate Form I.

[0084] FIG. 31C depicts a DSC thermogram for Benzoate Form I on first heat.

[0085] FIG. 31D depicts (a) a DVS isotherm pattern and (b) a DVS kinetic pattern forBenzoate Form I.

[0086] FIG. 32 depicts an experimental XRPD pattern of a crystalline form of a succinate salt of Compound A, Succinate Form I.

[0087] FIG. 33A depicts an experimental XRPD pattern of a crystalline form of an acetate salt of Compound A, Acetate Form I.

[0088] FIG. 33B depicts a simultaneous TGA / DSC thermogram for Acetate Form I.DETAILED DESCRIPTION

[0089] The following description sets forth exemplary methods, parameters and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments.I. DEFINITIONS

[0090] As used herein, the following definitions shall apply unless otherwise indicated. Further, if any term or symbol used herein is not defined as set forth below, it shall have its ordinary meaning in the art.

[0091] As used herein, reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X”. As used herein, and unless otherwise specified, the terms “about” and “approximately,” when used in connection withdoses, amounts, or weight percent of ingredients of a composition or a dosage form, mean a dose, amount, or weight percent that is recognized by those of ordinary skill in the art to provide a pharmacological effect equivalent to that obtained from the specified dose, amount, or weight percent. Specifically, the terms “about” and “approximately,” when used in this context, contemplate a dose, amount, or weight percent within 20%, within 15%, within 10%, within 5%, within 4%, within 3%, within 2%, within 1%, or within 0.5% of the specified dose, amount, or weight percent.

[0092] As used herein, the term “crystalline form” refers to a crystalline solid form of a chemical compound, including, but not limited to, a single-component or multiple-component crystal form, e.g., a polymorph of a compound. The term “crystal forms” and related terms herein refer to the various crystalline modifications of a given substance, including, but not limited to, polymorphs and solvates thereof. Crystal forms of a substance can be obtained by a number of methods, as known in the art. Such methods include, but are not limited to, melt recrystallization, melt cooling, solvent recrystallization, slurrying, recrystallization in confined spaces such as, e.g., in nanopores or capillaries, recrystallization on surfaces or templates such as, e.g., on polymers, recrystallization in the presence of additives, such as, e.g., anti-solvents, co-crystal counter-molecules, desolvation, dehydration, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, sublimation, grinding and solvent-drop grinding.

[0093] As used herein, “solvate” encompasses solvates, partial solvates, and channel solvates. As such, a solvate need not contain an exact stoichiometric ratio of compound: solvent, but may include ratios of compound: solvent permitted by experimental variance. The term “solvate” is further intended to include aqueous and non-aqueous solvated forms (e.g., hydrates, ethanolates, etc.). Thus, it is understood that a solvate encompasses stoichiometric solvates, channel solvates and partial solvates. It is also understood that a hydrate encompasses stoichiometric hydrates, channel hydrates and partial hydrates. An exemplary solvate of a phosphate salt is a channel hydrate.

[0094] As used herein, the term “substantially as shown in” when referring, for example, to an XRPD pattern, a DSC graph, a TGA graph, or a GVS graph, includes a pattern or graph that is not necessarily identical to those depicted herein, but that falls within the limits of experimental error or deviations when considered by one of ordinary skill in the art.

[0095] The term “excipient” as used herein means an inert or inactive substance that may be used in the production of a drug or pharmaceutical, such as a tablet containing a compound of the present disclosure as an active ingredient. Various substances may be embraced by the term excipient, including without limitation any substance used as a binder, disintegrant, coating, compression / encapsulation aid, cream or lotion, lubricant, solutions for parenteral administration, materials for chewable tablets, sweetener or flavoring, suspending / gelling agent, or wet granulation agent. Binders include, e.g., carbomers, povidone, xanthan gum, etc.; coatings include, e.g., cellulose acetate phthalate, ethylcellulose, gellan gum, maltodextrin, enteric coatings, etc.; compression / encapsulation aids include, e.g., calcium carbonate, dextrose, fructose de (de = “directly compressible”), honey de, lactose (anhydrate or monohydrate; optionally in combination with aspartame, cellulose, or microcrystalline cellulose), starch de, sucrose, etc.; disintegrants include, e.g., croscarmellose sodium, gellan gum, sodium starch glycolate, etc.; creams or lotions include, e.g., maltodextrin, carrageenans, etc.; lubricants include, e.g., magnesium stearate, stearic acid, sodium stearyl fumarate, etc.; materials for chewable tablets include, e.g., dextrose, fructose de, lactose (monohydrate, optionally in combination with aspartame or cellulose), etc.; suspending / gelling agents include, e.g., carrageenan, sodium starch glycolate, xanthan gum, etc.; sweeteners include, e.g., aspartame, dextrose, fructose de, sorbitol, sucrose de, etc.; and wet granulation agents include, e.g., calcium carbonate, maltodextrin, microcrystalline cellulose, etc.

[0096] The terms “individual”, “subject” and “patient” refer to mammals and includes humans and non-human mammals. Examples of patients include, but are not limited to, mice, rats, hamsters, guinea pigs, pigs, rabbits, cats, dogs, goats, sheep, cows, and humans. In some embodiments, patient refers to a human.

[0097] As used herein, the term “mammal” includes, but is not limited to, humans, mice, rats, guinea pigs, monkeys, dogs, cats, horses, cows, pigs, and sheep.

[0098] “Pharmaceutically acceptable” refers to safe and non-toxic, and suitable for in vivo or for human administration.

[0099] As used herein, the term “solvate” refers to an association or complex of one or more solvent molecules and a compound of the present disclosure. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO,ethyl acetate, acetic acid, and ethanolamine. The term “hydrate” refers to the complex where the solvent molecule is water. Certain compounds of the present disclosure can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present disclosure.

[0100] The term “co-crystal” as used herein refers to a solid that is a crystalline single phase material composed of two or more different molecular or ionic compounds generally in a stoichiometric ratio which are neither solvates nor simple salts. A co-crystal consists of two or more components that form a unique crystalline structure having unique properties. Co- crystals are typically characterized by a crystalline structure, which is generally held together by freely reversible, non-covalent interactions. As used herein, a co-crystal refers to a compound of the present disclosure and at least one other component in a defined stoichiometric ratio that form a crystalline structure.

[0101] As used herein, the term “pharmaceutically acceptable salts” is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present disclosure contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of salts derived from pharmaceutically-acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like. Salts derived from pharmaceutically-acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, N,N'- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like. When compounds of the present disclosure contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acidaddition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S. M., et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

[0102] The neutral forms of the compounds can be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present disclosure.

[0103] Certain compounds of the present disclosure possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers, regioisomers and individual isomers (e.g., separate enantiomers) are all intended to be encompassed within the scope of the present disclosure.

[0104] The compounds of the present disclosure can also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the present disclosure also embraces isotopically-labeled variants of the present disclosure which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having the atomic mass or mass number different from the predominant atomic mass or mass number usually found in nature for the atom. All isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the present disclosure and include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine and iodine, such as2H (“D”),3H,nC,13C,14C,13N,15N,15O,17O,18O,32P,33P,35S,18F,36C1,123I and125I. Certain isotopically labeled compounds of the present disclosure (e.g., those labeled with3H or14C) are useful in compound and / or substrate tissue distribution assays. Tritiated (3H) and carbon-14 (14C) isotopes are useful for their ease ofpreparation and detectability. Further substitution with heavier isotopes such as deuterium (z.e.,2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Positron emitting isotopes such as15O,13N,nC, and18F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds of the present disclosure can generally be prepared by following procedures analogous to those disclosed in the Schemes and / or in the Examples herein below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

[0105] “Treating” or “treatment” of a disease in a patient refers to inhibiting the disease or arresting its development; or ameliorating or causing regression of the disease. As used herein, “treatment” or “treating” is an approach for obtaining beneficial or desired results including clinical results. For purposes of this disclosure, beneficial or desired results include, but are not limited to, one or more of the following: decreasing one more symptoms resulting from the disease or disorder, diminishing the extent of the disease or disorder, stabilizing the disease or disorder (e.g., preventing or delaying the worsening of the disease or disorder), delaying the occurrence or recurrence of the disease or disorder, delay or slowing the progression of the disease or disorder, ameliorating the disease or disorder state, providing a remission (whether partial or total) of the disease or disorder, decreasing the dose of one or more other medications required to treat the disease or disorder, enhancing the effect of another medication used to treat the disease or disorder, delaying the progression of the disease or disorder, increasing the quality of life, and / or prolonging survival of a patient. Also encompassed by “treatment” is a reduction of pathological consequence of the disease or disorder. The methods of the present disclosure contemplate any one or more of these aspects of treatment.

[0106] “Preventing”, “prevention”, or “prophylaxis” of a disease in a patient refers to preventing the disease from occurring in a patient that is predisposed or does not yet display symptoms of the disease.

[0107] The phrase “therapeutically effective amount” means an amount of a compound of the present disclosure that (i) treats or prevents the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease,condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein.

[0108] The terms “cancer” and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.

[0109] It is appreciated that certain features of the present disclosure, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. All combinations of the embodiments pertaining to the chemical groups represented by the variables are specifically embraced by the present invention and are disclosed herein just as if each and every combination was individually and explicitly disclosed, to the extent that such combinations embrace compounds that are stable compounds (i.e., compounds that can be isolated, characterized, and tested for biological activity). In addition, all subcombinations of the chemical groups listed in the embodiments describing such variables are also specifically embraced by the present invention and are disclosed herein just as if each and every such sub-combination of chemical groups was individually and explicitly disclosed herein. II. COMPOUNDS

[0110] In one aspect, provided herein is a crystalline form of a salt of (E)-1-((10S)-4-((4- ([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-fluoro-5-methylphenyl)amino)-7,8,10,11- tetrahydro-9H-6,10-methanopyrimido[4',5':5,6]pyrido[3,2-b][1,4,7]oxadiazonin-9-yl)-4- (dimethylamino)but-2-en-1-one (Compound A), having the structure shown below.(Compound A)

[0111] As used herein, a reference to the “parent compound” means the salt-free form of “(E)-1-((10S)-4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-fluoro-5-methylphenyl)amino)-7,8,10,11 -tetrahydro-9H-6, 10-methanopyrimido[4', 5' : 5,6]pyrido[3 ,2-b] [ 1 ,4,7]oxadiazonin-9- yl)-4-(dimethylamino)but-2-en-l-one” or “Compound A” alone, or its structural formula alone, unless otherwise noted or made clear in the context in which the reference is used.

[0112] The crystalline forms disclosed herein may provide the advantages of bioavailability and stability and may be suitable for use as an active agent in a pharmaceutical composition. Variations in the crystal structure of a pharmaceutical drug substance may affect the dissolution rate (which may affect bioavailability, etc.), manufacturability (e.g., ease of handling, ease of purification, ability to consistently prepare doses of known strength, etc.) and stability (e.g., thermal stability, shelf life (including resistance to degradation), etc.) of a pharmaceutical drug product. Such variations may affect the methods of preparation or formulation of pharmaceutical compositions in different dosage or delivery forms, such as solid oral dosage forms including tablets and capsules. Compared to other forms such as non- crystalline or amorphous forms, crystalline forms may provide desired or suitable hygroscopicity, particle size control, dissolution rate, solubility, purity, physical and chemical stability, manufacturability, yield, reproducibility, and / or process control. Thus, the crystalline forms disclosed herein may provid advantages of improving the manufacturing process of an active agent or the stability or storability of a drug product form of the active agent or having suitable bioavailability and / or stability as an active agent.

[0113] In one aspect, provided herein is a crystalline form of a salt of Compound A. In some embodiments, the crystalline form is a crystalline form of a HBr, HC1, sulfate, esylate, tosylate, mesylate, napsylate, besylate, maleate, aspartate, phosphate, glutamate, malonate, fumarate, tartarate, citrate, glucuronate, glycolate, malate, lactate, benzoate, succinate, or acetate salt. In some embodiments, the crystalline form is a crystalline form of a HBr, HC1, sulfate, tosylate, mesylate, napsylate, besylate, aspartate, maleate, esylate, malonate, glucuronate, glycolate, lactate, benzoate, succinate, or acetate salt.HBr Forms

[0114] In some embodiments, the crystalline form is a crystalline form of a HBr salt of Compound A. In some embodiments, the crystalline form of the HBr salt of Compound A is HBr Form I, HBr Form II, or HBr Form III.HBr Form I

[0115] In some embodiments, the crystalline form of the HBr salt of Compound A is HBr Form I. In some embodiments, HBr Form I has an XRPD pattern substantially as shown in FIG. 1A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 1.Table 1.

[0116] In some embodiments, HBr Form I has an XRPD pattern comprising peaks provided in Table 1. In some embodiments, HBr Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 1A, or as provided in Table 1.

[0117] In some embodiments, HBr Form I has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 1, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, HBr Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.59 (e.g., 4.59±0.2), about 13.32 (e.g., 13.32±0.2), about 13.99 (e.g., 13.99±0.2), about 14.42 (e.g., 14.42±0.2), about 15.58 (e.g., 15.58±0.2), about 16.33 (e.g., 16.33±0.2), about 16.77 (e.g., 16.77±0.2), about 17.81 (e.g., 17.81±0.2), about 18.47 (e.g., 18.47±0.2), about 19.44 (e.g., 19.44±0.2), about 19.99 (e.g., 19.99±0.2), about 21.55 (e.g., 21.55±0.2), about 23.19 (e.g., 23.19±0.2), about 24.20 (e.g., 24.20±0.2), about 24.77 (e.g., 24.77±0.2), about 25.60 (e.g., 25.60±0.2), about 26.17 (e.g., 26.17±0.2), about 27.83 (e.g., 27.83±0.2), about 29.18 (e.g., 29.18±0.2), and about 31.51 (e.g., 31.51±0.2). In some embodiments, HBr Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.59 (e.g., 4.59±0.2), about 13.32 (e.g., 13.32±0.2), about 13.99 (e.g., 13.99±0.2), about 14.42 (e.g., 14.42±0.2), about 15.58 (e.g., 15.58±0.2), about 16.33 (e.g., 16.33±0.2), about 16.77 (e.g.,16.77±0.2), about 17.81 (e.g., 17.81±0.2), about 18.47 (e.g., 18.47±0.2), about 19.44 (e.g.,19.44±0.2), about 19.99 (e.g., 19.99±0.2), about 21.55 (e.g., 21.55±0.2), about 23.19 (e.g.,23.19±0.2), about 24.20 (e.g., 24.20±0.2), about 24.77 (e.g., 24.77±0.2), about 25.60 (e.g.,25.60±0.2), about 26.17 (e.g., 26.17±0.2), about 27.83 (e.g., 27.83±0.2), about 29.18 (e.g.,29.18±0.2), and about 31.51 (e.g., 31.51±0.2). In some embodiments, HBr Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.59 (e.g., 4.59±0.2), about 13.32 (e.g., 13.32±0.2), about 15.58 (e.g., 15.58±0.2), about 16.33 (e.g., 16.33±0.2), about 16.77 (e.g., 16.77±0.2), about 18.47 (e.g., 18.47±0.2), about 19.44 (e.g., 19.44±0.2), about 19.99 (e.g., 19.99±0.2), about 21.55 (e.g., 21.55±0.2), about 25.60 (e.g., 25.60±0.2), about 26.17 (e.g., 26.17±0.2), about 27.83 (e.g., 27.83±0.2). In some embodiments, HBr Form I has an XRPD pattern comprising one or more (e.g., at least one, atleast two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.59 (e.g., 4.59±0.2), about 13.32 (e.g., 13.32±0.2), about 15.58 (e.g., 15.58±0.2), about 16.33 (e.g., 16.33±0.2), about 16.77 (e.g., 16.77±0.2), about 18.47 (e.g., 18.47±0.2), about 19.44 (e.g., 19.44±0.2), about 19.99 (e.g., 19.99±0.2), about 21.55 (e.g., 21.55±0.2), about 25.60 (e.g., 25.60±0.2), about 26.17 (e.g., 26.17±0.2), and about 27.83 (e.g., 27.83±0.2). In some embodiments, HBr Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.59 (e.g., 4.50±0.2), about 13.32 (e.g., 13.32±0.2), about 16.33 (e.g., 16.33±0.2), about 19.44 (e.g., 19.44±0.2), about 21.55 (e.g., 21.55±0.2), and about 26.17 (e.g., 26.17±0.2). In some embodiments, HBr Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, or at least six) peaks each assigned at angles 2-theta in degrees of about 4.59 (e.g., 4.59±0.2), about 13.32 (e.g., 13.32±0.2), about 16.33 (e.g., 16.33±0.2), about 19.44 (e.g., 19.44±0.2), about 21.55 (e.g., 21.55±0.2), and about 26.17 (e.g., 26.17±0.2). In some embodiments, HBr Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.59, about 18.47, and about 26.17. In some embodiments, HBr Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.59±0.2, 18.47±0.2, and about 26.17±0.2. In some embodiments, HBr Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.59, and about 18.47. In some embodiments, HBr Form I has an XRPD pattern comprising peaks each assigned at angles 2- theta in degrees of about: 4.59±0.2, and 18.47±0.2. In some embodiments, HBr Form I has an XRPD pattern comprising a peak assigned at an angle 2-theta in degrees of about 18.47. In some embodiments, HBr Form I has an XRPD pattern comprising a peak assigned at angle 2- theta in degrees of about 18.47±0.2.

[0118] In some embodiments, HBr Form I is characterized as having a simultaneous TGA / DSC thermogram substantially as shown in FIG. IB.

[0119] In some embodiments, HBr Form I is characterized as having a TGA thermogram substantially as shown in FIG. IB. In some embodiments, HBr Form I is characterized as having a mass loss of about 3.6 % after heating from about 24.8 °C to about 238.7 °C, as determined by TGA.

[0120] In some embodiments, HBr Form I is characterized as having a DSC thermogram substantially as shown in FIG. IB. In some embodiments, the crystalline form ischaracterized as having no thermal events at a temperature selected from the range of about 50.0 °C to about 400.0 °C.

[0121] In some embodiments of HBr Form I, at least one, at least two, at least three, at least four, at least five, or all of the following (a)-(f) apply: a. HBr Form I has an XRPD pattern substantially as shown in FIG. 1A, b. HBr Form I has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 1, c. HBr Form I has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 4.59±0.2, 18.47±0.2, and about 26.17±0.2, ii. peaks at an angle 2-theta in degrees of about 4.59 (e.g., 4.58±0.2), about 13.32 (e.g., 13.32±0.2), about 16.33 (e.g., 16.33±0.2), about 19.44 (e.g., 19.44±0.2), about 21.55 (e.g., 21.55±0.2), and about 26.17 (e.g., 26.17±0.2), iii. peaks at an angle 2-theta in degrees of about 4.59 (e.g., 4.58±0.2), about 13.32 (e.g., 13.32±0.2), about 15.58 (e.g., 15.58±0.2), about 16.33 (e.g., 16.33±0.2), about 16.77 (e.g., 16.77±0.2), about 18.47 (e.g., 18.47±0.2), about 19.44 (e.g., 19.44±0.2), about 19.99 (e.g., 19.99±0.2), about 21.55 (e.g., 21.55±0.2), about 25.60 (e.g., 25.60±0.2), about 26.17 (e.g., 26.17±0.2), about 27.83 (e.g., 27.83±0.2), or iv. peaks at an angle 2-theta in degrees of about 4.59 (e.g., 4.58±0.2), about 13.32 (e.g., 13.32±0.2), about 13.99 (e.g., 13.99±0.2), about 14.42 (e.g., 14.42±0.2), about 15.58 (e.g., 15.58±0.2), about 16.33 (e.g., 16.33±0.2), about 16.77 (e.g., 16.77±0.2), about 17.81 (e.g., 17.81±0.2), about 18.47 (e.g., 18.47±0.2), about 19.44 (e.g., 19.44±0.2), about 19.99 (e.g., 19.99±0.2), about 21.55 (e.g., 21.55±0.2), about 23.19 (e.g., 23.19±0.2), about 24.20 (e.g., 24.20±0.2), about 24.77 (e.g., 24.77±0.2), about 25.60 (e.g., 25.60±0.2), about 26.17 (e.g., 26.17±0.2), about 27.83 (e.g., 27.83±0.2), about 29.18 (e.g., 29.18±0.2); d. HBr Form I has a TGA thermogram substantially as shown in FIG. IB; e. HBr Form I has a mass loss of about 3.6 % after heating from about 24.8 °C to about 238.7 °C; and f. HBr Form I has a DSC thermogram substantially as shown in FIG. IB.HBr Form II

[0122] In some embodiments, the crystalline form of the HBr salt of Compound A is HBr Form II. In some embodiments, HBr Form II has an XRPD pattern substantially as shown in FIG. 2. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 2.Table 2.

[0123] In some embodiments, HBr Form II has an XRPD pattern comprising peaks provided in Table 2. In some embodiments, HBr Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 2, or as provided in Table 2.

[0124] In some embodiments, HBr Form II has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 2, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, HBr Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.36 (e.g., 4.36±0.2), about 8.73 (e.g., 8.73±0.2), about 12.83 (e.g., 12.83±0.2), about 13.42 (e.g., 13.42±0.2), about 13.68 (e.g., 13.68±0.2), about15.33 (e.g., 15.33±0.2), about 15.65 (e.g., 15.65±0.2), about 16.48 (e.g., 16.48±0.2), about17.48 (e.g., 17.48±0.2), about 18.07 (e.g., 18.07±0.2), about 18.66 (e.g., 18.66±0.2), about19.27 (e.g., 19.27±0.2), about 19.83 (e.g., 19.83±0.2), about 21.31 (e.g., 21.31±0.2), about22.20 (e.g., 22.20±0.2), about 23.49 (e.g., 23.49±0.2), about 23.93 (e.g., 23.93±0.2), about24.49 (e.g., 24.49±0.2), about 25.23 (e.g., 25.23±0.2), about 25.97 (e.g., 25.97±0.2), about26.24 (e.g., 26.24±0.2), about 27.41 (e.g., 27.41±0.2), about 28.52 (e.g., 28.52±0.2), about29.47 (e.g., 29.47±0.2), about 30.89 (e.g., 30.89±0.2), about 31.75 (e.g., 31.75±0.2), and about 33.33 (e.g., 33.33±0.2). In some embodiments, HBr Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.36 (e.g., 4.36±0.2), about 8.73 (e.g., 8.73±0.2), about12.83 (e.g., 12.83±0.2), about 13.42 (e.g., 13.42±0.2), about 13.68 (e.g., 13.68±0.2), about15.33 (e.g., 15.33±0.2), about 15.65 (e.g., 15.65±0.2), about 16.48 (e.g., 16.48±0.2), about17.48 (e.g., 17.48±0.2), about 18.07 (e.g., 18.07±0.2), about 18.66 (e.g., 18.66±0.2), about19.27 (e.g., 19.27±0.2), about 19.83 (e.g., 19.83±0.2), about 21.31 (e.g., 21.31±0.2), about22.20 (e.g., 22.20±0.2), about 23.49 (e.g., 23.49±0.2), about 23.93 (e.g., 23.93±0.2), about24.49 (e.g., 24.49±0.2), about 25.23 (e.g., 25.23±0.2), about 25.97 (e.g., 25.97±0.2), about26.24 (e.g., 26.24±0.2), about 27.41 (e.g., 27.41±0.2), about 28.52 (e.g., 28.52±0.2), about29.47 (e.g., 29.47±0.2), about 30.89 (e.g., 30.89±0.2), about 31.75 (e.g., 31.75±0.2), and about 33.33 (e.g., 33.33±0.2). In some embodiments, HBr Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.36 (e.g., 4.36±0.2), about 13.42 (e.g., 13.42±0.2), about 15.33 (e.g., 15.33±0.2), about 15.65 (e.g., 15.65±0.2), about 16.48 (e.g., 16.48±0.2), about 17.48 (e.g., 17.48±0.2), about 18.66 (e.g., 18.66±0.2), about 19.27 (e.g., 19.27±0.2), about 22.20 (e.g., 22.20±0.2), about 24.49 (e.g., 24.49±0.2), about 25.97 (e.g., 25.97±0.2), about 26.24 (e.g., 26.24±0.2), and about 27.41 (e.g.,27.41±0.2). In some embodiments, HBr Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.36 (e.g., 4.36±0.2), about 13.42 (e.g., 13.42±0.2), about 15.33 (e.g., 15.33±0.2), about 15.65 (e.g., 15.65±0.2), about 16.48 (e.g., 16.48±0.2), about 17.48 (e.g.,17.48±0.2), about 18.66 (e.g., 18.66±0.2), about 19.27 (e.g., 19.27±0.2), about 22.20 (e.g.,22.20±0.2), about 24.49 (e.g., 24.49±0.2), about 25.97 (e.g., 25.97±0.2), about 26.24 (e.g.,26.24±0.2), and about 27.41 (e.g., 27.41±0.2). In some embodiments, HBr Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.36 (e.g., 4.36±0.2), about 15.33 (e.g., 15.33±0.2), about 16.48 (e.g., 16.48±0.2), about 22.20 (e.g., 22.20±0.2), about 25.97 (e.g., 25.97±0.2), and about 26.24 (e.g., 26.24±0.2). In some embodiments, HBr Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, or at least seven) peaks each assigned at angles 2-theta in degrees of about 4.36 (e.g., 4.36±0.2), about 15.33 (e.g., 15.33±0.2), about 16.48 (e.g., 16.48±0.2), about 22.20 (e.g., 22.20±0.2), about 25.97 (e.g., 25.97±0.2), and about 26.24 (e.g., 26.24±0.2). In some embodiments, HBr Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.36, about 16.48, about 22.20 and about 25.97. In some embodiments, HBr Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.36±0.2, 16.48±0.2, 22.20±0.2 and 25.97±0.2. In some embodiments, HBr Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.36, about 16.48, and about 25.97. In some embodiments, HBr Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.36±0.2, 16.48±0.2 and 25.97±0.2.In some embodiments, HBr Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.36, and about 16.48. In some embodiments, HBr Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.36±0.2 and 16.48±0.2. In some embodiments, HBr Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 16.48. In some embodiments, HBr Form II has an XRPD pattern comprising peaks each assigned at angles 2- theta in degrees of about 16.48±0.2.

[0125] In some embodiments of HBr Form II, at least one, at least two, or all of the following (a)-(c) apply: a. HBr Form II has an XRPD pattern substantially as shown in FIG. 2; b. HBr Form II has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 2; and c. HBr Form II has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 4.36±0.2, 16.48±0.2 and 25.97±0.2, ii. peaks at an angle 2-theta in degrees of about 4.36±0.2, 16.48±0.2, 22.20±0.2 and 25.97±0.2, iii. peaks at an angle 2-theta in degrees of about 4.36 (e.g., 4.36±0.2), about 15.33 (e.g., 15.33±0.2), about 16.48 (e.g., 16.48±0.2), about 22.20 (e.g., 22.20±0.2), about 25.97 (e.g., 25.97±0.2), and about 26.24 (e.g., 26.24±0.2), iv. peaks at an angle 2-theta in degrees of about 4.36 (e.g., 4.36±0.2), about 13.42 (e.g., 13.42±0.2), about 15.33 (e.g., 15.33±0.2), about 15.65 (e.g., 15.65±0.2), about 16.48 (e.g., 16.48±0.2), about 17.48 (e.g., 17.48±0.2), about 18.66 (e.g., 18.66±0.2), about 19.27 (e.g., 19.27±0.2), about 22.20 (e.g., 22.20±0.2), about 24.49 (e.g., 24.49±0.2), about 25.97 (e.g., 25.97±0.2), about 26.24 (e.g., 26.24±0.2), and about 27.41 (e.g., 27.41±0.2), or v. peaks at an angle 2-theta of about 4.36 (e.g., 4.36±0.2), about 8.73 (e.g., 8.73±0.2), about 12.83 (e.g., 12.83±0.2), about 13.42 (e.g., 13.42±0.2), about 13.68 (e.g., 13.68±0.2), about 15.33 (e.g., 15.33±0.2), about 15.65 (e.g., 15.65±0.2), about 16.48 (e.g., 16.48±0.2), about 17.48 (e.g., 17.48±0.2), about 18.07 (e.g., 18.07±0.2), about 18.66 (e.g., 18.66±0.2), about 19.27 (e.g., 19.27±0.2), about 19.83 (e.g., 19.83±0.2), about 21.31 (e.g., 21.31±0.2), about 22.20 (e.g., 22.20±0.2), about 23.49 (e.g., 23.49±0.2), about 23.93 (e.g.,23.93±0.2), about 24.49 (e.g., 24.49±0.2), about 25.23 (e.g., 25.23±0.2), about 25.97 (e.g., 25.97±0.2), about 26.24 (e.g., 26.24±0.2), about 27.41 (e.g., 27.41±0.2), about 28.52 (e.g., 28.52±0.2), about 29.47 (e.g., 29.47±0.2), about 30.89 (e.g., 30.89±0.2), about 31.75 (e.g., 31.75±0.2), and about 33.33 (e.g., 33.33±0.2).HBr Form III

[0126] In some embodiments, the crystalline form of the HBr salt of Compound A is HBr Form III. In some embodiments, HBr Form III has an XRPD pattern substantially as shown in FIG. 3A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 3.Table 3.

[0127] In some embodiments, HBr Form III has an XRPD pattern comprising peaks provided in Table 3. In some embodiments, HBr Form III has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 3A, or as provided in Table 3.

[0128] In some embodiments, HBr Form III has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 3, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, HBr Form III may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.41 (e.g., 4.41±0.2), about 8.81 (e.g., 8.81±0.2), about 13.05 (e.g., 13.05±0.2), about 13.66 (e.g., 13.66±0.2), about 13.94 (e.g., 13.94±0.2), about15.56 (e.g., 15.56±0.2), about 16.48 (e.g., 16.48±0.2), about 16.58 (e.g., 16.58±0.2), about17.75 (e.g., 17.75±0.2), about 18.36 (e.g., 18.36±0.2), about 18.66 (e.g., 18.66±0.2), about18.95 (e.g., 18.95±0.2), about 19.53 (e.g., 19.53±0.2), about 19.98 (e.g., 19.98±0.2), about21.47 (e.g., 21.47±0.2), about 22.61 (e.g., 22.61±0.2), about 23.89 (e.g., 23.89±0.2), about25.00 (e.g., 25.00±0.2), about 25.46 (e.g., 25.46±0.2), about 26.18 (e.g., 26.18±0.2), about26.79 (e.g., 26.79±0.2), about 27.68 (e.g., 27.68±0.2), about 29.12 (e.g., 29.12±0.2), about29.92 (e.g., 29.92±0.2), about 31.40 (e.g., 31 ,40±0.2), about 31.92 (e.g., 31 ,92±0.2), and about 33.48 (e.g., 33.48±0.2). In some embodiments, HBr Form III has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.41 (e.g., 4.41±0.2), about 8.81 (e.g., 8.81±0.2), about 13.05 (e.g., 13.05±0.2), about 13.66 (e.g., 13.66±0.2), about 13.94 (e.g., 13.94±0.2), about15.56 (e.g., 15.56±0.2), about 16.48 (e.g., 16.48±0.2), about 16.58 (e.g., 16.58±0.2), about17.75 (e.g., 17.75±0.2), about 18.36 (e.g., 18.36±0.2), about 18.66 (e.g., 18.66±0.2), about18.95 (e.g., 18.95±0.2), about 19.53 (e.g., 19.53±0.2), about 19.98 (e.g., 19.98±0.2), about21.47 (e.g., 21.47±0.2), about 22.61 (e.g., 22.61±0.2), about 23.89 (e.g., 23.89±0.2), about25.00 (e.g., 25.00±0.2), about 25.46 (e.g., 25.46±0.2), about 26.18 (e.g., 26.18±0.2), about26.79 (e.g., 26.79±0.2), about 27.68 (e.g., 27.68±0.2), about 29.12 (e.g., 29.12±0.2), about29.92 (e.g., 29.92±0.2), about 31.40 (e.g., 31 ,40±0.2), about 31.92 (e.g., 31 ,92±0.2), and about 33.48 (e.g., 33.48±0.2). In some embodiments, HBr Form III has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.41 (e.g., 4.41±0.2), about 13.66 (e.g., 13.66±0.2), about 15.56 (e.g., 15.56±0.2), about 16.48 (e.g., 16.48±0.2), about 16.58 (e.g., 16.58±0.2), about 17.75 (e.g., 17.75±0.2), about 19.53 (e.g., 19.53±0.2), about 22.61 (e.g., 22.61±0.2), about 25.00 (e.g., 25.00±0.2), about 26.18 (e.g., 26.18±0.2), and about 26.79 (e.g., 26.79±0.2). In some embodiments, HBr Form III has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.41 (e.g., 4.41±0.2), about 13.66 (e.g., 13.66±0.2), about 15.56 (e.g., 15.56±0.2), about 16.48 (e.g., 16.48±0.2), about 16.58 (e.g., 16.58±0.2), about 17.75 (e.g., 17.75±0.2), about 19.53 (e.g., 19.53±0.2), about 22.61 (e.g., 22.61±0.2), about 25.00 (e.g., 25.00±0.2), about 26.18 (e.g., 26.18±0.2), and about 26.79 (e.g., 26.79±0.2). In some embodiments, HBr Form III has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.41 (e.g., 4.41±0.2), about 15.56 (e.g., 15.56±0.2), about 16.48 (e.g., 16.48±0.2), about 16.58 (e.g., 16.58±0.2), about 17.75 (e.g., 17.75±0.2), about 26.18 (e.g., 26.18±0.2). In some embodiments, HBr Form III has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, or at least seven) peaks each assigned at angles 2-theta in degrees of about 4.41 (e.g., 4.41±0.2), about 15.56 (e.g., 15.56±0.2), about 16.48 (e.g., 16.48±0.2), about 16.58 (e.g., 16.58±0.2), about 17.75 (e.g., 17.75±0.2), about 26.18 (e.g., 26.18±0.2). In some embodiments, HBr Form III has an XRPD pattern comprising peaks each assigned at anangle 2-theta in degrees of about 4.41, about 15.56, about 16.48 and about 16.58. In some embodiments, HBr Form III has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.41±0.2, 15.56±0.2, 16.48±0.2 and 16.58±0.2. In some embodiments, HBr Form III has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.41, about 15.56, and about 16.48. In some embodiments, HBr Form III has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.41±0.2, 15.56±0.2, and 16.48±0.2. In some embodiments, HBr Form III has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.41, and about 16.48. In some embodiments, HBr Form III has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.41±0.2, and 16.48±0.2. In some embodiments, HBr Form III has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.41. In some embodiments, HBr Form III has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.41±0.2.

[0129] In some embodiments, HBr Form III is characterized as having a TGA thermogram substantially as shown in FIG. 3B. In some embodiments, HBr Form III is characterized as having a TGA thermogram substantially as shown in FIG. 3B. In some embodiments, HBr Form III is characterized as having a mass loss of about 3.6 %, after heating from about 50.0 °C to about 200.0 °C, as determined by TGA. In some embodiments, HBr Form III is characterized as having a mass loss of about 3.7 %, after heating from about 25.0 °C to about 200.0 °C, as determined by TGA.

[0130] In some embodiments, HBr Form III is characterized as having a DSC thermogram substantially as shown in FIG. 3B, or FIG. 3C. In some embodiments, the crystalline form is characterized as having a DSC thermogram substantially as shown in FIG. 3B. In some embodiments, HBr Form III is characterized as having an endothermic / exothermic event with onsets / peaks of about 221.8 °C / 233.3 °C and about 233.6 °C / 237.0 °C. In some embodiments, HBr Form III is characterized as having a DSC thermogram substantially as shown in FIG. 3C. In some embodiments, HBr Form III is characterized as having an endothermic event with onset of about 20.0 °C and a peak of about 38.4 °C. In some embodiments, HBr Form III is characterized as having an exothermic event with onset of about 225.1 °C and peak of about 230.4 °C.

[0131] In some embodiments, HBr Form III has (a) a DVS isotherm pattern and / or (b) a DVS kinetic pattern substantially as shown in FIG. 3D.

[0132] In some embodiments of HBr Form III, at least one, at least two, at least three, at least four, at least five, at least six, or all of the following (a)-(g) apply: a. HBr Form III has an XRPD pattern substantially as shown in FIG. 3A; b. HBr Form III has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 3; and c. HBr Form III has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 4.41±0.2, 15.56±0.2, 16.48±0.2 and 16.58±0.2, ii. peaks at an angle 2-theta in degrees of about 4.41 (e.g., 4.41±0.2), about 15.56 (e.g., 15.56±0.2), about 16.48 (e.g., 16.48±0.2), about 16.58 (e.g., 16.58±0.2), about 17.75 (e.g., 17.75±0.2), about 26.18 (e.g., 26.18±0.2), iii. peaks at an angle 2-theta in degrees of about 4.41 (e.g., 4.41±0.2), about 13.66 (e.g., 13.66±0.2), about 15.56 (e.g., 15.56±0.2), about 16.48 (e.g., 16.48±0.2), about 16.58 (e.g., 16.58±0.2), about 17.75 (e.g., 17.75±0.2), about 19.53 (e.g., 19.53±0.2), about 22.61 (e.g., 22.61±0.2), about 25.00 (e.g., 25.00±0.2), about 26.18 (e.g., 26.18±0.2), and about 26.79 (e.g., 26.79±0.2), or iv. peaks at an angle 2-theta in degrees of about 4.41 (e.g., 4.41±0.2), about 8.81 (e.g., 8.81±0.2), about 13.05 (e.g., 13.05±0.2), about 13.66 (e.g., 13.66±0.2), about 13.94 (e.g., 13.94±0.2), about 15.56 (e.g., 15.56±0.2), about 16.48 (e.g., 16.48±0.2), about 16.58 (e.g., 16.58±0.2), about 17.75 (e.g., 17.75±0.2), about 18.36 (e.g., 18.36±0.2), about 18.66 (e.g., 18.66±0.2), about 18.95 (e.g., 18.95±0.2), about 19.53 (e.g., 19.53±0.2), about 19.98 (e.g., 19.98±0.2), about 21.47 (e.g., 21.47±0.2), about 22.61 (e.g., 22.61±0.2), about 23.89 (e.g., 23.89±0.2), about 25.00 (e.g., 25.00±0.2), about 25.46 (e.g., 25.46±0.2), about 26.18 (e.g., 26.18±0.2), about 26.79 (e.g., 26.79±0.2), about 27.68 (e.g., 27.68±0.2), about 29.12 (e.g., 29.12±0.2), about 29.92 (e.g., 29.92±0.2), about 31.40 (e.g., 31.40±0.2), about 31.92 (e.g., 31.92±0.2), and about 33.48 (e.g., 33.48±0.2); d. HBr Form III has a TGA thermogram substantially as shown in FIG. 3B; e. HBr Form III is characterized as having a mass loss of about 3.6 % after heating from about 50.0 °C to about 200.0 °C, or 3.7% after heating from about 24.7 °C to about 199.5.0 °C, as determined by TGA; f. HBr Form III has a DSC thermogram substantially as shown in FIG. 3B or FIG. 3C; andg. HBr Form III is characterized as having an endothermic / exothermic event with onsets / peaks of about 221.8 °C / 233.3 °C and about 233.6 °C / 237.0 °C, an endothermic event with onset of about 20.0 °C and a peak of about 38.4 °C, or an exothermic event with onset of about 225.1 °C and peak of about 230.4 °C.HCl Forms

[0133] In some embodiments, the crystalline form of a salt of Compound A is a crystalline form of a HC1 salt. In some embodiments, the crystalline form of the HC1 salt of Compound A is HC1 Form I, or HC1 Form II.HCl Form I

[0134] In some embodiments, the crystalline form of the HCl salt of Compound A is HCl Form I. In some embodiments, HCl Form I has an XRPD pattern substantially as shown in FIG. 4A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 4.Table 4.

[0135] In some embodiments, HC1 Form I has an XRPD pattern comprising peaks provided in Table 4. In some embodiments, HC1 Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 4A, or as provided in Table 4.

[0136] In some embodiments, HC1 Form I has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 5, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, HC1 Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.45 (e.g., 4.45±0.2), about 8.94 (e.g., 8.94±0.2), about 13.60 (e.g., 13.60±0.2), about 14.17 (e.g., 14.17±0.2), about 15.40 (e.g., 15.40±0.2), about 16.34(e.g., 16.34±0.2), about 16.53 (e.g., 16.53±0.2), about 17.71 (e.g., 17.71±0.2), about 17.91(e.g., 17.91±0.2), about 18.21 (e.g., 18.21±0.2), about 18.47 (e.g., 18.47±0.2), about 19.48(e.g., 19.48±0.2), about 19.87 (e.g., 19.87±0.2), about 21.55 (e.g., 21.55±0.2), about 22.52(e.g., 22.52±0.2), about 23.79 (e.g., 23.79±0.2), about 24.88 (e.g., 24.88±0.2), about 26.26(e.g., 26.26±0.2), about 26.75 (e.g., 26.75±0.2), about 27.65 (e.g., 27.65±0.2), about 29.28(e.g., 29.28±0.2), about 29.76 (e.g., 29.76±0.2), about 30.57 (e.g., 30.57±0.2), about 31.71 (e.g., 31.71±0.2), and about 32.40 (e.g., 32.40±0.2). In some embodiments, HC1 Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.45 (e.g., 4.45±0.2), about 8.94 (e.g., 8.94±0.2), about 13.60 (e.g., 13.60±0.2), about 14.17 (e.g., 14.17±0.2), about 15.40 (e.g., 15.40±0.2), about 16.34 (e.g., 16.34±0.2), about 16.53 (e.g., 16.53±0.2), about 17.71(e.g., 17.71±0.2), about 17.91 (e.g., 17.91±0.2), about 18.21 (e.g., 18.21±0.2), about 18.47(e.g., 18.47±0.2), about 19.48 (e.g., 19.48±0.2), about 19.87 (e.g., 19.87±0.2), about 21.55(e.g., 21.55±0.2), about 22.52 (e.g., 22.52±0.2), about 23.79 (e.g., 23.79±0.2), about 24.88(e.g., 24.88±0.2), about 26.26 (e.g., 26.26±0.2), about 26.75 (e.g., 26.75±0.2), about 27.65(e.g., 27.65±0.2), about 29.28 (e.g., 29.28±0.2), about 29.76 (e.g., 29.76±0.2), about 30.57(e.g., 30.57±0.2), about 31.71 (e.g., 31.71±0.2), and about 32.40 (e.g., 32.40±0.2). In some embodiments, HC1 Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.45 (e.g., 4.45±0.2), about 13.60 (e.g., 13.60±0.2), about 14.17 (e.g., 14.17±0.2), about 15.40 (e.g., 15.40±0.2), about 16.34 (e.g., 16.34±0.2), about 16.53(e.g., 16.53±0.2), about 17.71 (e.g., 17.71±0.2), about 17.91 (e.g., 17.91±0.2), about 18.21(e.g., 18.21±0.2), about 19.48 (e.g., 19.48±0.2), about 22.52 (e.g., 22.52±0.2), and about24.88 (e.g., 24.88±0.2). In some embodiments, HC1 Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2- theta in degrees of about 4.45 (e.g., 4.45±0.2), about 13.60 (e.g., 13.60±0.2), about 14.17 (e.g., 14.17±0.2), about 15.40 (e.g., 15.40±0.2), about 16.34 (e.g., 16.34±0.2), about 16.53(e.g., 16.53±0.2), about 17.71 (e.g., 17.71±0.2), about 17.91 (e.g., 17.91±0.2), about 18.21(e.g., 18.21±0.2), about 19.48 (e.g., 19.48±0.2), about 22.52 (e.g., 22.52±0.2), and about24.88 (e.g., 24.88±0.2). In some embodiments, HC1 Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.45 (e.g., 4.45±0.2), about 15.40 (e.g., 15.40±0.2), about 16.53 (e.g., 16.53±0.2), about 19.48 (e.g., 19.48±0.2), and about 22.52 (e.g., 22.52±0.2). In some embodiments, HC1 Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, or at least seven) peaks each assigned at angles 2-theta in degrees of about 4.45 (e.g., 4.45±0.2), about 15.40 (e.g., 15.40±0.2), about 16.53 (e.g., 16.53±0.2), about 19.48 (e.g., 19.48±0.2), and about 22.52 (e.g., 22.52±0.2). In some embodiments, HC1 Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.45,about 15.40, and about 16.53. In some embodiments, HC1 Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.45±0.2, 15.40 and 16.53±0.2. In some embodiments, HC1 Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.45, and about 15.40. In some embodiments, HC1 Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.45±0.2, and 15.40. In some embodiments, HC1 Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.45. In some embodiments, HC1 Form I has an XRPD pattern comprising peaks each assigned at angles 2- theta in degrees of about 4.45±0.2.

[0137] In some embodiments, HC1 Form I is characterized as having a TGA thermogram substantially as shown in FIG. 4B. In some embodiments, HC1 Form I is characterized as having an initial mass loss of about 4.6 % after heating from about 25.0 °C to about 187.5 °C, as determined by TGA. In some embodiments, HC1 Form I is characterized as having a further mass loss of about 4.2 % after heating from about 187.5 °C to about 250.0 °C, as determined by TGA. In some embodiments, HC1 Form I is characterized as having an initial mass loss of about 4.8 % after heating from about 50.0 °C to about 131.3 °C, as determined by TGA. In some embodiments, HC1 Form I is characterized as having a further mass loss of about 3.8 % after heating from about 146.6 °C to about 246.8 °C, as determined by TGA.

[0138] In some embodiments, HC1 Form I is characterized as having a DSC thermogram substantially as shown in FIG. 4B or FIG. 4C. In some embodiments, HC1 Form I is characterized as having a DSC thermogram substantially as shown in FIG. 4B. In some embodiments, HC1 Form I is characterized as having endothermic / exothermic event with onsets / peaks of 200.2 °C / 212.72 °C and 220.8 °C / 226.9 °C. HC1 Form I is characterized as having a DSC thermogram substantially as shown in FIG. 4C. In some embodiments, HC1 Form I is characterized as having an endothermic event with an onset of 20.0 °C. In some embodiments, HC1 Form I is characterized as having endothermic event with a peak at 52.7 °C.

[0139] In some embodiments, HC1 Form I is characterized as having (a) a DVS isotherm pattern and (b) a DVS kinetic pattern substantially as shown in FIG. 4D.

[0140] In some embodiments of HC1 Form I, at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or all of the following (a)-(h) apply:a. HC1 Form I has an XRPD pattern substantially as shown in FIG. 4A; b. HC1 Form I has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 4; and c. HC1 Form I has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 4.45, about 15.40, and about 16.53, ii. peaks at an angle 2-theta in degrees of about 4.45 (e.g., 4.45±0.2), about 15.40 (e.g., 15.40±0.2), about 16.53 (e.g., 16.53±0.2), about 19.48 (e.g., 19.48±0.2), and about 22.52 (e.g., 22.52±0.2), iii. peaks at an angle 2-theta in degrees of about 4.45 (e.g., 4.45±0.2), about 13.60 (e.g., 13.60±0.2), about 14.17 (e.g., 14.17±0.2), about 15.40 (e.g., 15.40±0.2), about 16.34 (e.g., 16.34±0.2), about 16.53 (e.g., 16.53±0.2), about 17.71 (e.g., 17.71±0.2), about 17.91 (e.g., 17.91±0.2), about 18.21 (e.g., 18.21±0.2), about 19.48 (e.g., 19.48±0.2), about 22.52 (e.g., 22.52±0.2), and about 24.88 (e.g., 24.88±0.2), or iv. peaks at an angle 2-theta in degrees of about 4.45 (e.g., 4.45±0.2), about 8.94 (e.g., 8.94±0.2), about 13.60 (e.g., 13.60±0.2), about 14.17 (e.g., 14.17±0.2), about 15.40 (e.g., 15.40±0.2), about 16.34 (e.g., 16.34±0.2), about 16.53 (e.g., 16.53±0.2), about 17.71 (e.g., 17.71±0.2), about 17.91 (e.g., 17.91±0.2), about 18.21 (e.g., 18.21±0.2), about 18.47 (e.g., 18.47±0.2), about 19.48 (e.g., 19.48±0.2), about 19.87 (e.g., 19.87±0.2), about 21.55 (e.g., 21.55±0.2), about 22.52 (e.g., 22.52±0.2), about 23.79 (e.g., 23.79±0.2), about 24.88 (e.g., 24.88±0.2), about 26.26 (e.g., 26.26±0.2), about 26.75 (e.g., 26.75±0.2), about 27.65 (e.g., 27.65±0.2), about 29.28 (e.g., 29.28±0.2), about 29.76 (e.g., 29.76±0.2), about 30.57 (e.g., 30.57±0.2), about 31.71 (e.g., 31.71±0.2), and about 32.40 (e.g., 32.40±0.2); d. HC1 Form I has a TGA thermogram substantially as shown in FIG. 4B; e. HC1 Form I is characterized as having a mass loss of about 4.6 % after heating from about 25.0 °C to about 187.5 °C and a further mass loss of about 4.2 % after heating from about 187.5 °C to about 250.0 °C, or an initial mass loss of about 4.8 % after heating from about 50.0 °C to about 131.3 °C and a further mass loss of about 3.8 % after heating from about 146.6 °C to about 246.8 °C, as determined by TGA; f. HC1 Form I has a DSC thermogram substantially as shown in FIG. 4B or FIG. 4C;g. HCl Form I is characterized as having an endothermic / exothermic event with onsets / peaks of 200.2 °C / 212.72 °C and 220.8 °C / 226.9 °C, or an endothermic event with an onset of 20.0 °C and a peak at 52.7 °C; and h. HCl Form I is characterized as having (a) a DVS isotherm pattern and (b) a DVS kinetic pattern substantially as shown in FIG. 4D.HCl Form II

[0141] In some embodiments, the crystalline form of the HCl salt of Compound A is HCl Form II. In some embodiments, HCl Form II has an XRPD pattern substantially as shown in FIG. 5. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 5.Table 5.

[0142] In some embodiments, HC1 Form II has an XRPD pattern comprising peaks provided in Table 5. In some embodiments, HC1 Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 5, or as provided in Table 5.

[0143] In some embodiments, HC1 Form II has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 5, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, HC1 Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.38 (e.g., 4.38±0.2), about 12.94 (e.g., 12.94±0.2), about13.49 (e.g., 13.49±0.2), about 13.84 (e.g., 13.84±0.2), about 15.32 (e.g., 15.32±0.2), about15.96 (e.g., 15.96±0.2), about 16.29 (e.g., 16.29±0.2), about 16.52 (e.g., 16.52±0.2), about17.59 (e.g., 17.59±0.2), about 18.10 (e.g., 18.10±0.2), about 18.37 (e.g., 18.37±0.2), about18.90 (e.g., 18.90±0.2), about 19.27 (e.g., 19.27±0.2), about 19.86 (e.g., 19.86±0.2), about21.43 (e.g., 21.43±0.2), about 22.25 (e.g., 22.25±0.2), about 23.38 (e.g., 23.38±0.2), about23.84 (e.g., 23.84±0.2), about 24.42 (e.g., 24.42±0.2), about 25.12 (e.g., 25.12±0.2), about25.50 (e.g., 25.50±0.2), about 26.16 (e.g., 26.16±0.2), about 26.24 (e.g., 26.24±0.2), about26.58 (e.g., 26.58±0.2), about 27.60 (e.g., 27.60±0.2), about 28.71 (e.g., 28.71±0.2), about29.69 (e.g., 29.69±0.2), about 30.93 (e.g., 30.93±0.2), about 31.62 (e.g., 31.62±0.2) about32.50 (e.g., 32.50±0.2), about 33.53 (e.g., 33.53±0.2), and about 34.25 (e.g., 34.25±0.2). In some embodiments, HC1 Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.38 (e.g., 4.38±0.2), about 12.94 (e.g., 12.94±0.2), about 13.49 (e.g., 13.49±0.2), about13.84 (e.g., 13.84±0.2), about 15.32 (e.g., 15.32±0.2), about 15.96 (e.g., 15.96±0.2), about16.29 (e.g., 16.29±0.2), about 16.52 (e.g., 16.52±0.2), about 17.59 (e.g., 17.59±0.2), about18.10 (e.g., 18.10±0.2), about 18.37 (e.g., 18.37±0.2), about 18.90 (e.g., 18.90±0.2), about19.27 (e.g., 19.27±0.2), about 19.86 (e.g., 19.86±0.2), about 21.43 (e.g., 21.43±0.2), about22.25 (e.g., 22.25±0.2), about 23.38 (e.g., 23.38±0.2), about 23.84 (e.g., 23.84±0.2), about24.42 (e.g., 24.42±0.2), about 25.12 (e.g., 25.12±0.2), about 25.50 (e.g., 25.50±0.2), about26.16 (e.g., 26.16±0.2), about 26.24 (e.g., 26.24±0.2), about 26.58 (e.g., 26.58±0.2), about27.60 (e.g., 27.60±0.2), about 28.71 (e.g., 28.71±0.2), about 29.69 (e.g., 29.69±0.2), about30.93 (e.g., 30.93±0.2), about 31.62 (e.g., 31.62±0.2) about 32.50 (e.g., 32.50±0.2), about 33.53 (e.g., 33.53±0.2), and about 34.25 (e.g., 34.25±0.2). In some embodiments, HC1 Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.38 (e.g., 4.38±0.2), about 13.49 (e.g., 13.49±0.2), about 13.84 (e.g., 13.84±0.2), about 15.32 (e.g., 15.32±0.2), about 16.29 (e.g., 16.29±0.2), about 16.52 (e.g., 16.52±0.2), about 17.59 (e.g., 17.59±0.2), about 19.27 (e.g., 19.27±0.2), about 22.25 (e.g., 22.25±0.2), about 23.84 (e.g., 23.84±0.2), about 24.42 (e.g., 24.42±0.2), about 26.16 (e.g., 26.16±0.2), and about 26.24 (e.g., 26.24±0.2). In some embodiments, HC1 Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.38 (e.g., 4.38±0.2), about 13.49 (e.g., 13.49±0.2), about 13.84 (e.g., 13.84±0.2), about 15.32 (e.g., 15.32±0.2), about 16.29 (e.g., 16.29±0.2), about 16.52 (e.g., 16.52±0.2), about 17.59 (e.g., 17.59±0.2), about 19.27 (e.g., 19.27±0.2), about 22.25 (e.g., 22.25±0.2), about 23.84 (e.g., 23.84±0.2), about 24.42 (e.g., 24.42±0.2), about 26.16 (e.g., 26.16±0.2), and about 26.24 (e.g., 26.24±0.2). In some embodiments, HC1Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.38 (e.g., 4.38±0.2), about 15.32 (e.g., 15.32±0.2), about 16.52 (e.g., 16.52±0.2), about 22.25 (e.g., 22.25±0.2), about 23.84 (e.g., 23.84±0.2), about 26.16 (e.g., 26.16±0.2), and about 26.24 (e.g., 26.24±0.2). In some embodiments, HC1 Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, or at least seven) peaks each assigned at angles 2-theta in degrees of about 4.38 (e.g., 4.38±0.2), about 15.32 (e.g., 15.32±0.2), about 16.52 (e.g., 16.52±0.2), about 22.25 (e.g., 22.25±0.2), about 23.84 (e.g., 23.84±0.2), about 26.16 (e.g., 26.16±0.2), and about 26.24 (e.g., 26.24±0.2). In some embodiments, HC1 Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.38, about 23.84, about 26.16 and about 26.24. In some embodiments, HC1 Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.38±0.2, 23.84, 26.16±0.2 and 26.24±0.2. In some embodiments, HC1 Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.38, about 26.16 and about 26.24. In some embodiments, HC1 Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.38±0.2, 26.16±0.2 and 26.24±0.2. In some embodiments, HC1 Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.38, and about 26.16. In some embodiments, HC1 Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.38±0.2, and 26.16±0.2. In some embodiments, HC1 Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.38. In some embodiments, HC1 Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.38±0.2.

[0144] In some embodiments of HC1 Form I, at least one, at least two, or all of the following (a)-(c) apply: a. HC1 Form II has an XRPD pattern substantially as shown in FIG. 5; b. HC1 Form II has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 5; and c. HC1 Form II has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 4.38±0.2, 26.16±0.2 and 26.24±0.2,ii. peaks at an angle 2-theta in degrees of about 4.38 (e.g., 4.38±0.2), about 15.32 (e.g., 15.32±0.2), about 16.52 (e.g., 16.52±0.2), about 22.25 (e.g., 22.25±0.2), about 23.84 (e.g., 23.84±0.2), about 26.16 (e.g., 26.16±0.2), and about 26.24 (e.g., 26.24±0.2), iii. peaks at an angle 2-theta in degrees of about 4.38 (e.g., 4.38±0.2), about 13.49 (e.g., 13.49±0.2), about 13.84 (e.g., 13.84±0.2), about 15.32 (e.g., 15.32±0.2), about 16.29 (e.g., 16.29±0.2), about 16.52 (e.g., 16.52±0.2), about 17.59 (e.g., 17.59±0.2), about 19.27 (e.g., 19.27±0.2), about 22.25 (e.g., 22.25±0.2), about 23.84 (e.g., 23.84±0.2), about 24.42 (e.g., 24.42±0.2), about 26.16 (e.g., 26.16±0.2), and about 26.24 (e.g., 26.24±0.2), or iv. peaks at an angle 2-theta in degrees of about 4.38 (e.g., 4.38±0.2), about 12.94 (e.g., 12.94±0.2), about 13.49 (e.g., 13.49±0.2), about 13.84 (e.g., 13.84±0.2), about 15.32 (e.g., 15.32±0.2), about 15.96 (e.g., 15.96±0.2), about 16.29 (e.g., 16.29±0.2), about 16.52 (e.g., 16.52±0.2), about 17.59 (e.g., 17.59±0.2), about 18.10 (e.g., 18.10±0.2), about 18.37 (e.g., 18.37±0.2), about 18.90 (e.g., 18.90±0.2), about 19.27 (e.g., 19.27±0.2), about 19.86 (e.g., 19.86±0.2), about 21.43 (e.g., 21.43±0.2), about 22.25 (e.g., 22.25±0.2), about 23.38 (e.g., 23.38±0.2), about 23.84 (e.g., 23.84±0.2), about 24.42 (e.g., 24.42±0.2), about 25.12 (e.g., 25.12±0.2), about 25.50 (e.g., 25.50±0.2), about 26.16 (e.g., 26.16±0.2), about 26.24 (e.g., 26.24±0.2), about 26.58 (e.g., 26.58±0.2), about 27.60 (e.g., 27.60±0.2), about 28.71 (e.g., 28.71±0.2), about 29.69 (e.g., 29.69±0.2), about 30.93 (e.g., 30.93±0.2), about 31.62 (e.g., 31.62±0.2) about 32.50 (e.g., 32.50±0.2), about 33.53 (e.g., 33.53±0.2), and about 34.25 (e.g., 34.25±0.2).Sulfate Forms

[0145] In some embodiments, the crystalline form is a crystalline form of a sulfate salt. In some embodiments, the crystalline form of the sulfate salt of Compound A is Sulfate Form I, Sulfate Form II, or Sulfate Form III.Sulfate Form I

[0146] In some embodiments, the crystalline form of the sulfate salt of Compound A is Sulfate Form I. In some embodiments, Sulfate Form I has an XRPD pattern substantially asshown in FIG. 6A. In some embodiments, Sulfate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 6A.

[0147] In some embodiments, Sulfate Form I is characterized as having an X-ray powder diffraction (XRPD) pattern comprising a peak at an angle 2-theta of about 15.50 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2-theta of about 4.33 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2-theta of about 13.33 degrees.

[0148] In some embodiments, Sulfate Form I is characterized as having a TGA thermogram substantially as shown in FIG. 6B. In some embodiments, Sulfate Form I is characterized as having a mass loss of about 5.5 % after heating from about 50.0 °C to about 93.8 °C, as determined by TGA. In some embodiments, Sulfate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 6B. In some embodiments, Sulfate Form I is characterized as having no thermal events at a temperature selected from the range of about 50.0 °C to about 400.0 °C.

[0149] In some embodiments of Sulfate Form I, at least one, at least two, at least three, or all of the following (a)-(d) apply: a. Sulfate Form I has an XRPD pattern substantially as shown in FIG. 6A; b. Sulate Form I has a TGA thermogram substantially as shown in FIG. 6B; c. Sulate Form I is characterized as having a mass loss of about 5.5 % after heating from about 50.0 °C to about 93.8 °C, as determined by TGA; and d. Sulate Form I has a DSC thermogram substantially as shown in FIG. 6B.Sulfate Form II

[0150] In some embodiments, the crystalline form of the sulfate salt of Compound A is Sulfate Form II. In some embodiments, Sulfate Form II has an XRPD pattern substantially as shown in FIG. 7A. In some embodiments, Sulfate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 7A.

[0151] In some embodiments, Sulfate Form II is characterized as having an X-ray powder diffraction (XRPD) pattern comprising a peak at an angle 2-theta of about 13.00 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2-theta of about 4.50 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2-theta of about 18.00 degrees.

[0152] In some embodiments, the crystalline form is characterized as having a TGA thermogram substantially as shown in FIG. 7B. In some embodiments, the crystalline form is characterized as having a mass loss of about 6.3 % after heating from about 25.6 °C to about 104.9 °C, as determined by TGA.

[0153] In some embodiments, the crystalline form is characterized as having a DSC thermogram substantially as shown in FIG. 7B. In some embodiments, the crystalline form is characterized as having no thermal events at a temperature selected from the range of about 50.0 °C to about 400.0 °C.

[0154] In some embodiments of Sulfate Form II, at least one, at least two, at least three, or all of the following (a)-(d) apply: a. Sulfate Form II has an XRPD pattern substantially as shown in FIG. 7A; b. Sulate Form II has a TGA thermogram substantially as shown in FIG. 7B; c. Sulate Form II is characterized as having a mass loss of about 6.3 % after heating from about 25.6 °C to about 104.9 °C, as determined by TGA; and d. Sulate Form II has a DSC thermogram substantially as shown in FIG. 7B.Sulfate Form III

[0155] In some embodiments, the crystalline form of the sulfate salt of Compound A is Sulfate Form III. In some embodiments, Sulfate Form III has an XRPD pattern substantially as shown in FIG. 8. In some embodiments, Sulfate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 8.

[0156] In some embodiments, Sulfate Form III is characterized as having an X-ray powder diffraction (XRPD) pattern comprising a peak at an angle 2-theta of about 16.66 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2-theta of about 4.50 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2-theta of about 15.50 degrees.Tosylate Forms

[0157] In some embodiments, the crystalline form is a crystalline form of a tosylate salt. In some embodiments, the tosylate salt of Compound A is a mono tosylate salt.Tosylate Form I

[0158] In some embodiments, the crystalline form of the tosylate salt of Compound A is Tosylate Form I. In some embodiments, Tosylate Form I is a mono tosylate salt. In some embodiments, Tosylate Form I has an XRPD pattern substantially as shown in FIG. 9A.Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 6.Table 6.

[0159] In some embodiments, Tosylate Form I has an XRPD pattern comprising peaks provided in Table 6. In some embodiments, Tosylate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-thetawith the greatest intensity in the XRPD pattern substantially as shown in FIG. 9A, or as provided in Table 6.

[0160] In some embodiments, Tosylate Form I has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 6, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Tosylate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.19 (e.g., 4.19±0.2), about 8.38 (e.g., 8.38±0.2), about 12.69 (e.g., 12.69±0.2), about 13.19 (e.g., 13.19±0.2), about 14.02 (e.g., 14.02±0.2), about15.08 (e.g., 15.08±0.2), about 15.25 (e.g., 15.25±0.2), about 15.67 (e.g., 15.67±0.2), about15.94 (e.g., 15.94±0.2), about 16.11 (e.g., 16.11±0.2), about 16.36 (e.g., 16.36±0.2), about16.81 (e.g., 16.81±0.2), about 17.14 (e.g., 17.14±0.2), about 17.78 (e.g., 17.78±0.2), about18.07 (e.g., 18.07±0.2), about 18.43 (e.g., 18.43±0.2), about 19.35 (e.g., 19.35±0.2), about19.71 (e.g., 19.71±0.2), about 20.39 (e.g., 20.39±0.2), about 21.14 (e.g., 21.14±0.2), about21.75 (e.g., 21.75±0.2), about 22.67 (e.g., 22.67±0.2), about 23.15 (e.g., 23.15±0.2), about23.64 (e.g., 23.64±0.2), about 24.30 (e.g., 24.30±0.2), about 24.87 (e.g., 24.87±0.2), about25.16 (e.g., 25.16±0.2), about 25.36 (e.g., 25.36±0.2), about 26.10 (e.g., 26.10±0.2), about26.76 (e.g., 26.76±0.2), about 27.32 (e.g., 27.32±0.2), about 27.65 (e.g., 27.65±0.2), about28.43 (e.g., 28.43±0.2), about 29.29 (e.g., 29.29±0.2), about 29.79 (e.g., 29.79±0.2), about30.47 (e.g., 30.47±0.2), about 31.19 (e.g., 31.19±0.2), and about 32.28 (e.g., 32.28±0.2). In some embodiments, Tosylate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.19 (e.g., 4.19±0.2), about 8.38 (e.g., 8.38±0.2), about 12.69 (e.g., 12.69±0.2), about 13.19 (e.g., 13.19±0.2), about 14.02 (e.g., 14.02±0.2), about 15.08 (e.g., 15.08±0.2), about15.25 (e.g., 15.25±0.2), about 15.67 (e.g., 15.67±0.2), about 15.94 (e.g., 15.94±0.2), about16.11 (e.g., 16.11±0.2), about 16.36 (e.g., 16.36±0.2), about 16.81 (e.g., 16.81±0.2), about17.14 (e.g., 17.14±0.2), about 17.78 (e.g., 17.78±0.2), about 18.07 (e.g., 18.07±0.2), about18.43 (e.g., 18.43±0.2), about 19.35 (e.g., 19.35±0.2), about 19.71 (e.g., 19.71±0.2), about20.39 (e.g., 20.39±0.2), about 21.14 (e.g., 21.14±0.2), about 21.75 (e.g., 21.75±0.2), about22.67 (e.g., 22.67±0.2), about 23.15 (e.g., 23.15±0.2), about 23.64 (e.g., 23.64±0.2), about24.30 (e.g., 24.30±0.2), about 24.87 (e.g., 24.87±0.2), about 25.16 (e.g., 25.16±0.2), about25.36 (e.g., 25.36±0.2), about 26.10 (e.g., 26.10±0.2), about 26.76 (e.g., 26.76±0.2), about27.32 (e.g., 27.32±0.2), about 27.65 (e.g., 27.65±0.2), about 28.43 (e.g., 28.43±0.2), about29.29 (e.g., 29.29±0.2), about 29.79 (e.g., 29.79±0.2), about 30.47 (e.g., 30.47±0.2), about 31.19 (e.g., 31.19±0.2), and about 32.28 (e.g., 32.28±0.2). In some embodiments, Tosylate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.19 (e.g., 4.19±0.2), about 12.69 (e.g., 12.69±0.2), about 14.02 (e.g., 14.02±0.2), about 15.08 (e.g., 15.08±0.2), about 15.25 (e.g., 15.25±0.2), about 15.94 (e.g., 15.94±0.2), about 16.11 (e.g., 16.11±0.2), about 16.36 (e.g., 16.36±0.2), about 16.81 (e.g., 16.81±0.2), about 17.14 (e.g., 17.14±0.2), about 17.78 (e.g., 17.78±0.2), about 18.07 (e.g., 18.07±0.2), about 19.35 (e.g., 19.35±0.2), about 20.39 (e.g., 20.39±0.2), about 21.14 (e.g., 21.14±0.2), about 22.67 (e.g., 22.67±0.2), about 25.16 (e.g., 25.16±0.2), about 26.10 (e.g., 26.10±0.2), and about 26.76 (e.g., 26.76±0.2). In some embodiments, Tosylate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.19 (e.g., 4.19±0.2), about 12.69 (e.g., 12.69±0.2), about 14.02 (e.g., 14.02±0.2), about 15.08 (e.g., 15.08±0.2), about 15.25 (e.g.,15.25±0.2), about 15.94 (e.g., 15.94±0.2), about 16.11 (e.g., 16.11±0.2), about 16.36 (e.g.,16.36±0.2), about 16.81 (e.g., 16.81±0.2), about 17.14 (e.g., 17.14±0.2), about 17.78 (e.g.,17.78±0.2), about 18.07 (e.g., 18.07±0.2), about 19.35 (e.g., 19.35±0.2), about 20.39 (e.g.,20.39±0.2), about 21.14 (e.g., 21.14±0.2), about 22.67 (e.g., 22.67±0.2), about 25.16 (e.g.,25.16±0.2), about 26.10 (e.g., 26.10±0.2), and about 26.76 (e.g., 26.76±0.2). In some embodiments, Tosylate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.19 (e.g., 4.19±0.2), about 12.69 (e.g., 12.69±0.2), about 15.08 (e.g., 15.08±0.2), about 16.11 (e.g., 16.11±0.2), about 16.36 (e.g., 16.36±0.2), about 16.81 (e.g., 16.81±0.2), about 19.35 (e.g., 19.35±0.2), and about 21.14 (e.g., 21.14±0.2). In some embodiments, Tosylate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, or at least seven) peaks each assigned at angles 2-theta in degrees of about 4.19 (e.g., 4.19±0.2), about 12.69 (e.g., 12.69±0.2), about 15.08 (e.g., 15.08±0.2), about 16.11 (e.g., 16.11±0.2), about 16.36 (e.g., 16.36±0.2), about 16.81 (e.g., 16.81±0.2), about 19.35 (e.g., 19.35±0.2), and about 21.14 (e.g., 21.14±0.2). In some embodiments, Tosylate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.19, about 16.11, and about 19.35. In some embodiments, Tosylate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.19±0.2, 16.11 and 19.35±0.2. In some embodiments, Tosylate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.19, and about 19.35. In some embodiments, TosylateForm I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.19±0.2, and 19.35±0.2. In some embodiments, Tosylate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.19. In some embodiments, Tosylate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.19±0.2.

[0161] In some embodiments, Tosylate Form I is characterized as having a TGA thermogram substantially as shown in FIG. 9B. In some embodiments, Tosylate Form I is characterized as having an initial mass loss of about 1.6 % after heating from about 25.0 °C to about 200.0 °C, as determined by TGA.

[0162] In some embodiments, Tosylate Form I is characterized as having a further mass loss of about 1.8 % after heating from about 200.0 °C to about 250.0 °C, as determined by TGA. In some embodiments, Tosylate Form I is characterized as having a mass loss of about 4.0 % after heating from about 25.0 °C to about 248.0 °C, as determined by TGA.

[0163] In some embodiments, Tosylate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 9B or FIG. 9C. In some embodiments, Tosylate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 9B. In some embodiments, Tosylate Form I is characterized as having an endothermic / exothermic event with onsets / peaks of 210.7 °C / 216.9 °C and 219.1 °C / 224.8 °C. Tosylate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 9C. In some embodiments, Tosylate Form I is characterized as having an endothermic event with an onset of 159.8 °C and two peaks at 173.9 °C and 183.4 °C. In some embodiments, Tosylate Form I is characterized as having an exothermic event with an onset of 213.4 °C and a peak at 222.1 °C.

[0164] In some embodiments, Tosylate Form I is characterized as having (a) a DVS isotherm pattern and (b) a DVS kinetic pattern as shown in FIG. 9D.

[0165] In some embodiments, Tosylate Form I is characterized as having a Polarized Loght Microscopy (PLM) micrograph (a) under plane polarized and (b) cross polarized light as shown in FIG. 9E. In some embodiments Tosylate Form I has a needle-like morphology.

[0166] In some embodiments of Tosylate Form I, at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or all of the following (a)-(h) apply:a. Tosylate Form I has an XRPD pattern substantially as shown in FIG. 9A; b. Tosylate Form I has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 6; and c. Tosylate Form I has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 4.19±0.2, about 16.11 and about 19.35±0.2, ii. peaks at an angle 2-theta in degrees of about 4.19 (e.g., 4.19±0.2), about 12.69 (e.g., 12.69±0.2), about 15.08 (e.g., 15.08±0.2), about 16.11 (e.g., 16.11±0.2), about 16.36 (e.g., 16.36±0.2), about 16.81 (e.g., 16.81±0.2), about 19.35 (e.g., 19.35±0.2), and about 21.14 (e.g., 21.14±0.2), iii. peaks at an angle 2-theta in degrees of about 4.19 (e.g., 4.19±0.2), about 12.69 (e.g., 12.69±0.2), about 14.02 (e.g., 14.02±0.2), about 15.08 (e.g., 15.08±0.2), about 15.25 (e.g., 15.25±0.2), about 15.94 (e.g., 15.94±0.2), about 16.11 (e.g., 16.11±0.2), about 16.36 (e.g., 16.36±0.2), about 16.81 (e.g., 16.81±0.2), about17.14 (e.g., 17.14±0.2), about 17.78 (e.g., 17.78±0.2), about 18.07 (e.g., 18.07±0.2), about 19.35 (e.g., 19.35±0.2), about 20.39 (e.g., 20.39±0.2), about21.14 (e.g., 21.14±0.2), about 22.67 (e.g., 22.67±0.2), about 25.16 (e.g., 25.16±0.2), about 26.10 (e.g., 26.10±0.2), and about 26.76 (e.g., 26.76±0.2), or iv. peaks at an angle 2-theta in degrees of about 4.19 (e.g., 4.19±0.2), about 8.38 (e.g., 8.38±0.2), about 12.69 (e.g., 12.69±0.2), about 13.19 (e.g., 13.19±0.2), about 14.02 (e.g., 14.02±0.2), about 15.08 (e.g., 15.08±0.2), about 15.25 (e.g., 15.25±0.2), about 15.67 (e.g., 15.67±0.2), about 15.94 (e.g., 15.94±0.2), about 16.11 (e.g., 16.11±0.2), about 16.36 (e.g., 16.36±0.2), about 16.81 (e.g., 16.81±0.2), about 17.14 (e.g., 17.14±0.2), about 17.78 (e.g., 17.78±0.2), about 18.07 (e.g., 18.07±0.2), about 18.43 (e.g., 18.43±0.2), about 19.35 (e.g., 19.35±0.2), about 19.71 (e.g., 19.71±0.2), about 20.39 (e.g., 20.39±0.2), about21.14 (e.g., 21.14±0.2), about 21.75 (e.g., 21.75±0.2), about 22.67 (e.g., 22.67±0.2), about 23.15 (e.g., 23.15±0.2), about 23.64 (e.g., 23.64±0.2), about 24.30 (e.g., 24.30±0.2), about 24.87 (e.g., 24.87±0.2), about 25.16 (e.g., 25.16±0.2), about 25.36 (e.g., 25.36±0.2), about 26.10 (e.g., 26.10±0.2), about 26.76 (e.g., 26.76±0.2), about 27.32 (e.g., 27.32±0.2), about 27.65 (e.g., 27.65±0.2), about 28.43 (e.g., 28.43±0.2), about 29.29 (e.g., 29.29±0.2), about29.79 (e.g., 29.79±0.2), about 30.47 (e.g., 30.47±0.2), about 31.19 (e.g., 31.19±0.2), and about 32.28 (e.g., 32.28±0.2); d. Tosylate Form I has a TGA thermogram substantially as shown in FIG. 9B; e. Tosylate Form I is characterized as having a mass loss of about 1.8 % after heating from about 200.0 °C to about 250.0 °C, or about 4.0 % after heating from about 25.0 °C to about 271.9 °C, as determined by TGA; f. Tosylate Form I has a DSC thermogram substantially as shown in FIG. 9B or FIG. 9C; g. Tosylate Form I is characterized as having an endothermic / exothermic event with onsets / peaks of 210.7 °C / 216.9 °C and 219.1 °C / 224.8 °C, an endothermic event with an onset of 159.8 °C and two peaks at 173.9 °C and 183.4 °C, or an exothermic event with an onset of 213.4 °C and a peak at 222.1 °C. h. Tosylate Form I has (a) a DVS isotherm pattern and (b) a DVS kinetic pattern as shown in FIG. 9D.Mesylate Forms

[0167] In some embodiments, the crystalline form is a crystalline form of a mesylate salt. In some embodiments, the tosylate salt of Compound A is a mono mesylate salt. In some embodiments, the crystalline form of the mesylate salt of Compound A is Mesylate Form I or Mesylate Form II.Mesylate Form I

[0168] In some embodiments, the crystalline form of the mesylate salt of Compound A is Mesylate Form I. In some embodiments, Mesylate Form I is a mono mesylate salt.

[0169] In some embodiments, Mesylate Form I has an XRPD pattern substantially as shown in FIG. 10. In some embodiments, Mesylate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 10.

[0170] In some embodiments, Mesylate Form I is characterized as having an X-ray powder diffraction (XRPD) pattern comprising a peak at an angle 2-theta of about 18.50 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2-theta of about 13.33 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2-theta of about 4.50 degrees.Mesylate Form II

[0171] In some embodiments, the crystalline form of the mesylate salt of Compound A is Mesylate Form II. In some embodiments, Mesylate Form II is a mono mesylate salt.

[0172] In some embodiments, Mesylate Form II has an XRPD pattern substantially as shown in FIG. 11A. In some embodiments, Mesylate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG.11A

[0173] In some embodiments, Mesylate Form II is characterized as having an X-ray powder diffraction (XRPD) pattern comprising a peak at an angle 2-theta of about 19.00 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2- theta of about 15.50 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2-theta of about 4.66 degrees. In some embodiments, the crystalline form is characterized as having an XRPD pattern substantially as shown in FIG. 11 A.

[0174] In some embodiments, Mesylate Form II is characterized as having a TGA thermogram substantially as shown in FIG. 11B. In some embodiments, Mesylate Form II is characterized as having a mass loss of about 3.6 % after heating from about 25.0 °C to about 200.0 °C, as determined by TGA.

[0175] In some embodiments, Mesylate Form II is characterized as having a DSC thermogram substantially as shown in FIG. 11B. In some embodiments, Mesylate Form II is characterized as having an exothermic event with an onset of about 201.7 °C. In some embodiments, Mesylate Form II is characterized as having an exotherm peak at about 218.5 °C.

[0176] In some embodiments of Mesylate Form II, at least one, at least two, at least three, at least four, or all of the following (a)-(e) apply: a. Mesylate Form II has an XRPD pattern substantially as shown in FIG. 11 A;b. Mesylate Form II has a TGA thermogram substantially as shown in FIG. 11B; c. Mesylate Form II is characterized as having a mass loss of about 3.6 % after heating from about 25.0 °C to about 200.0 °C, as determined by TGA; d. Mesylate Form II has a DSC thermogram substantially as shown in FIG. 11B; and e. Mesylate Form II is characterized as having an exothermic event with an onset of about 201.7 °C, and a peak at about 218.5 °C.Nap sy late Forms

[0177] In some embodiments, the crystalline form is a crystalline form of a napsylate salt. In some embodiments, the tosylate salt of Compound A is a mono napsylate salt. In some embodiments, the crystalline form of the napsylate salt of Compound A is Napsylate Form I, Napsylate Form II, or Napsylate Form III.Napsylate Form I

[0178] In some embodiments, the crystalline form of the mesylate salt of Compound A is Napsylate Form I. In some embodiments, Napsylate Form I is a mono napsylate salt.

[0179] In some embodiments, Napsylate Form I has an XRPD pattern substantially as shown in FIG. 12A. In some embodiments, Napsylate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG.12A

[0180] In some embodiments, Napsylate Form I is characterized as having an X-ray powder diffraction (XRPD) pattern comprising a peak at an angle 2-theta of about 5.50 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2- theta of about 4.25 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2-theta of about 6.25 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2-theta of about 21.75 degrees.

[0181] In some embodiments, Napsylate Form I is characterized as having a TGA thermogram substantially as shown in FIG. 12B. In some embodiments, Napsylate Form I is characterized as having a mass loss of about 1.1 % after heating from about 25.0 °C to about62.5 °C, as determined by TGA. In some embodiments, Napsylate Form I is characterized as having a further mass loss of about 4.1 % after heating from about 62.5 °C to about 258.3 °C, as determined by TGA.

[0182] In some embodiments, Napsylate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 12B. In some embodiments, Napsylate Form I is characterized as having no thermal events at a temperature selected from the range of about 25 °C to about 400 °C.

[0183] In some embodiments of Napsylate Form I, at least one, at least two, at least three, at least four, at least five, at least six, or all of the following (a)-(g) apply: a. Napsylate Form I has an XRPD pattern substantially as shown in FIG. 12A; b. Napsylate Form I has a TGA thermogram substantially as shown in FIG. 12B; c. Napsylate Form I is characterized as having a mass loss of aboutl .1 % after heating from about 25.0 °C to about 62.5 °C, or about 4.1 % after heating from about 62.5 °C to about 258.3 °C, as determined by TGA; and d. Napsylate Form I has a DSC thermogram substantially as shown in FIG. 12B.Napsylate Form II

[0184] In some embodiments, the crystalline form of the mesylate salt of Compound A is Napsylate Form II. In some embodiments, Napsylate Form II is a mono napsylate salt.

[0185] In some embodiments, Napsylate Form II has an XRPD pattern substantially as shown in FIG. 13. In some embodiments, Napsylate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG.13

[0186] In some embodiments, Napsylate Form II is characterized as having an X-ray powder diffraction (XRPD) pattern comprising a peak at an angle 2-theta of about 21.75 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2- theta of about 4.25 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2-theta of about 6.75 degrees.Napsylate Form III

[0187] In some embodiments, the crystalline form of the mesylate salt of Compound A is Napsylate Form III. In some embodiments, Napsylate Form III is a mono napsylate salt.

[0188] In some embodiments, Napsylate Form III has an XRPD pattern substantially as shown in FIG. 14. In some embodiments, Napsylate Form III has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG.14

[0189] In some embodiments, Napsylate Form III is characterized as having an X-ray powder diffraction (XRPD) pattern comprising a peak at an angle 2-theta of about 4.33 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2- theta of about 12.75 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2-theta of about 19.75 degrees.Besylate Forms

[0190] In some embodiments, the crystalline form is a crystalline form of a besylate salt. In some embodiments, the besylate salt of Compound A is a mono besylate salt. In some embodiments, the crystalline form of the besylate salt of Compound A is Besylate Form I or Besylate Form II.Besylate Form I

[0191] In some embodiments, the crystalline form of the besylate salt of Compound A is Besylate Form I. In some embodiments, Besylate Form I is a mono besylate salt.

[0192] In some embodiments, Besylate Form I has an XRPD pattern substantially as shown in FIG. 15A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 7.Table 7.

[0193] In some embodiments, Besylate Form I has an XRPD pattern comprising peaks provided in Table 7. In some embodiments, Besylate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 15A, or as provided in Table 7.

[0194] In some embodiments, Besylate Form I has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 7, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Besylate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 8.63 (e.g., 8.63±0.2), about 12.71 (e.g., 12.71±0.2), about 13.23 (e.g., 13.23±0.2), about 14.11 (e.g., 14.11±0.2), about15.28 (e.g., 15.28±0.2), about 15.89 (e.g., 15.89±0.2), about 16.12 (e.g., 16.12±0.2), about16.61 (e.g., 16.61±0.2), about 17.27 (e.g., 17.27±0.2), about 18.03 (e.g., 18.03±0.2), about18.75 (e.g., 18.75±0.2), about 19.66 (e.g., 19.66±0.2), about 20.05 (e.g., 20.05±0.2), about20.58 (e.g., 20.58±0.2), about 21.57 (e.g., 21.57±0.2), about 22.06 (e.g., 22.06±0.2), about23.16 (e.g., 23.16±0.2), about 23.44 (e.g., 23.44±0.2), about 23.97 (e.g., 23.97±0.2), about24.62 (e.g., 24.62±0.2), about 25.28 (e.g., 25.28±0.2), about 25.53 (e.g., 25.53±0.2), about25.98 (e.g., 25.98±0.2), about 26.48 (e.g., 26.48±0.2), about 26.74 (e.g., 26.74±0.2), about27.46 (e.g., 27.46±0.2), about 27.69 (e.g., 27.69±0.2), about 28.37 (e.g., 28.37±0.2), about28.86 (e.g., 28.86±0.2), about 29.48 (e.g., 29.48±0.2), about 30.32 (e.g., 30.32±0.2), about30.74 (e.g., 30.74±0.2), about 31.77 (e.g., 31 ,77±0.2), about 32.77 (e.g., 29.79±0.2), and about 33.47 (e.g., 33.47±0.2). In some embodiments, Besylate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at leastfive, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of 4.30 (e.g., 4.30±0.2), about 8.63 (e.g., 8.63±0.2), about 12.71 (e.g., 12.71±0.2), about 13.23 (e.g., 13.23±0.2), about 14.11 (e.g., 14.11±0.2), about 15.28(e.g., 15.28±0.2), about 15.89 (e.g., 15.89±0.2), about 16.12 (e.g., 16.12±0.2), about 16.61(e.g., 16.61±0.2), about 17.27 (e.g., 17.27±0.2), about 18.03 (e.g., 18.03±0.2), about 18.75(e.g., 18.75±0.2), about 19.66 (e.g., 19.66±0.2), about 20.05 (e.g., 20.05±0.2), about 20.58(e.g., 20.58±0.2), about 21.57 (e.g., 21.57±0.2), about 22.06 (e.g., 22.06±0.2), about 23.16(e.g., 23.16±0.2), about 23.44 (e.g., 23.44±0.2), about 23.97 (e.g., 23.97±0.2), about 24.62(e.g., 24.62±0.2), about 25.28 (e.g., 25.28±0.2), about 25.53 (e.g., 25.53±0.2), about 25.98(e.g., 25.98±0.2), about 26.48 (e.g., 26.48±0.2), about 26.74 (e.g., 26.74±0.2), about 27.46(e.g., 27.46±0.2), about 27.69 (e.g., 27.69±0.2), about 28.37 (e.g., 28.37±0.2), about 28.86(e.g., 28.86±0.2), about 29.48 (e.g., 29.48±0.2), about 30.32 (e.g., 30.32±0.2), about 30.74(e.g., 30.74±0.2), about 31.77 (e.g., 31.77±0.2), about 32.77 (e.g., 29.79±0.2), and about 33.47 (e.g., 33.47±0.2). In some embodiments, Besylate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 12.71 (e.g., 12.71±0.2), about 14.11 (e.g., 14.11±0.2), about 15.28 (e.g., 15.28±0.2), about 15.89 (e.g., 15.89±0.2), about 16.12 (e.g., 16.12±0.2), about 16.61 (e.g., 16.61±0.2), about 17.27 (e.g., 17.27±0.2), about 18.03 (e.g., 18.03±0.2), about 19.66 (e.g., 19.66±0.2), about 20.05 (e.g., 20.05±0.2), about 20.58 (e.g., 20.58±0.2), about 21.57 (e.g., 21.57±0.2), about 23.16 (e.g., 23.16±0.2), about 23.97 (e.g., 23.97±0.2), about 25.28 (e.g., 25.28±0.2), about 26.48 (e.g., 26.48±0.2), about 26.74 (e.g., 26.74±0.2), about 27.46 (e.g., 27.46±0.2), and about 27.69 (e.g., 27.69±0.2). In some embodiments, Besylate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 12.71 (e.g., 12.71±0.2), about 14.11 (e.g., 14.11±0.2), about 15.28 (e.g., 15.28±0.2), about 15.89 (e.g.,15.89±0.2), about 16.12 (e.g., 16.12±0.2), about 16.61 (e.g., 16.61±0.2), about 17.27 (e.g.,17.27±0.2), about 18.03 (e.g., 18.03±0.2), about 19.66 (e.g., 19.66±0.2), about 20.05 (e.g.,20.05±0.2), about 20.58 (e.g., 20.58±0.2), about 21.57 (e.g., 21.57±0.2), about 23.16 (e.g.,23.16±0.2), about 23.97 (e.g., 23.97±0.2), about 25.28 (e.g., 25.28±0.2), about 26.48 (e.g.,26.48±0.2), about 26.74 (e.g., 26.74±0.2), about 27.46 (e.g., 27.46±0.2), and about 27.69 (e.g., 27.69±0.2). In some embodiments, Besylate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 12.71 (e.g., 12.71±0.2), about 14.11 (e.g., 14.11±0.2), about 15.28 (e.g., 15.28±0.2), about 15.89(e.g., 15.89±0.2), about 16.12 (e.g., 16.12±0.2), about 17.27 (e.g., 17.27±0.2), about 18.03 (e.g., 18.03±0.2), about 19.66 (e.g., 19.66±0.2), about 23.16 (e.g., 23.16±0.2), about 26.48 (e.g., 26.48±0.2), and about 26.74 (e.g., 26.74±0.2). In some embodiments, Besylate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, or at least seven) peaks each assigned at angles 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 12.71 (e.g., 12.71±0.2), about 14.11 (e.g., 14.11±0.2), about 15.28 (e.g., 15.28±0.2), about 15.89 (e.g., 15.89±0.2), about 16.12 (e.g., 16.12±0.2), about 17.27 (e.g., 17.27±0.2), about 18.03 (e.g., 18.03±0.2), about 19.66 (e.g., 19.66±0.2), about 23.16 (e.g., 23.16±0.2), about 26.48 (e.g., 26.48±0.2), and about 26.74 (e.g., 26.74±0.2). In some embodiments, Besylate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 12.71 (e.g., 12.71±0.2), about 14.11 (e.g., 14.11±0.2), about 15.28 (e.g., 15.28±0.2about 16.12 (e.g., 16.12±0.2), about 17.27 (e.g., 17.27±0.2), and about 19.66 (e.g., 19.66±0.2). In some embodiments, Besylate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, or at least seven) peaks each assigned at angles 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 12.71 (e.g., 12.71±0.2), about 14.11 (e.g., 14.11±0.2), about 15.28 (e.g., 15.28±0.2about 16.12 (e.g., 16.12±0.2), about 17.27 (e.g., 17.27±0.2), and about 19.66 (e.g., 19.66±0.2). In some embodiments, Besylate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.30, about 15.28, and about 19.66. In some embodiments, Besylate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.30±0.2, 15.28±0.2 and 19.66±0.2. In some embodiments, Besylate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.30, and about 15.28. In some embodiments, Besylate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.30±0.2, and 15.28±0.2. In some embodiments, Besylate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 15.28. In some embodiments, Besylate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 15.28±0.2.

[0195] In some embodiments, Besylate Form I is characterized as having a TGA thermogram substantially as shown in FIG. 15B. In some embodiments, Besylate Form I is characterized as having an initial mass loss of about 1.1 % after heating from about 25.0 °C to about 100.0 °C, as determined by TGA. In some embodiments, Besylate Form I ischaracterized as having a further mass loss of about 0.8 % after heating from about 25.0 °C to about 200.0 °C, as determined by TGA. In some embodiments, the initial mass loss is equal to 0.47 equivalents of water. In some embodiments, the initial mass loss is equal to 0.19 equivalents of ethanol. In some embodiments, the further mass loss is equal to 0.34 equivalents of water. In some embodiments, the further mass loss is equal to 0.13 equivalents of water. In some embodiments, Besylate Form I is characterized as having a yet further mass loss of about 2.7 % after heating from about 200.0 °C to about 262.5 °C, as determined by TGA.

[0196] In some embodiments, Besylate Form I is characterized as having a TGA thermogram substantially as shown in FIG. 15C. In some embodiments, Besylate Form I is characterized as having a mass loss of about 4.3 % after heating from about 25.0 °C to about243.8 °C, as determined by TGA. In some embodiments, Besylate Form I is characterized as having an initial mass loss of about 0.6 % after heating from about 25.0 °C to about 112.6 °C, as determined by TGA. In some embodiments, Besylate Form I is characterized as having a further mass loss of about 3.7 % after heating from about 118.4 °C to about 247.1 °C, as determined by TGA.

[0197] In some embodiments, Besylate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 15B, FIG. 15C, or FIG. 15D. In some embodiments, Besylate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 15B. In some embodiments, Besylate Form I is characterized as having an endotherm / exotherm event. In some embodiments, Besylate Form I is characterized as having an endothermic / exothermic event with onsets / peaks of about 201.7 °C / 226.7 °C and about226.9 °C / 231.5 °C. In some embodiments, Besylate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 15C. In some embodiments, Besylate Form I is characterized as having an endotherm / exotherm event between about 215 °C and about 230 °C. In some embodiments, Besylate Form I is characterized as having an endothermic / exothermic event with onsets / peaks of about 215.8 °C / 229.3.7 °C and about230.9 °C / 234.4 °C. In some embodiments, Besylate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 15D. In some embodiments, Besylate Form I is characterized as having an endothermic event with an onset of about 25.0 °C. In some embodiments, Besylate Form I is characterized as having an endothermic event with a peak at about 59.5 °C.

[0198] In some embodiments, Besylate Form I is characterized as having a) a DVS isotherm pattern and (b) a DVS kinetic pattern for Maleate Form I substantially as shown in FIG. 15E

[0199] In some embodiments, Besylate Form I is characterized as having a PLM micrograph (a) under plane polarized and / or (b) cross polarized light substantially as shown in FIG. 15F. In some embodiments, Besylate Form I particles are birefringent. In some embodiments Besylate Form I particles exhibit lath morphology. In some embodiments Besylate Form I particles exhibit lath morphology with various sizes.

[0200] In some embodiments, Besylate Form I is characterized as having a molecular structure substantially as shown in FIG. 15G.

[0201] In some embodiments, the crystal structure of Besylate Form I is characterized by a monoclinic space group 12, as characterized by single crystal X-ray crystallography. In some embodiments, the crystal structure of Besylate Form I is characterized by a monoclinic space group 12 with cell parameters of a = about 6.19250(10) A, b = about 40.4143(6), c = about 7.50600(10) A, / = 90°, and a cell volume (V) = about 1754.23(5) A3, as characterized by single crystal X-ray crystallography. In some embodiments, the crystal structure of Besylate Form I is characterized by one or more of the structural parameters reported in Table 8.Table 8.

[0202] In some embodiments of Besylate Form I, at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or all of the following (a)-(h) apply: a. Besylate Form I has an XRPD pattern substantially as shown in FIG. 15A; b. Besylate Form I has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 7; c. Besylate Form I has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 4.30±0.2, 15.28±0.2 and 19.66±0.2, ii. peaks at an angle 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 12.71 (e.g., 12.71±0.2), about 14.11 (e.g., 14.11±0.2), about 15.28 (e.g., 15.28±0.2about 16.12 (e.g., 16.12±0.2), about 17.27 (e.g., 17.27±0.2), and about 19.66 (e.g., 19.66±0.2), iii. peaks at an angle 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 12.71 (e.g., 12.71±0.2), about 14.11 (e.g., 14.11±0.2), about 15.28 (e.g., 15.28±0.2), about 15.89 (e.g., 15.89±0.2), about 16.12 (e.g., 16.12±0.2), about 17.27 (e.g., 17.27±0.2), about 18.03 (e.g., 18.03±0.2), about 19.66 (e.g., 19.66±0.2), about 23.16 (e.g., 23.16±0.2), about 26.48 (e.g., 26.48±0.2), and about 26.74 (e.g., 26.74±0.2), iv. peaks at an angle 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 12.71 (e.g., 12.71±0.2), about 14.11 (e.g., 14.11±0.2), about 15.28 (e.g., 15.28±0.2), about 15.89 (e.g., 15.89±0.2), about 16.12 (e.g., 16.12±0.2), about 16.61 (e.g., 16.61±0.2), about 17.27 (e.g., 17.27±0.2), about 18.03 (e.g., 18.03±0.2), about 19.66 (e.g., 19.66±0.2), about 20.05 (e.g., 20.05±0.2), about 20.58 (e.g.,20.58±0.2), about 21.57 (e.g., 21.57±0.2), about 23.16 (e.g., 23.16±0.2), about 23.97 (e.g., 23.97±0.2), about 25.28 (e.g., 25.28±0.2), about 26.48 (e.g., 26.48±0.2), about 26.74 (e.g., 26.74±0.2), about 27.46 (e.g., 27.46±0.2), and about 27.69 (e.g., 27.69±0.2), or v. peaks at an angle 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 8.63 (e.g., 8.63±0.2), about 12.71 (e.g., 12.71±0.2), about 13.23 (e.g., 13.23±0.2), about 14.11 (e.g., 14.11±0.2), about 15.28 (e.g., 15.28±0.2), about 15.89 (e.g., 15.89±0.2), about 16.12 (e.g., 16.12±0.2), about 16.61 (e.g., 16.61±0.2), about 17.27 (e.g., 17.27±0.2), about 18.03 (e.g., 18.03±0.2), about 18.75 (e.g., 18.75±0.2), about 19.66 (e.g., 19.66±0.2), about 20.05 (e.g., 20.05±0.2), about 20.58 (e.g., 20.58±0.2), about 21.57 (e.g., 21.57±0.2), about 22.06 (e.g., 22.06±0.2), about 23.16 (e.g., 23.16±0.2), about 23.44 (e.g., 23.44±0.2), about 23.97 (e.g., 23.97±0.2), about 24.62 (e.g., 24.62±0.2), about 25.28 (e.g., 25.28±0.2), about 25.53 (e.g., 25.53±0.2), about 25.98 (e.g., 25.98±0.2), about 26.48 (e.g., 26.48±0.2), about 26.74 (e.g., 26.74±0.2), about 27.46 (e.g., 27.46±0.2), about 27.69 (e.g., 27.69±0.2), about 28.37 (e.g., 28.37±0.2), about 28.86 (e.g., 28.86±0.2), about 29.48 (e.g., 29.48±0.2), about 30.32 (e.g., 30.32±0.2), about 30.74 (e.g., 30.74±0.2), about 31.77 (e.g., 31.77±0.2), about 32.77 (e.g., 29.79±0.2), and about 33.47 (e.g., 33.47±0.2); d. Besylate Form I has a TGA thermogram substantially as shown in FIG. 15B, or FIG. 15c; e. Besylate Form I is characterized as having a mass loss of about 1.1 % after heating from about 25.0 °C to about 100.0 °C and a further mass loss of about 0.8 % after heating from about 25.0 °C to about 200.0 °C, about 2.7 % after heating from about 200.0 °C to about 262.5 °C, as determined by TGA, about 4.3 % after heating from about 25.0 °C to about 243.8 °C, or about 0.6 % after heating from about 25.0 °C to about 112.6 °C and a further mass loss of about 3.7 % after heating from about 118.4 °C to about 247.1 °C; f. Besylate Form I has a DSC thermogram substantially as shown in FIG. 15B, FIG. 15C, or FIG. 15D; g. Besylate Form I is characterized as having an endothermic / exothermic event with onsets / peaks of about 201.7 °C / 226.7 °C and about 226.9 °C / 231.5 °C, an endothermic / exothermic event with onsets / peaks of about 215.8 °C / 229.3.7 °C andabout 230.9 °C / 234.4 °C, or an endothermic event with an onset of about 25.0 °C and a peak at about 59.5 °C. h. Besylate Form I is characterized as having (a) a DVS isotherm pattern and (b) a DVS kinetic pattern substantially as shown in FIG. 15E; and i. Besylate Form I is characterized by one or more of the structural parameters reported in Table 8.Besylate Form II

[0203] In some embodiments, the crystalline form of the besylate salt of Compound A is Besylate Form II. In some embodiments, Besylate Form II is a mono besylate salt.

[0204] In some embodiments, Besylate Form II has an XRPD pattern substantially as shown in FIG. 15G. In some embodiments, Besylate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG.16A

[0205] In some embodiments, Besylate Form II is characterized as having an X-ray powder diffraction (XRPD) pattern comprising a peak at an angle 2-theta of about 3.50 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2- theta of about 18.5 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2-theta of about 12.5 degrees.

[0206] In some embodiments, Besylate Form II is characterized as having a TGA thermogram substantially as shown in FIG. 16B. In some embodiments, Besylate Form II is characterized as having a mass loss of about 11.2 %after heating from about 25.0 °C to about 175.0 °C, as determined by TGA.

[0207] In some embodiments, Besylate Form II is characterized as having a DSC thermogram substantially as shown in FIG. 16B. In some embodiments, Besylate Form II is characterized as having an endothermic / exothermic event between 210 and 225 °C. In some embodiments, Besylate Form II is characterized as having an endothermic / exothermic event with onsets / peaks at 210.2 °C / 215.8 °C and 218.8 °C / 223.5 °C.

[0208] In some embodiments of Besylate Form II, at least one, at least two, at least three, at least four, or all of the following (a)-(e) apply: a. Besylate Form II has an XRPD pattern substantially as shown in FIG. 16A; b. Besylate Form II has a TGA thermogram substantially as shown in FIG. 16B; c. Besylate Form II is characterized as having a mass loss of about 11.2 %after heating from about 25.0 °C to about 175.0 °C, as determined by TGA; d. Besylate Form II has a DSC thermogram substantially as shown in FIG. 16B; and e. Besylate Form II is characterized as having an endothermic / exothermic event with onsets / peaks at 210.2 °C / 215.8 °C and 218.8 °C / 223.5 °C.Aspartate Forms

[0209] In some embodiments, the crystalline form is a crystalline form of an aspartate salt. In some embodiments, the aspartate salt of Compound A is a hemi aspartate salt. In some embodiments, the crystalline form of the aspartate salt of Compound A is Aspartate Form I, or Aspartate Form II.Aspartate Form I

[0210] In some embodiments, the crystalline form of the aspartate salt of Compound A is Aspartate Form I. In some embodiments, Aspartate Form I is a hemi aspartate salt.

[0211] In some embodiments, Aspartate Form I has an XRPD pattern substantially as shown in FIG. 17. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 9.Table 9.

[0212] In some embodiments, Aspartate Form I has an XRPD pattern comprising peaks provided in Table 9. In some embodiments, Aspartate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 17, or as provided in Table 9.

[0213] In some embodiments, Aspartate Form I has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 9, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Aspartate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 4.68 (e.g., 4.68±0.2), about 7.37 (e.g., 7.37±0.2), about 8.59 (e.g., 8.59±0.2), about 13.87 (e.g., 13.87±0.2), about 14.45 (e.g., 15.28±0.2), about 14.71 (e.g., 14.71±0.2), about 15.55 (e.g., 15.55±0.2), about 16.26 (e.g.,16.26±0.2), about 17.32 (e.g., 17.32±0.2), about 18.06 (e.g., 18.06±0.2), about 19.03 (e.g.,19.03±0.2), about 20.00 (e.g., 20.00±0.2), about 20.65 (e.g., 20.65±0.2), about 21.35 (e.g.,21.35±0.2), about 21.67 (e.g., 21.67±0.2), about 22.78 (e.g., 22.78±0.2), about 23.33 (e.g.,23.33±0.2), about 25.53 (e.g., 25.53±0.2), about 25.86 (e.g., 25.86±0.2), about 26.66 (e.g.,26.66±0.2), about 28.18 (e.g., 28.18±0.2), about 28.84 (e.g., 28.84±0.2), about 29.68 (e.g.,29.68±0.2), about 31.07 (e.g., 31.07±0.2), about 32.30 (e.g., 32.30±0.2), about 33.96 (e.g.,33.96±0.2), and about 34.49 (e.g., 34.49±0.2). In some embodiments, Aspartate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of 4.30 (e.g., 4.30±0.2), about 4.68 (e.g., 4.68±0.2), about 7.37 (e.g., 7.37±0.2), about 8.59 (e.g., 8.59±0.2), about 13.87 (e.g., 13.87±0.2), about 14.45 (e.g., 15.28±0.2), about 14.71 (e.g., 14.71±0.2), about 15.55 (e.g.,15.55±0.2), about 16.26 (e.g., 16.26±0.2), about 17.32 (e.g., 17.32±0.2), about 18.06 (e.g.,18.06±0.2), about 19.03 (e.g., 19.03±0.2), about 20.00 (e.g., 20.00±0.2), about 20.65 (e.g.,20.65±0.2), about 21.35 (e.g., 21.35±0.2), about 21.67 (e.g., 21.67±0.2), about 22.78 (e.g.,22.78±0.2), about 23.33 (e.g., 23.33±0.2), about 25.53 (e.g., 25.53±0.2), about 25.86 (e.g.,25.86±0.2), about 26.66 (e.g., 26.66±0.2), about 28.18 (e.g., 28.18±0.2), about 28.84 (e.g.,28.84±0.2), about 29.68 (e.g., 29.68±0.2), about 31.07 (e.g., 31.07±0.2), about 32.30 (e.g.,32.30±0.2), about 33.96 (e.g., 33.96±0.2), and about 34.49 (e.g., 34.49±0.2). In some embodiments, Aspartate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 8.59 (e.g., 8.59±0.2), about 14.45 (e.g., 15.28±0.2), about 18.06 (e.g., 18.06±0.2), about 19.03 (e.g., 19.03±0.2), about20.00 (e.g., 20.00±0.2), about 20.65 (e.g., 20.65±0.2), about 21.35 (e.g., 21.35±0.2), about21.67 (e.g., 21.67±0.2), about 22.78 (e.g., 22.78±0.2), about 23.33 (e.g., 23.33±0.2), about25.53 (e.g., 25.53±0.2), about 25.86 (e.g., 25.86±0.2), about 26.66 (e.g., 26.66±0.2), and about 28.18 (e.g., 28.18±0.2). In some embodiments, Aspartate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at leastfive, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 8.59 (e.g., 8.59±0.2), about 14.45 (e.g., 15.28±0.2), about 18.06 (e.g., 18.06±0.2), about 19.03 (e.g., 19.03±0.2), about20.00 (e.g., 20.00±0.2), about 20.65 (e.g., 20.65±0.2), about 21.35 (e.g., 21.35±0.2), about21.67 (e.g., 21.67±0.2), about 22.78 (e.g., 22.78±0.2), about 23.33 (e.g., 23.33±0.2), about25.53 (e.g., 25.53±0.2), about 25.86 (e.g., 25.86±0.2), about 26.66 (e.g., 26.66±0.2), and about 28.18 (e.g., 28.18±0.2). In some embodiments, Aspartate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 20.00 (e.g., 20.00±0.2), about 20.65 (e.g., 20.65±0.2), about 21.35 (e.g., 21.35±0.2), about 21.67 (e.g., 21.67±0.2), about 22.78 (e.g., 22.78±0.2), and about 23.33 (e.g., 23.33±0.2). In some embodiments, Aspartate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, or at least seven) peaks each assigned at angles 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 20.00 (e.g., 20.00±0.2), about 20.65 (e.g., 20.65±0.2), about 21.35 (e.g., 21.35±0.2), about 21.67 (e.g., 21.67±0.2), about 22.78 (e.g., 22.78±0.2), and about 23.33 (e.g., 23.33±0.2). In some embodiments, Aspartate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.30, about 21.67, and about 23.33. In some embodiments, Aspartate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.30±0.2, 21.67±0.2 and 23.33±0.2. In some embodiments, Aspartate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.30, and about 23.33. In some embodiments, Aspartate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.30±0.2, and 23.33±0.2. In some embodiments, Aspartate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 23.33. In some embodiments, Aspartate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 23.33±0.2.

[0214] In some embodiments of Aspartate Form I, at least one, at least two, or all of the following (a)-(c) apply: a. Aspartate Form I has an XRPD pattern substantially as shown in FIG. 17; b. Aspartate Form I has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 9; and c. Aspartate Form I has an XRPD pattern comprising:i. peaks at an angle 2-theta in degrees of about 4.30±0.2, 21.67±0.2 and 23.33±0.2, ii. peaks at an angle 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 20.00 (e.g., 20.00±0.2), about 20.65 (e.g., 20.65±0.2), about 21.35 (e.g., 21.35±0.2), about 21.67 (e.g., 21.67±0.2), about 22.78 (e.g., 22.78±0.2), and about 23.33 (e.g., 23.33±0.2), iii. peaks at an angle 2-theta in degrees of about 4.30 (e.g., 4.30±0.2), about 8.59 (e.g., 8.59±0.2), about 14.45 (e.g., 15.28±0.2), about 18.06 (e.g., 18.06±0.2), about 19.03 (e.g., 19.03±0.2), about 20.00 (e.g., 20.00±0.2), about 20.65 (e.g., 20.65±0.2), about 21.35 (e.g., 21.35±0.2), about 21.67 (e.g., 21.67±0.2), about 22.78 (e.g., 22.78±0.2), about 23.33 (e.g., 23.33±0.2), about 25.53 (e.g., 25.53±0.2), about 25.86 (e.g., 25.86±0.2), about 26.66 (e.g., 26.66±0.2), and about 28.18 (e.g., 28.18±0.2), or iv. peaks at an angle 2-theta in degrees of about about 4.30 (e.g., 4.30±0.2), about 4.68 (e.g., 4.68±0.2), about 7.37 (e.g., 7.37±0.2), about 8.59 (e.g., 8.59±0.2), about 13.87 (e.g., 13.87±0.2), about 14.45 (e.g., 15.28±0.2), about 14.71 (e.g., 14.71±0.2), about 15.55 (e.g., 15.55±0.2), about 16.26 (e.g., 16.26±0.2), about 17.32 (e.g., 17.32±0.2), about 18.06 (e.g., 18.06±0.2), about 19.03 (e.g., 19.03±0.2), about 20.00 (e.g., 20.00±0.2), about 20.65 (e.g., 20.65±0.2), about 21.35 (e.g., 21.35±0.2), about 21.67 (e.g., 21.67±0.2), about 22.78 (e.g., 22.78±0.2), about 23.33 (e.g., 23.33±0.2), about 25.53 (e.g., 25.53±0.2), about 25.86 (e.g., 25.86±0.2), about 26.66 (e.g., 26.66±0.2), about 28.18 (e.g., 28.18±0.2), about 28.84 (e.g., 28.84±0.2), about 29.68 (e.g., 29.68±0.2), about 31.07 (e.g., 31.07±0.2), about 32.30 (e.g., 32.30±0.2), about 33.96 (e.g., 33.96±0.2), and about 34.49 (e.g., 34.49±0.2).Aspartate Form II

[0215] In some embodiments, the crystalline form of the aspartate salt of Compound A is Aspartate Form II. In some embodiments, Aspartate Form II is a hemi aspartate salt.

[0216] In some embodiments, Aspartate Form II has an XRPD pattern substantially as shown in FIG. 18A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 10.Table 10.

[0217] In some embodiments, Aspartate Form II has an XRPD pattern comprising peaks provided in Table 10. In some embodiments, Aspartate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 18A, or as provided in Table 10.

[0218] In some embodiments, Aspartate Form II has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 10, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Aspartate Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.22 (e.g., 4.22±0.2), about 7.08 (e.g., 7.08±0.2), about 9.02 (e.g., 9.02±0.2), about 12.96 (e.g., 12.96±0.2), about 21.73 (e.g., 21.73±0.2), about 22.79 (e.g., 22.79±0.2), about 23.72 (e.g., 23.72±0.2), about 25.55 (e.g., 25.55±0.2), about 26.18 (e.g., 26.18±0.2), about 28.20 (e.g., 28.20±0.2), and about 31.18 (e.g., 31.18±0.2). In some embodiments, Aspartate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at leasteight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.22 (e.g., 4.22±0.2), about 7.08 (e.g., 7.08±0.2), about 9.02 (e.g., 9.02±0.2), about 12.96 (e.g., 12.96±0.2), about 21.73 (e.g., 21.73±0.2), about 22.79 (e.g., 22.79±0.2), about 23.72 (e.g., 23.72±0.2), about 25.55 (e.g., 25.55±0.2), about 26.18 (e.g., 26.18±0.2), about 28.20 (e.g., 28.20±0.2), and about 31.18 (e.g., 31.18±0.2). In some embodiments, Aspartate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.22 (e.g., 4.22±0.2), about 7.08 (e.g., 7.08±0.2), about 21.73 (e.g., 21.73±0.2), about 23.72 (e.g., 23.72±0.2), and about 25.55 (e.g., 25.55±0.2). In some embodiments, Aspartate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.22 (e.g., 4.22±0.2), about 7.08 (e.g., 7.08±0.2), about 21.73 (e.g., 21.73±0.2), about 23.72 (e.g., 23.72±0.2), and about 25.55 (e.g., 25.55±0.2). In some embodiments, Aspartate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.22, about 21.73, and about 23.72. In some embodiments, Aspartate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.22±0.2, 21.73±0.2 and 23.72±0.2. In some embodiments, Aspartate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.22, and about 21.73. In some embodiments, Aspartate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.22±0.2, and 21.73±0. In some embodiments, Aspartate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 21.73. In some embodiments, Aspartate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 21.73±0.

[0219] In some embodiments, Aspartate Form II is characterized as having a TGA thermogram substantially as shown in FIG. 18B. In some embodiments, Aspartate Form II is characterized as having a mass loss of about 2.2 % after heating from about 25.0 °C to about 164.7 °C, as determined by TGA.

[0220] In some embodiments, Aspartate Form II is characterized as having a DSC thermogram substantially as shown in FIG. 18B. In some embodiments, Aspartate Form II is characterized as having an endotherm event with an onset at about 207.0 °C. In some embodiments, Aspartate Form II is characterized as having an endotherm peak at about 220.6

[0221] In some embodiments of Aspartate Form II, at least one, at least two, at least three, at least four, at least five, at least six, or all of the following (a)-(g) apply: a. Aspartate Form II has an XRPD pattern substantially as shown in FIG. 18A; b. Aspartate Form II has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 10; and c. Aspartate Form II has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 4.22±0.2, 21 ,73±0.2 and 23.72±0.2, ii. peaks at an angle 2-theta in degrees of about 4.22 (e.g., 4.22±0.2), about 7.08 (e.g., 7.08±0.2), about 21.73 (e.g., 21.73±0.2), about 23.72 (e.g., 23.72±0.2), and about 25.55 (e.g., 25.55±0.2), or iii. peaks at an angle 2-theta in degrees of about 4.22 (e.g., 4.22±0.2), about 7.08 (e.g., 7.08±0.2), about 9.02 (e.g., 9.02±0.2), about 12.96 (e.g., 12.96±0.2), about 21.73 (e.g., 21.73±0.2), about 22.79 (e.g., 22.79±0.2), about 23.72 (e.g., 23.72±0.2), about 25.55 (e.g., 25.55±0.2), about 26.18 (e.g., 26.18±0.2), about 28.20 (e.g., 28.20±0.2), and about 31.18 (e.g., 31.18±0.2); d. Aspartate Form II has a TGA thermogram substantially as shown in FIG. 18B; e. Aspartate Form II is characterized as having a mass loss of about 2.2 % after heating from about 25.0 °C to about 164.7 °C, as determined by TGA; f. Aspartate Form II has a DSC thermogram substantially as shown in FIG. 18B; and g. Aspartate Form II is characterized as having an endotherm event with an onset at about 207.0 °C and peak at about 220.6 °C.Maleate Forms

[0222] In some embodiments, the crystalline form is a crystalline form of a maleate salt. In some embodiments, the maleate salt of Compound A is a mono or a hemi maleate salt. In some embodiments, the crystalline form of the maleate salt of Compound A is Maleate Form I, or Maleate Form II.Maleate Form I

[0223] In some embodiments, the crystalline form of the maleate salt of Compound A is Maleate Form I. In some embodiments, Maleate Form I is a mono maleate salt.

[0224] In some embodiments, Maleate Form I has an XRPD pattern substantially as shown in FIG. 19A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 11.Table 11.

[0225] In some embodiments, Maleate Form I has an XRPD pattern comprising peaks provided in Table 11. In some embodiments, Maleate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 19A, or as provided in Table 11.

[0226] In some embodiments, Maleate Form I has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 11, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Maleate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.62 (e.g., 5.62±0.2), about 9.69 (e.g., 9.69±0.2), about 10.31 (e.g., 10.31±0.2), about 10.57 (e.g., 10.57±0.2), about 11.64 (e.g., 11.64±0.2), about12.09 (e.g., 12.09±0.2), about 14.00 (e.g., 14.00±0.2), about 14.62 (e.g., 14.62±0.2), about15.45 (e.g., 15.45±0.2), about 16.22 (e.g., 16.22±0.2), about 16.68 (e.g., 16.68±0.2), about17.29 (e.g., 17.29±0.2), about 17.74 (e.g., 17.74±0.2), about 18.36 (e.g., 18.36±0.2), about18.81 (e.g., 18.81±0.2), about 19.43 (e.g., 19.43±0.2), about 20.21 (e.g., 20.21±0.2), about20.70 (e.g., 20.70±0.2), about 21.30 (e.g., 21.30±0.2), about 22.39 (e.g., 22.39±0.2), about23.16 (e.g., 23.16±0.2), about 24.00 (e.g., 24.00±0.2), about 24.26 (e.g., 24.26±0.2), about24.72 (e.g., 24.72±0.2), about 25.17 (e.g., 25.17±0.2), about 26.22 (e.g., 26.22±0.2), about27.34 (e.g., 27.34±0.2), about 28.95 (e.g., 28.95±0.2), about 29.55 (e.g., 29.55±0.2), about30.01 (e.g., 30.01±0.2), about 30.94 (e.g., 30.94±0.2), and about 32.10 (e.g., 32.10±0.2). Insome embodiments, Maleate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.62 (e.g., 5.62±0.2), about 9.69 (e.g., 9.69±0.2), about 10.31 (e.g., 10.31±0.2), about 10.57 (e.g., 10.57±0.2), about 11.64 (e.g., 11.64±0.2), about 12.09 (e.g., 12.09±0.2), about14.00 (e.g., 14.00±0.2), about 14.62 (e.g., 14.62±0.2), about 15.45 (e.g., 15.45±0.2), about16.22 (e.g., 16.22±0.2), about 16.68 (e.g., 16.68±0.2), about 17.29 (e.g., 17.29±0.2), about17.74 (e.g., 17.74±0.2), about 18.36 (e.g., 18.36±0.2), about 18.81 (e.g., 18.81±0.2), about19.43 (e.g., 19.43±0.2), about 20.21 (e.g., 20.21±0.2), about 20.70 (e.g., 20.70±0.2), about21.30 (e.g., 21.30±0.2), about 22.39 (e.g., 22.39±0.2), about 23.16 (e.g., 23.16±0.2), about24.00 (e.g., 24.00±0.2), about 24.26 (e.g., 24.26±0.2), about 24.72 (e.g., 24.72±0.2), about25.17 (e.g., 25.17±0.2), about 26.22 (e.g., 26.22±0.2), about 27.34 (e.g., 27.34±0.2), about28.95 (e.g., 28.95±0.2), about 29.55 (e.g., 29.55±0.2), about 30.01 (e.g., 30.01±0.2), about30.94 (e.g., 30.94±0.2), and about 32.10 (e.g., 32.10±0.2). In some embodiments, Maleate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 9.69 (e.g., 9.69±0.2), about 10.31 (e.g., 10.31±0.2), about 11.64 (e.g., 11.64±0.2), about 12.09 (e.g., 12.09±0.2), about 17.29 (e.g., 17.29±0.2), about 17.74 (e.g., 17.74±0.2), about 18.36 (e.g., 18.36±0.2), about 18.81 (e.g., 18.81±0.2), about 19.43 (e.g., 19.43±0.2), about 20.21 (e.g., 20.21±0.2), about 22.39 (e.g., 22.39±0.2), about 24.00 (e.g., 24.00±0.2), about 24.26 (e.g., 24.26±0.2), about 24.72 (e.g., 24.72±0.2), and about 25.17 (e.g.,25.17±0.2). In some embodiments, Maleate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 9.69 (e.g., 9.69±0.2), about 10.31 (e.g., 10.31±0.2), about 11.64 (e.g., 11.64±0.2), about 12.09 (e.g., 12.09±0.2), about 17.29 (e.g., 17.29±0.2), about 17.74 (e.g.,17.74±0.2), about 18.36 (e.g., 18.36±0.2), about 18.81 (e.g., 18.81±0.2), about 19.43 (e.g.,19.43±0.2), about 20.21 (e.g., 20.21±0.2), about 22.39 (e.g., 22.39±0.2), about 24.00 (e.g.,24.00±0.2), about 24.26 (e.g., 24.26±0.2), about 24.72 (e.g., 24.72±0.2), and about 25.17(e.g., 25.17±0.2). In some embodiments, Maleate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 9.69 (e.g., 9.69±0.2), about 10.31 (e.g., 10.31±0.2), about 11.64 (e.g., 11.64±0.2), about 12.09 (e.g., 12.09±0.2), about 17.74 (e.g., 17.74±0.2), about 18.36 (e.g., 18.36±0.2), about 18.81 (e.g., 18.81±0.2), and about 20.21 (e.g., 20.21±0.2). In some embodiments, Maleate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at leastfive, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 9.69 (e.g., 9.69±0.2), about 10.31 (e.g., 10.31±0.2), about 11.64 (e.g., 11.64±0.2), about 12.09 (e.g., 12.09±0.2), about 17.74 (e.g., 17.74±0.2), about 18.36 (e.g., 18.36±0.2), about 18.81 (e.g., 18.81±0.2), and about 20.21 (e.g., 20.21±0.2). In some embodiments, Maleate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 9.69, about 11.64, and about 17.74. In some embodiments, Maleate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 9.69±0.2, 11.64±0.2 and 17.74±0.2. In some embodiments, Maleate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 11.64, and about 17.74. In some embodiments, Maleate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 11.64±0.2 and 17.74±0.2. In some embodiments, Maleate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 17.74. In some embodiments, Maleate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 17.74±0.2.

[0227] In some embodiments, Maleate Form I is characterized as having a TGA thermogram substantially as shown in FIG. 19B. In some embodiments, Maleate Form I is characterized as having an initial mass loss of about 0.9 % after heating from about 25.0 °C to about 150.0 °C, as determined by TGA. In some embodiments, Maleate Form I is characterized as having a further mass loss of about 8.1 % after heating from about 150.0 °C to about 250 °C, as determined by TGA. In some embodiments, Maleate Form I is characterized as having an initial mass loss of 0.8 % after heating from about 25.0 °C to about 137.5 °C and a further mass loss of 12.6 % after heating from about 135.9 °C to about 271.2 °C.

[0228] In some embodiments, Maleate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 19B. In some embodiments, Maleate Form I is characterized as having an endothermic / exothermic event with onsets / peaks of 185.5 °C / 200.5 °C and 202.7 °C / 207.1 °C. In some embodiments, Maleate Form I is characterized as having an endothermic / exothermic event with onsets / peaks of 221.8 °C / 233.3 °C and 233.6 °C / 237.0 °C. In some embodiments, Maleate Form I is characterized as having an endothermic event with an onset of 199.6 °C and a peak at 202.8 °C.

[0229] In some embodiments, Maleate Form I is characterized as having a DSC thermogram (a) on first heating and / or (b) on first cooling, substantially as shown in FIG. 19C. In some embodiments, Maleate Form I is characterized as having no thermal events on heating to 200 °C and / or an exothermic event with an onset of 192.3 °C and a peak of 166.6 °C. In some embodiments, Maleate Form I is characterized as having a slight dip in the heat flow on heating to 200 °C.

[0230] In some embodiments, Maleate Form I is characterized as having a) a DVS isotherm pattern and (b) a DVS kinetic pattern for Maleate Form I substantially as shown in FIG. 19D

[0231] In some embodiments of Maleate Form I, at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or all of the following (a)-(h) apply: a. Maleate Form I has an XRPD pattern substantially as shown in FIG. 19A; b. Maleate Form I has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 11; and c. Maleate Form I has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 9.69±0.2, 11 ,64±0.2 and 17.74±0.2, ii. peaks at an angle 2-theta in degrees of about 9.69 (e.g., 9.69±0.2), about 10.31 (e.g., 10.31±0.2), about 11.64 (e.g., 11.64±0.2), about 12.09 (e.g., 12.09±0.2), about 17.74 (e.g., 17.74±0.2), about 18.36 (e.g., 18.36±0.2), about 18.81 (e.g., 18.81±0.2), and about 20.21 (e.g., 20.21±0.2), iii. peaks at an angle 2-theta in degrees of about 9.69 (e.g., 9.69±0.2), about 10.31 (e.g., 10.31±0.2), about 11.64 (e.g., 11.64±0.2), about 12.09 (e.g., 12.09±0.2), about 17.29 (e.g., 17.29±0.2), about 17.74 (e.g., 17.74±0.2), about 18.36 (e.g., 18.36±0.2), about 18.81 (e.g., 18.81±0.2), about 19.43 (e.g., 19.43±0.2), about 20.21 (e.g., 20.21±0.2), about 22.39 (e.g., 22.39±0.2), about 24.00 (e.g., 24.00±0.2), about 24.26 (e.g., 24.26±0.2), about 24.72 (e.g., 24.72±0.2), and about 25.17 (e.g., 25.17±0.2), or iv. peaks at an angle 2-theta in degrees of about 5.62 (e.g., 5.62±0.2), about 9.69 (e.g., 9.69±0.2), about 10.31 (e.g., 10.31±0.2), about 10.57 (e.g., 10.57±0.2), about 11.64 (e.g., 11.64±0.2), about 12.09 (e.g., 12.09±0.2), about 14.00 (e.g., 14.00±0.2), about 14.62 (e.g., 14.62±0.2), about 15.45 (e.g., 15.45±0.2), about16.22 (e.g., 16.22±0.2), about 16.68 (e.g., 16.68±0.2), about 17.29 (e.g., 17.29±0.2), about 17.74 (e.g., 17.74±0.2), about 18.36 (e.g., 18.36±0.2), about 18.81 (e.g., 18.81±0.2), about 19.43 (e.g., 19.43±0.2), about 20.21 (e.g., 20.21±0.2), about 20.70 (e.g., 20.70±0.2), about 21.30 (e.g., 21.30±0.2), about 22.39 (e.g., 22.39±0.2), about 23.16 (e.g., 23.16±0.2), about 24.00 (e.g., 24.00±0.2), about 24.26 (e.g., 24.26±0.2), about 24.72 (e.g., 24.72±0.2), about 25.17 (e.g., 25.17±0.2), about 26.22 (e.g., 26.22±0.2), about 27.34 (e.g., 27.34±0.2), about 28.95 (e.g., 28.95±0.2), about 29.55 (e.g., 29.55±0.2), about 30.01 (e.g., 30.01±0.2), about 30.94 (e.g., 30.94±0.2), and about 32.10 (e.g., 32.10±0.2); d. Maleate Form I has a TGA thermogram substantially as shown in FIG. 19B; e. Maleate Form I is characterized as having a mass loss of about 0.9 % after heating from about 25.0 °C to about 150.0 °C, about 8.1 % after heating from about 150.0 °C to about 250 °C, or 0.8 % after heating from about 25.0 °C to about 137.5 °C and a further mass loss of 12.6 % after heating from about 135.9 °C to about 271.2 °C, as determined by TGA; f. Maleate Form I has a DSC thermogram substantially as shown in FIG. 19B, or FIG. 19C; g. Maleate Form I is characterized as having an endothermic / exothermic event with onsets / peaks of 185.5 °C / 200.5 °C and 202.7 °C / 207.1 °C, an endothermic / exothermic event with onsets / peaks of 221.8 °C / 233.3 °C and 233.6 °C / 237.0 °C, or an endothermic event with an onset of 199.6 °C and a peak at 202.8 °C; and h. Maleate Form I is characterized as having (a) a DVS isotherm pattern and (b) a DVS kinetic pattern substantially as shown in FIG. 19D.Maleate Form II

[0232] In some embodiments, the crystalline form of the maleate salt of Compound A is Maleate Form II. In some embodiments, Maleate Form II is a hemi maleate salt.

[0233] In some embodiments, Maleate Form II has an XRPD pattern substantially as shown in FIG. 20A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 12.Table 12.

[0234] In some embodiments, Maleate Form II has an XRPD pattern comprising peaks provided in Table 12. In some embodiments, Maleate Form II has an XRPD patterncomprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 20A, or as provided in Table 12.

[0235] In some embodiments, Maleate Form II has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 12, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Maleate Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.07 (e.g., 5.07±0.2), about 5.26 (e.g., 5.26±0.2), about 6.97 (e.g., 6.97±0.2), about 10.08 (e.g., 10.08±0.2), about 10.61 (e.g., 10.61±0.2), about 11.55 (e.g., 11.55±0.2), about 12.87 (e.g., 12.87±0.2), about 13.78 (e.g., 13.78±0.2), about 14.62(e.g., 14.62±0.2), about 15.80 (e.g., 15.80±0.2), about 16.52 (e.g., 16.52±0.2), about 17.44(e.g., 17.44±0.2), about 18.46 (e.g., 18.46±0.2), about 19.64 (e.g., 19.64±0.2), about 20.66(e.g., 20.66±0.2), about 21.19 (e.g., 21.19±0.2), about 23.13 (e.g., 23.13±0.2), about 23.74(e.g., 23.74±0.2), about 24.88 (e.g., 24.88±0.2), about 25.48 (e.g., 25.48±0.2), about 27.86(e.g., 27.86±0.2), about 28.35 (e.g., 28.35±0.2), about 29.77 (e.g., 29.77±0.2), and about 31.18 (e.g., 31.18±0.2). In some embodiments, Maleate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.07 (e.g., 5.07±0.2), about 5.26 (e.g., 5.26±0.2), about 6.97 (e.g., 6.97±0.2), about 10.08 (e.g., 10.08±0.2), about 10.61 (e.g., 10.61±0.2), about 11.55 (e.g., 11.55±0.2), about 12.87 (e.g., 12.87±0.2), about 13.78 (e.g., 13.78±0.2), about14.62 (e.g., 14.62±0.2), about 15.80 (e.g., 15.80±0.2), about 16.52 (e.g., 16.52±0.2), about17.44 (e.g., 17.44±0.2), about 18.46 (e.g., 18.46±0.2), about 19.64 (e.g., 19.64±0.2), about20.66 (e.g., 20.66±0.2), about 21.19 (e.g., 21.19±0.2), about 23.13 (e.g., 23.13±0.2), about23.74 (e.g., 23.74±0.2), about 24.88 (e.g., 24.88±0.2), about 25.48 (e.g., 25.48±0.2), about27.86 (e.g., 27.86±0.2), about 28.35 (e.g., 28.35±0.2), about 29.77 (e.g., 29.77±0.2), and about 31.18 (e.g., 31.18±0.2). For example, Maleate Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.07 (e.g., 5.07±0.2), about 5.26 (e.g., 5.26±0.2), about 6.97 (e.g., 6.97±0.2), about 11.55 (e.g., 11.55±0.2), about 16.52 (e.g., 16.52±0.2), about 17.44 (e.g., 17.44±0.2), about 19.64 (e.g., 19.64±0.2), about20.66 (e.g., 20.66±0.2), about 21.19 (e.g., 21.19±0.2), about 23.13 (e.g., 23.13±0.2), about23.74 (e.g., 23.74±0.2), about 24.88 (e.g., 24.88±0.2), about 27.86 (e.g., 27.86±0.2), andabout 28.35 (e.g., 28.35±0.2). In some embodiments, Maleate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.07 (e.g., 5.07±0.2), about 5.26 (e.g., 5.26±0.2), about 6.97 (e.g., 6.97±0.2), about 11.55 (e.g., 11.55±0.2), about 16.52 (e.g., 16.52±0.2), about 17.44 (e.g., 17.44±0.2), about 19.64 (e.g., 19.64±0.2), about 20.66 (e.g., 20.66±0.2), about 21.19 (e.g., 21.19±0.2), about 23.13 (e.g., 23.13±0.2), about 23.74 (e.g., 23.74±0.2), about 24.88 (e.g., 24.88±0.2), about 27.86 (e.g., 27.86±0.2), and about 28.35 (e.g., 28.35±0.2). For example, Maleate Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.07 (e.g., 5.07±0.2), about 5.26 (e.g., 5.26±0.2), about 16.52 (e.g., 16.52±0.2), about 19.64 (e.g., 19.64±0.2), about 23.74 (e.g., 23.74±0.2), and about 28.35 (e.g., 28.35±0.2). In some embodiments, Maleate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.07 (e.g., 5.07±0.2), about 5.26 (e.g., 5.26±0.2), about 16.52 (e.g., 16.52±0.2), about 19.64 (e.g., 19.64±0.2), about 23.74 (e.g., 23.74±0.2), and about 28.35 (e.g., 28.35±0.2). In some embodiments, Maleate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.07, about 5.26, and about 23.74. In some embodiments, Maleate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 5.07±0.2, 5.26±0.2 and 23.74±0.2. In some embodiments, Maleate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.07, and about 5.26. In some embodiments, Maleate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 5.26±0.2. In some embodiments, Maleate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.07, and about 5.26. In some embodiments, Maleate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 5.26±0.2.

[0236] In some embodiments, Maleate Form II is characterized as having a TGA thermogram substantially as shown in FIG. 20B. In some embodiments, Maleate Form II is characterized as having a mass loss of about 4.3 % after heating from about 25.0 °C to about 91.7 °C, as determined by TGA.

[0237] In some embodiments, Maleate Form II is characterized as having a DSC thermogram substantially as shown in FIG. 20B. In some embodiments, Maleate Form II is characterized as having no thermal events at temperature selected from a range of about 25 °C to 400 °C.

[0238] In some embodiments of Maleate Form II, at least one, at least two, at least three, at least four, at least five, or all of the following (a)-(f) apply: a. Maleate Form II has an XRPD pattern substantially as shown in FIG. 20A; b. Maleate Form II has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 12; and c. Maleate Form II has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 5.07±0.2, 5.26±0.2 and 23.74±0.2, ii. peaks at an angle 2-theta in degrees of about 5.07 (e.g., 5.07±0.2), about 5.26 (e.g., 5.26±0.2), about 16.52 (e.g., 16.52±0.2), about 19.64 (e.g., 19.64±0.2), about 23.74 (e.g., 23.74±0.2), and about 28.35 (e.g., 28.35±0.2), iii. peaks at an angle 2-theta in degrees of about 5.07 (e.g., 5.07±0.2), about 5.26 (e.g., 5.26±0.2), about 6.97 (e.g., 6.97±0.2), about 11.55 (e.g., 11.55±0.2), about 16.52 (e.g., 16.52±0.2), about 17.44 (e.g., 17.44±0.2), about 19.64 (e.g., 19.64±0.2), about 20.66 (e.g., 20.66±0.2), about 21.19 (e.g., 21.19±0.2), about 23.13 (e.g., 23.13±0.2), about 23.74 (e.g., 23.74±0.2), about 24.88 (e.g., 24.88±0.2), about 27.86 (e.g., 27.86±0.2), and about 28.35 (e.g., 28.35±0.2), or iv. peaks at an angle 2-theta in degrees of about 5.07 (e.g., 5.07±0.2), about 5.26 (e.g., 5.26±0.2), about 6.97 (e.g., 6.97±0.2), about 10.08 (e.g., 10.08±0.2), about 10.61 (e.g., 10.61±0.2), about 11.55 (e.g., 11.55±0.2), about 12.87 (e.g., 12.87±0.2), about 13.78 (e.g., 13.78±0.2), about 14.62 (e.g., 14.62±0.2), about 15.80 (e.g., 15.80±0.2), about 16.52 (e.g., 16.52±0.2), about 17.44 (e.g., 17.44±0.2), about 18.46 (e.g., 18.46±0.2), about 19.64 (e.g., 19.64±0.2), about 20.66 (e.g., 20.66±0.2), about 21.19 (e.g., 21.19±0.2), about 23.13 (e.g., 23.13±0.2), about 23.74 (e.g., 23.74±0.2), about 24.88 (e.g., 24.88±0.2), about 25.48 (e.g., 25.48±0.2), about 27.86 (e.g., 27.86±0.2), about 28.35 (e.g., 28.35±0.2), about 29.77 (e.g., 29.77±0.2), and about 31.18 (e.g., 31.18±0.2)d. Maleate Form II has a TGA thermogram substantially as shown in FIG. 20B; e. Maleate Form II is characterized as having a mass loss of about 4.3 % after heating from about 25.0 °C to about 91.7 °C, as determined by TGA; and f. Maleate Form II has a DSC thermogram substantially as shown in FIG. 20B.Esylate Forms

[0239] In some embodiments, the crystalline form is a crystalline form of an esylate salt. In some embodiments, the esylate salt of Compound A is a mono esylate salt. In some embodiments, the crystalline form of the esylate salt of Compound A is Esylate Form I, or Esylate Form II.Esylate Form I

[0240] In some embodiments, the crystalline form of the esylate salt of Compound A is Esylate Form I. In some embodiments, Esylate Form l is a mono esylate salt.

[0241] In some embodiments, Esylate Form I has an XRPD pattern substantially as shown in FIG. 21A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 13.Table 13.

[0242] In some embodiments, Esylate Form I has an XRPD pattern comprising peaks provided in Table 13. In some embodiments, Esylate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 21A, or as provided in Table 13.

[0243] In some embodiments, Esylate Form I has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 13, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Esylate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.36 (e.g., 4.36±0.2), about 13.20 (e.g., 13.20±0.2), about 14.02 (e.g., 14.02±0.2), about 15.34 (e.g., 15.34±0.2), about 16.16 (e.g., 16.16±0.2), about 17.50 (e.g., 17.50±0.2), about 18.23 (e.g., 18.23±0.2), about 20.79 (e.g., 20.79±0.2), about 22.10 (e.g., 22.10±0.2), and about 25.59 (e.g., 25.59±0.2). In some embodiments, Esylate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.36 (e.g., 4.36±0.2), about 13.20 (e.g., 13.20±0.2), about 14.02 (e.g., 14.02±0.2), about 15.34 (e.g., 15.34±0.2), about 16.16 (e.g., 16.16±0.2), about 17.50 (e.g., 17.50±0.2), about 18.23 (e.g., 18.23±0.2), about 20.79 (e.g., 20.79±0.2), about 22.10 (e.g., 22.10±0.2), and about 25.59 (e.g., 25.59±0.2). For example, Esylate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.36 (e.g., 4.36±0.2), about 15.34 (e.g., 15.34±0.2), about 16.16 (e.g., 16.16±0.2), about 17.50 (e.g., 17.50±0.2), about 18.23 (e.g., 18.23±0.2). In some embodiments, Esylate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.36 (e.g., 4.36±0.2), about 15.34 (e.g., 15.34±0.2), about 16.16 (e.g., 16.16±0.2), about 17.50 (e.g., 17.50±0.2), about 18.23 (e.g., 18.23±0.2). In some embodiments, Esylate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.36, about 15.34, and about 18.23. In some embodiments, Esylate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.36±0.2, 15.34±0.2 and 18.23±0.2. In some embodiments, Esylate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about4.36, and about 15.34. In some embodiments, Esylate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.36±0.2 andl5.34±0.2. In some embodiments, Esylate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.36. In some embodiments, Esylate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.36±0.2.

[0244] In some embodiments, Esylate Form I is characterized as having a TGA thermogram substantially as shown in FIG. 20B. In some embodiments, Esylate Form I is characterized as having a mass loss of about 3.4 % after heating from about 25.0 °C to about 125.0 °C, as determined by TGA. In some embodiments, Esylate Form I is characterized as having a further mass loss of about 2.5 % after heating from about 156.3 °C to about 256.3 °C, as determined by TGA.

[0245] In some embodiments, Esylate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 20B. In some embodiments, Esylate Form I is characterized as having an endothermic event with an onset at about 204.7 °C. In some embodiments, Esylate Form I is characterized as having an endotherm peak at about 213.4 °C. In some embodiments, Esylate Form I is characterized as having an endotherm peak at about 223.2 °C.Esylate Form II

[0246] In some embodiments, the crystalline form of the esylate salt of Compound A is Esylate Form II. In some embodiments, Esylate Form II is a mono esylate salt.

[0247] In some embodiments, Esylate Form II has an XRPD pattern substantially as shown in FIG. 21A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 14.Table 14.

[0248] In some embodiments, Esylate Form II has an XRPD pattern comprising peaks provided in Table 14. In some embodiments, Esylate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 21A, or as provided in Table 14.

[0249] In some embodiments, Esylate Form II has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 14, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Esylate Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.13 (e.g., 4.13±0.2), about 8.24 (e.g., 8.24±0.2), about12.59 (e.g., 12.59±0.2), about 13.45 (e.g., 13.45±0.2), about 14.69 (e.g., 14.69±0.2), about15.56 (e.g., 15.56±0.2), about 16.77 (e.g., 16.77±0.2), about 17.36 (e.g., 17.36±0.2), about18.08 (e.g., 18.08±0.2), about 18.45 (e.g., 18.45±0.2), about 18.72 (e.g., 18.72±0.2), about20.15 (e.g., 20.15±0.2), about 21.39 (e.g., 21.39±0.2), about 23.52 (e.g., 23.52±0.2), about24.90 (e.g., 24.90±0.2), about 25.45 (e.g., 25.45±0.2), about 26.40 (e.g., 26.40±0.2), about26.90 (e.g., 26.90±0.2), about 28.03 (e.g., 28.03±0.2), and about 29.29 (e.g., 29.29±0.2). In some embodiments, Esylate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.13 (e.g., 4.13±0.2), about 8.24 (e.g., 8.24±0.2), about 12.59 (e.g., 12.59±0.2), about13.45 (e.g., 13.45±0.2), about 14.69 (e.g., 14.69±0.2), about 15.56 (e.g., 15.56±0.2), about16.77 (e.g., 16.77±0.2), about 17.36 (e.g., 17.36±0.2), about 18.08 (e.g., 18.08±0.2), about18.45 (e.g., 18.45±0.2), about 18.72 (e.g., 18.72±0.2), about 20.15 (e.g., 20.15±0.2), about21.39 (e.g., 21.39±0.2), about 23.52 (e.g., 23.52±0.2), about 24.90 (e.g., 24.90±0.2), about25.45 (e.g., 25.45±0.2), about 26.40 (e.g., 26.40±0.2), about 26.90 (e.g., 26.90±0.2), about28.03 (e.g., 28.03±0.2), and about 29.29 (e.g., 29.29±0.2). For example, Esylate Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.13 (e.g., 4.13±0.2), about 15.56 (e.g., 15.56±0.2), about 16.77 (e.g., 16.77±0.2), about 17.36 (e.g., 17.36±0.2), about 18.08 (e.g., 18.08±0.2), about 18.45 (e.g., 18.45±0.2), about 18.72 (e.g., 18.72±0.2), about 21.39 (e.g., 21.39±0.2), about 23.52 (e.g., 23.52±0.2), and about 24.90 (e.g., 24.90±0.2). In some embodiments, Esylate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.13 (e.g., 4.13±0.2), about 15.56 (e.g., 15.56±0.2), about 16.77 (e.g., 16.77±0.2), about 17.36 (e.g., 17.36±0.2), about 18.08 (e.g., 18.08±0.2), about 18.45 (e.g., 18.45±0.2), about 18.72 (e.g., 18.72±0.2), about 21.39 (e.g., 21.39±0.2), about 23.52 (e.g., 23.52±0.2), and about 24.90 (e.g., 24.90±0.2). For example, Esylate Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.13 (e.g., 4.13±0.2), about 15.56 (e.g., 15.56±0.2), about 16.77 (e.g., 16.77±0.2), and about 17.36 (e.g., 17.36±0.2). In some embodiments, Esylate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of 4.13 (e.g., 4.13±0.2), about 15.56 (e.g., 15.56±0.2), about 16.77 (e.g., 16.77±0.2), and about 17.36 (e.g., 17.36±0.2). In some embodiments, Esylate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 15.56, about 16.77, and about 17.36. In some embodiments, Esylate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about15.56±0.2, 16.77±0.2 and 17.36±0.2. In some embodiments, Esylate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 15.56, and about 17.36. In some embodiments, Esylate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 15.56±0.2 and 17.36±0.2. In some embodiments, Esylate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 15.56. In some embodiments, Esylate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 15.56±0.2.

[0250] In some embodiments, Esylate Form II is characterized as having a TGA thermogram substantially as shown in FIG. 21B. In some embodiments, Esylate Form II is characterized as having a mass loss of about 3.5 % after heating from about 25.0 °C to about 100.0 °C, as determined by TGA.

[0251] In some embodiments, Esylate Form II is characterized as having a DSC thermogram substantially as shown in FIG. 21B. In some embodiments, Esylate Form II is characterized as having an exothermic event with an onset at about 171.8 °C. In some embodiments, Esylate Form II is characterized as having an exotherm peak at about 183.6 °C. In some embodiments, Esylate Form II is characterized as having an exothermic event with an onset at about 199.8 °C. In some embodiments, Esylate Form II is characterized as having an exotherm peak at about 213.2 °C.

[0252] In some embodiments of Esylate Form II, at least one, at least two, at least three, at least four, at least five, at least six, or all of the following (a)-(g) apply: a. Esylate Form II has an XRPD pattern substantially as shown in FIG. 21A; b. Esylate Form II has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 13; and c. Esylate Form II has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 15.56±0.2, 16.77±0.2 and 17.36±0.2, ii. peaks at an angle 2-theta in degrees of about about 4.13 (e.g., 4.13±0.2), about 15.56 (e.g., 15.56±0.2), about 16.77 (e.g., 16.77±0.2), and about 17.36 (e.g., 17.36±0.2), iii. peaks at an angle 2-theta in degrees of about 4.13 (e.g., 4.13±0.2), about 15.56 (e.g., 15.56±0.2), about 16.77 (e.g., 16.77±0.2), about 17.36 (e.g., 17.36±0.2),about 18.08 (e.g., 18.08±0.2), about 18.45 (e.g., 18.45±0.2), about 18.72 (e.g., 18.72±0.2), about 21.39 (e.g., 21.39±0.2), about 23.52 (e.g., 23.52±0.2), and about 24.90 (e.g., 24.90±0.2), or iv. peaks at an angle 2-theta in degrees of about 4.13 (e.g., 4.13±0.2), about 8.24 (e.g., 8.24±0.2), about 12.59 (e.g., 12.59±0.2), about 13.45 (e.g., 13.45±0.2), about 14.69 (e.g., 14.69±0.2), about 15.56 (e.g., 15.56±0.2), about 16.77 (e.g., 16.77±0.2), about 17.36 (e.g., 17.36±0.2), about 18.08 (e.g., 18.08±0.2), about 18.45 (e.g., 18.45±0.2), about 18.72 (e.g., 18.72±0.2), about 20.15 (e.g., 20.15±0.2), about 21.39 (e.g., 21.39±0.2), about 23.52 (e.g., 23.52±0.2), about 24.90 (e.g., 24.90±0.2), about 25.45 (e.g., 25.45±0.2), about 26.40 (e.g., 26.40±0.2), about 26.90 (e.g., 26.90±0.2), about 28.03 (e.g., 28.03±0.2), and about 29.29 (e.g., 29.29±0.2); d. Maleate Form II has a TGA thermogram substantially as shown in FIG. 21B; e. Maleate Form II is characterized as having a mass loss of about 3.5 % after heating from about 25.0 °C to about 100.0 °C, as determined by TGA; and f. Maleate Form II has a DSC thermogram substantially as shown in FIG. 21B; and g. Maleate Form II is characterized as having an exothermic event with an onset at about 171.8 °C and an exotherm peak at about 183.6 °C, or an exothermic event with an onset at about 199.8 °C and an exotherm peak at about 213.2 °C.Mai onate Forms

[0253] In some embodiments, the crystalline form is a crystalline form of an esylate salt. In some embodiments, the malonate salt of Compound A is a mono malonate salt. In some embodiments, the crystalline form of the malonate salt of Compound A is Malonate Form I, or Malonate Form II.Malonate Form I

[0254] In some embodiments, the crystalline form of the esylate salt of Compound A is Malonate Form I. In some embodiments, Malonate Form I is a mono malonate salt.

[0255] In some embodiments, Malonate Form I has an XRPD pattern substantially as shown in FIG. 23A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 15.Table 15.

[0256] In some embodiments, Malonate Form I has an XRPD pattern comprising peaks provided in Table 15. In some embodiments, Malonate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks atangles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 23 A, or as provided in Table 15.

[0257] In some embodiments, Malonate Form I has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 15, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Malonate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.79 (e.g., 5.79±0.2), about 9.72 (e.g., 9.72±0.2), about 10.34 (e.g., 10.34±0.2), about 11.82 (e.g., 11.82±0.2), about 12.22 (e.g., 12.22±0.2), about14.55 (e.g., 14.55±0.2), about 17.28 (e.g., 17.28±0.2), about 17.65 (e.g., 17.65±0.2), about18.42 (e.g., 18.42±0.2), about 18.87 (e.g., 18.87±0.2), about 19.56 (e.g., 19.56±0.2), about20.47 (e.g., 20.47±0.2), about 22.59 (e.g., 22.59±0.2), about 23.85 (e.g., 23.85±0.2), about24.99 (e.g., 24.99±0.2), about 25.49 (e.g., 25.49±0.2), about 26.62 (e.g., 26.62±0.2), about27.88 (e.g., 27.88±0.2), about 29.07 (e.g., 29.07±0.2), about 30.22 (e.g., 30.22±0.2), about31.19 (e.g., 31.19±0.2), and about 32.60 (e.g., 32.60±0.2). In some embodiments, Malonate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.79 (e.g., 5.79±0.2), about 9.72 (e.g., 9.72±0.2), about 10.34 (e.g., 10.34±0.2), about 11.82 (e.g., 11.82±0.2), about 12.22 (e.g., 12.22±0.2), about 14.55 (e.g., 14.55±0.2), about 17.28 (e.g., 17.28±0.2), about 17.65 (e.g., 17.65±0.2), about 18.42 (e.g., 18.42±0.2), about 18.87 (e.g., 18.87±0.2), about 19.56 (e.g., 19.56±0.2), about 20.47 (e.g., 20.47±0.2), about 22.59 (e.g., 22.59±0.2), about 23.85 (e.g., 23.85±0.2), about 24.99 (e.g., 24.99±0.2), about 25.49 (e.g., 25.49±0.2), about 26.62 (e.g., 26.62±0.2), about 27.88 (e.g., 27.88±0.2), about 29.07 (e.g., 29.07±0.2), about 30.22 (e.g., 30.22±0.2), about 31.19 (e.g., 31.19±0.2), and about 32.60 (e.g., 32.60±0.2). For example, Malonate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 9.72 (e.g., 9.72±0.2), about 10.34 (e.g., 10.34±0.2), about 11.82 (e.g., 11.82±0.2), about 12.22 (e.g., 12.22±0.2), about 17.28 (e.g., 17.28±0.2), about 17.65 (e.g., 17.65±0.2), about 18.42 (e.g., 18.42±0.2), about 18.87 (e.g., 18.87±0.2), about 20.47 (e.g., 20.47±0.2), and about 24.99 (e.g., 24.99±0.2). In some embodiments, Malonate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 9.72 (e.g., 9.72±0.2), about 10.34 (e.g., 10.34±0.2), about 11.82 (e.g., 11.82±0.2), about12.22 (e.g., 12.22±0.2), about 17.28 (e.g., 17.28±0.2), about 17.65 (e.g., 17.65±0.2), about 18.42 (e.g., 18.42±0.2), about 18.87 (e.g., 18.87±0.2), about 20.47 (e.g., 20.47±0.2), and about 24.99 (e.g., 24.99±0.2). For example, Malonate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 11.82 (e.g., 11.82±0.2), about 17.28 (e.g., 17.28±0.2), about 17.65 (e.g., 17.65±0.2), about 18.42 (e.g., 18.42±0.2), and about 20.47 (e.g., 20.47±0.2). In some embodiments, Malonate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 11.82 (e.g., 11.82±0.2), about 17.28 (e.g., 17.28±0.2), about 17.65 (e.g., 17.65±0.2), about 18.42 (e.g., 18.42±0.2), and about 20.47 (e.g., 20.47±0.2). In some embodiments, Malonate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 11.82, about 17.65, and about 18.42. In some embodiments, Malonate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 11.82±0.2, 17.65±0.2 and 18.42±0.2. In some embodiments, Malonate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 17.65, and about 18.42. In some embodiments, Malonate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 17.65±0.2 and 18.42±0.2. In some embodiments, Malonate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 17.65. In some embodiments, Malonate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 17.65±0.2.

[0258] In some embodiments, Malonate Form I is characterized as having a TGA thermogram substantially as shown in FIG. 23B. In some embodiments, Malonate Form I is characterized as having a mass loss of about 0.9 % after heating from about 33.3 °C to about 62.5 °C, as determined by TGA. In some embodiments, Malonate Form I is characterized as having a further mass loss of about 8.5 % after heating from about 100.0 °C to about 225.0 °C, as determined by TGA.

[0259] In some embodiments, Malonate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 23B. In some embodiments, Malonate Form I is characterized as having no thermal events at a temperature selected from the range of about 25.0 °C to about 400.0 °C.

[0260] In some embodiments of Malonate Form I, at least one, at least two, at least three, at least four, at least five, or all of the following (a)-(f) apply: a. Malonate Form I has an XRPD pattern substantially as shown in FIG. 23A; b. Malonate Form I has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 15; and c. Malonate Form I has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 11.82±0.2, 17.65±0.2 and 18.42±0.2, ii. peaks at an angle 2-theta in degrees of about about 11.82 (e.g., 11.82±0.2), about 17.28 (e.g., 17.28±0.2), about 17.65 (e.g., 17.65±0.2), about 18.42 (e.g., 18.42±0.2), and about 20.47 (e.g., 20.47±0.2), iii. peaks at an angle 2-theta in degrees of 9.72 (e.g., 9.72±0.2), about 10.34 (e.g., 10.34±0.2), about 11.82 (e.g., 11.82±0.2), about 12.22 (e.g., 12.22±0.2), about 17.28 (e.g., 17.28±0.2), about 17.65 (e.g., 17.65±0.2), about 18.42 (e.g., 18.42±0.2), about 18.87 (e.g., 18.87±0.2), about 20.47 (e.g., 20.47±0.2), and about 24.99 (e.g., 24.99±0.2), or iv. peaks at an angle 2-theta in degrees of about 5.79 (e.g., 5.79±0.2), about 9.72 (e.g., 9.72±0.2), about 10.34 (e.g., 10.34±0.2), about 11.82 (e.g., 11.82±0.2), about 12.22 (e.g., 12.22±0.2), about 14.55 (e.g., 14.55±0.2), about 17.28 (e.g., 17.28±0.2), about 17.65 (e.g., 17.65±0.2), about 18.42 (e.g., 18.42±0.2), about 18.87 (e.g., 18.87±0.2), about 19.56 (e.g., 19.56±0.2), about 20.47 (e.g., 20.47±0.2), about 22.59 (e.g., 22.59±0.2), about 23.85 (e.g., 23.85±0.2), about 24.99 (e.g., 24.99±0.2), about 25.49 (e.g., 25.49±0.2), about 26.62 (e.g., 26.62±0.2), about 27.88 (e.g., 27.88±0.2), about 29.07 (e.g., 29.07±0.2), about 30.22 (e.g., 30.22±0.2), about 31.19 (e.g., 31.19±0.2), and about 32.60 (e.g., 32.60±0.2); d. Malonate Form I has a TGA thermogram substantially as shown in FIG. 23B; e. Malonate Form I is characterized as having a mass loss of about 0.9 % after heating from about 33.3 °C to about 62.5 °C and a further mass loss of about 8.5 % after heating from about 100.0 °C to about 225.0 °C, as determined by TGA; and f. Malonate Form I has a DSC thermogram substantially as shown in FIG. 23B.Malonate Form II

[0261] In some embodiments, the crystalline form of the malonate salt of Compound A is Malonate Form II. In some embodiments, Malonate Form II is a mono malonate salt.

[0262] In some embodiments, Malonate Form II has an XRPD pattern substantially as shown in FIG. 24A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 16.Table 16.

[0263] In some embodiments, Malonate Form II has an XRPD pattern comprising peaks provided in Table 16. In some embodiments, Malonate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 24A, or as provided in Table 16.

[0264] In some embodiments, Malonate Form II has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 16, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Malonate Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 3.25 (e.g., 3.25±0.2), about 5.58 (e.g., 5.58±0.2), about 10.89 (e.g., 10.89±0.2), about 12.20 (e.g., 12.20±0.2), about 14.70 (e.g., 14.70±0.2), about15.60 (e.g., 15.60±0.2), about 17.55 (e.g., 17.55±0.2), about 18.15 (e.g., 18.15±0.2), about20.63 (e.g., 20.63±0.2), about 22.16 (e.g., 22.16±0.2), about 24.50 (e.g., 24.50±0.2), about26.33 (e.g., 26.33±0.2), about 28.72 (e.g., 28.72±0.2), and about 29.30 (e.g., 29.30±0.2). In some embodiments, Malonate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 3.25 (e.g., 3.25±0.2), about 5.58 (e.g., 5.58±0.2), about 10.89 (e.g., 10.89±0.2), about 12.20 (e.g., 12.20±0.2), about 14.70 (e.g., 14.70±0.2), about 15.60 (e.g., 15.60±0.2), about17.55 (e.g., 17.55±0.2), about 18.15 (e.g., 18.15±0.2), about 20.63 (e.g., 20.63±0.2), about22.16 (e.g., 22.16±0.2), about 24.50 (e.g., 24.50±0.2), about 26.33 (e.g., 26.33±0.2), about28.72 (e.g., 28.72±0.2), and about 29.30 (e.g., 29.30±0.2). For example, Malonate Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.58 (e.g., 5.58±0.2), about 12.20 (e.g., 12.20±0.2), about 14.70 (e.g., 14.70±0.2), about 17.55 (e.g., 17.55±0.2), about 20.63 (e.g., 20.63±0.2), and about 24.50 (e.g., 24.50±0.2). In some embodiments, Malonate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.58 (e.g., 5.58±0.2), about 12.20 (e.g., 12.20±0.2), about 14.70 (e.g., 14.70±0.2), about 17.55 (e.g., 17.55±0.2), about 20.63 (e.g., 20.63±0.2), and about 24.50 (e.g., 24.50±0.2). In some embodiments, Malonate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.58, about 14.70, and about 24.50. In some embodiments, Malonate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 5.58±0.2, 14.70±0.2 and 24.50±0.2. In some embodiments, Malonate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.58, and about 14.70. In some embodiments, Malonate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 5.58±0.2, and 14.70±0.2. In some embodiments, Malonate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.58. In someembodiments, Malonate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 5.58±0.2.

[0265] In some embodiments, Malonate Form II is characterized as having a TGA thermogram substantially as shown in FIG. 24B. In some embodiments, Malonate Form II is characterized as having a mass loss of about 1.0 % after heating from about 19.8 °C to about 78.5 °C, as determined by TGA. In some embodiments, Malonate Form II is characterized as having a further mass loss of about 15.9 % after heating from about 81.3 °C to about 243.8 °C, as determined by TGA.

[0266] In some embodiments, Malonate Form II is characterized as having a DSC thermogram substantially as shown in FIG. 24B. In some embodiments, Malonate Form II is characterized as having an endothermic event with an onset of about 161.4 °C. In some embodiments, Malonate Form II is characterized as having an endotherm peak of about 169.2 °C.

[0267] In some embodiments of Malonate Form I, at least one, at least two, at least three, at least four, at least five, at least six, or all of the following (a)-(g) apply: a. Malonate Form II has an XRPD pattern substantially as shown in FIG. 24A; b. Malonate Form II has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 16; and c. Malonate Form II has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 5.58±0.2, 14.70±0.2 and 24.50±0.2, ii. peaks at an angle 2-theta in degrees of 5.58 (e.g., 5.58±0.2), about 12.20 (e.g., 12.20±0.2), about 14.70 (e.g., 14.70±0.2), about 17.55 (e.g., 17.55±0.2), about 20.63 (e.g., 20.63±0.2), and about 24.50 (e.g., 24.50±0.2), or iii. peaks at an angle 2-theta in degrees of about 3.25 (e.g., 3.25±0.2), about 5.58 (e.g., 5.58±0.2), about 10.89 (e.g., 10.89±0.2), about 12.20 (e.g., 12.20±0.2), about 14.70 (e.g., 14.70±0.2), about 15.60 (e.g., 15.60±0.2), about 17.55 (e.g., 17.55±0.2), about 18.15 (e.g., 18.15±0.2), about 20.63 (e.g., 20.63±0.2), about 22.16 (e.g., 22.16±0.2), about 24.50 (e.g., 24.50±0.2), about 26.33 (e.g., 26.33±0.2), about 28.72 (e.g., 28.72±0.2), and about 29.30 (e.g., 29.30±0.2); d. Malonate Form II has a TGA thermogram substantially as shown in FIG. 24B;e. Malonate Form II is characterized as having a mass loss of about 1.0 % after heating from about 19.8 °C to about 78.5 °C, as determined by TGA, and a further mass loss of about 15.9 % after heating from about 81.3 °C to about 243.8 °C, as determined by TGA; f. Malonate Form II has a DSC thermogram substantially as shown in FIG. 24B; and g. Malonate Form II is characterized as having an endothermic event with an onset of about 161.4 °C and an endotherm peak of about 169.2 °C.Glucuronate Forms

[0268] In some embodiments, the crystalline form is a crystalline form of a glucuronate salt. In some embodiments, the glucuronate salt of Compound A is a mono glucuronate salt. In some embodiments, the crystalline form of the glucuronate salt of Compound A is Glucuronate Form I, Glucuronate Form II, or Glucuronate Form III.Glucuronate Form I

[0269] In some embodiments, the crystalline form of the glucuronate salt of Compound A is Glucuronate Form I. In some embodiments, Glucuronate Form I is a mono glucuronate salt.

[0270] In some embodiments, Glucuronate Form I has an XRPD pattern substantially as shown in FIG. 25. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 17.Table 17.

[0271] In some embodiments, Glucuronate Form I has an XRPD pattern comprising peaks provided in Table 17. In some embodiments, Glucuronate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 25, or as provided in Table 17.

[0272] In some embodiments, Glucuronate Form I has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 17, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Glucuronate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.32 (e.g., 5.32±0.2), about 6.92 (e.g., 6.92±0.2), about 9.19 (e.g., 9.19±0.2), about 10.23 (e.g., 10.23±0.2), about 10.66 (e.g., 10.66±0.2), about 11.55 (e.g., 11.55±0.2), about 12.82 (e.g., 12.82±0.2), about 13.88 (e.g., 13.88±0.2), about14.11 (e.g., 14.11±0.2), about 14.78 (e.g., 14.78±0.2), about 16.02 (e.g., 16.02±0.2), about16.22 (e.g., 16.22±0.2), about 16.69 (e.g., 16.69±0.2), about 17.09 (e.g., 17.09±0.2), about18.31 (e.g., 18.31±0.2), about 18.58 (e.g., 18.58±0.2), about 19.05 (e.g., 19.05±0.2), about19.44 (e.g., 19.44±0.2), about 19.78 (e.g., 19.78±0.2), about 20.08 (e.g., 20.08±0.2), about20.54 (e.g., 20.54±0.2), about 20.91 (e.g., 20.91±0.2), about 21.26 (e.g., 21.26±0.2), about21.85 (e.g., 21.85±0.2), about 22.92 (e.g., 22.92±0.2), about 23.34 (e.g., 23.34±0.2), about23.77 (e.g., 23.77±0.2), about 24.76 (e.g., 24.76±0.2), about 25.00 (e.g., 25.00±0.2), about26.18 (e.g., 26.18±0.2), about 26.83 (e.g., 26.83±0.2), about 27.38 (e.g., 27.38±0.2), about28.34 (e.g., 28.34±0.2), about 28.82 (e.g., 28.82±0.2), about 29.61 (e.g., 29.61±0.2), about30.44 (e.g., 30.44±0.2), about 31.30 (e.g., 31.30±0.2), about 32.83 (e.g., 32.83±0.2), and about 34.02 (e.g., 34.02±0.2). In some embodiments, Glucuronate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.32 (e.g., 5.32±0.2), about 6.92 (e.g.,6.92±0.2), about 9.19 (e.g., 9.19±0.2), about 10.23 (e.g., 10.23±0.2), about 10.66 (e.g., 10.66±0.2), about 11.55 (e.g., 11.55±0.2), about 12.82 (e.g., 12.82±0.2), about 13.88 (e.g.,13.88±0.2), about 14.11 (e.g., 14.11±0.2), about 14.78 (e.g., 14.78±0.2), about 16.02 (e.g.,16.02±0.2), about 16.22 (e.g., 16.22±0.2), about 16.69 (e.g., 16.69±0.2), about 17.09 (e.g.,17.09±0.2), about 18.31 (e.g., 18.31±0.2), about 18.58 (e.g., 18.58±0.2), about 19.05 (e.g.,19.05±0.2), about 19.44 (e.g., 19.44±0.2), about 19.78 (e.g., 19.78±0.2), about 20.08 (e.g.,20.08±0.2), about 20.54 (e.g., 20.54±0.2), about 20.91 (e.g., 20.91±0.2), about 21.26 (e.g.,21.26±0.2), about 21.85 (e.g., 21.85±0.2), about 22.92 (e.g., 22.92±0.2), about 23.34 (e.g.,23.34±0.2), about 23.77 (e.g., 23.77±0.2), about 24.76 (e.g., 24.76±0.2), about 25.00 (e.g.,25.00±0.2), about 26.18 (e.g., 26.18±0.2), about 26.83 (e.g., 26.83±0.2), about 27.38 (e.g.,27.38±0.2), about 28.34 (e.g., 28.34±0.2), about 28.82 (e.g., 28.82±0.2), about 29.61 (e.g.,29.61±0.2), about 30.44 (e.g., 30.44±0.2), about 31.30 (e.g., 31.30±0.2), about 32.83 (e.g.,32.83±0.2), and about 34.02 (e.g., 34.02±0.2). For example, Glucuronate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.32 (e.g., 5.32±0.2), about 6.92 (e.g., 6.92±0.2), about 10.23 (e.g., 10.23±0.2), about 11.55 (e.g., 11.55±0.2), about 13.88 (e.g., 13.88±0.2), about 16.02 (e.g., 16.02±0.2), about 16.22 (e.g.,16.22±0.2), about 16.69 (e.g., 16.69±0.2), about 19.05 (e.g., 19.05±0.2), about 19.44 (e.g.,19.44±0.2), about 19.78 (e.g., 19.78±0.2), about 20.91 (e.g., 20.91±0.2), about 21.85 (e.g.,21.85±0.2), about 22.92 (e.g., 22.92±0.2), about 23.34 (e.g., 23.34±0.2), about 23.77 (e.g.,23.77±0.2), about 24.76 (e.g., 24.76±0.2), about 25.00 (e.g., 25.00±0.2), about 26.83 (e.g.,26.83±0.2), and about 27.38 (e.g., 27.38±0.2). In some embodiments, Glucuronate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.32 (e.g., 5.32±0.2), about 6.92 (e.g., 6.92±0.2), about 10.23 (e.g., 10.23±0.2), about 11.55 (e.g., 11.55±0.2), about 13.88 (e.g., 13.88±0.2), about 16.02 (e.g., 16.02±0.2), about 16.22 (e.g., 16.22±0.2), about 16.69(e.g., 16.69±0.2), about 19.05 (e.g., 19.05±0.2), about 19.44 (e.g., 19.44±0.2), about 19.78(e.g., 19.78±0.2), about 20.91 (e.g., 20.91±0.2), about 21.85 (e.g., 21.85±0.2), about 22.92(e.g., 22.92±0.2), about 23.34 (e.g., 23.34±0.2), about 23.77 (e.g., 23.77±0.2), about 24.76(e.g., 24.76±0.2), about 25.00 (e.g., 25.00±0.2), about 26.83 (e.g., 26.83±0.2), and about 27.38 (e.g., 27.38±0.2). For example, Glucuronate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.32 (e.g., 5.32±0.2), about 6.92 (e.g., 6.92±0.2), about 10.23 (e.g., 10.23±0.2), about 11.55 (e.g., 11.55±0.2), about 13.88 (e.g., 13.88±0.2), about 16.69 (e.g., 16.69±0.2), about 19.44 (e.g., 19.44±0.2),about 19.78 (e.g., 19.78±0.2), about 22.92 (e.g., 22.92±0.2), about 25.00 (e.g., 25.00±0.2), and about 26.83 (e.g., 26.83±0.2). In some embodiments, Glucuronate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.32 (e.g., 5.32±0.2), about 6.92 (e.g., 6.92±0.2), about 10.23 (e.g., 10.23±0.2), about 11.55 (e.g., 11.55±0.2), about 13.88 (e.g., 13.88±0.2), about 16.69 (e.g., 16.69±0.2), about 19.44 (e.g., 19.44±0.2), about 19.78 (e.g., 19.78±0.2), about 22.92 (e.g., 22.92±0.2), about 25.00 (e.g., 25.00±0.2), and about 26.83 (e.g., 26.83±0.2). In some embodiments, Glucuronate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 10.23, about 16.69, and about 22.92. In some embodiments, Glucuronate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 10.23±0.2, 16.69±0.2 and 22.92±0.2. In some embodiments, Glucuronate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 10.23, and about 16.69. In some embodiments, Glucuronate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 10.23±0.2, and 16.69±0.2. In some embodiments, Glucuronate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 10.23±0.2. In some embodiments, Glucuronate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 10.23, and about 16.69. In some embodiments, Glucuronate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 10.23±0.2.

[0273] In some embodiments of Glucuronate Form I, at least one, at least two, or all of the following (a)-(c) apply: d. Glucuronate Form I has an XRPD pattern substantially as shown in FIG. 25; e. Glucuronate Form I has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 17; and f. Glucuronate Form I has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 10.23±0.2, 16.69±0.2 and 22.92±0.2, ii. peaks at an angle 2-theta in degrees of about 5.32 (e.g., 5.32±0.2), about 6.92 (e.g., 6.92±0.2), about 10.23 (e.g., 10.23±0.2), about 11.55 (e.g., 11.55±0.2), about 13.88 (e.g., 13.88±0.2), about 16.69 (e.g., 16.69±0.2), about 19.44 (e.g.,19.44±0.2), about 19.78 (e.g., 19.78±0.2), about 22.92 (e.g., 22.92±0.2), about 25.00 (e.g., 25.00±0.2), and about 26.83 (e.g., 26.83±0.2), iii. peaks at an angle 2-theta in degrees of about 5.32 (e.g., 5.32±0.2), about 6.92 (e.g., 6.92±0.2), about 10.23 (e.g., 10.23±0.2), about 11.55 (e.g., 11.55±0.2), about 13.88 (e.g., 13.88±0.2), about 16.02 (e.g., 16.02±0.2), about 16.22 (e.g., 16.22±0.2), about 16.69 (e.g., 16.69±0.2), about 19.05 (e.g., 19.05±0.2), about 19.44 (e.g., 19.44±0.2), about 19.78 (e.g., 19.78±0.2), about 20.91 (e.g., 20.91±0.2), about 21.85 (e.g., 21.85±0.2), about 22.92 (e.g., 22.92±0.2), about 23.34 (e.g., 23.34±0.2), about 23.77 (e.g., 23.77±0.2), about 24.76 (e.g., 24.76±0.2), about 25.00 (e.g., 25.00±0.2), about 26.83 (e.g., 26.83±0.2), and about 27.38 (e.g., 27.38±0.2), or iv. peaks at an angle 2-theta in degrees of about about 5.32 (e.g., 5.32±0.2), about 6.92 (e.g., 6.92±0.2), about 9.19 (e.g., 9.19±0.2), about 10.23 (e.g., 10.23±0.2), about 10.66 (e.g., 10.66±0.2), about 11.55 (e.g., 11.55±0.2), about 12.82 (e.g., 12.82±0.2), about 13.88 (e.g., 13.88±0.2), about 14.11 (e.g., 14.11±0.2), about 14.78 (e.g., 14.78±0.2), about 16.02 (e.g., 16.02±0.2), about 16.22 (e.g., 16.22±0.2), about 16.69 (e.g., 16.69±0.2), about 17.09 (e.g., 17.09±0.2), about 18.31 (e.g., 18.31±0.2), about 18.58 (e.g., 18.58±0.2), about 19.05 (e.g., 19.05±0.2), about 19.44 (e.g., 19.44±0.2), about 19.78 (e.g., 19.78±0.2), about 20.08 (e.g., 20.08±0.2), about 20.54 (e.g., 20.54±0.2), about 20.91 (e.g., 20.91±0.2), about 21.26 (e.g., 21.26±0.2), about 21.85 (e.g., 21.85±0.2), about 22.92 (e.g., 22.92±0.2), about 23.34 (e.g., 23.34±0.2), about 23.77 (e.g., 23.77±0.2), about 24.76 (e.g., 24.76±0.2), about 25.00 (e.g., 25.00±0.2), about 26.18 (e.g., 26.18±0.2), about 26.83 (e.g., 26.83±0.2), about 27.38 (e.g., 27.38±0.2), about 28.34 (e.g., 28.34±0.2), about 28.82 (e.g., 28.82±0.2), about 29.61 (e.g., 29.61±0.2), about 30.44 (e.g., 30.44±0.2), about 31.30 (e.g., 31.30±0.2), about 32.83 (e.g., 32.83±0.2), and about 34.02 (e.g., 34.02±0.2).Glucur onate Form II

[0274] In some embodiments, the crystalline form of the glucuronate salt of Compound A is Glucuronate Form II. In some embodiments, Glucuronate Form II is a mono glucuronate salt.

[0275] In some embodiments, Glucuronate Form II has an XRPD pattern substantially as shown in FIG. 26A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 18.Table 18.

[0276] In some embodiments, Glucuronate Form II has an XRPD pattern comprising peaks provided in Table 18. In some embodiments, Glucuronate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 26A, or as provided in Table 18.

[0277] In some embodiments, Glucuronate Form II has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 18, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Glucuronate Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.72 (e.g., 4.72±0.2), about 7.42 (e.g., 7.42±0.2), about 7.86 (e.g., 7.86±0.2), about 9.87 (e.g., 9.87±0.2), about 13.86 (e.g., 13.86±0.2), about 15.17 (e.g., 15.17±0.2), about 15.43 (e.g., 15.43±0.2), about 16.05 (e.g., 16.05±0.2), about 16.83(e.g., 16.83±0.2), about 18.12 (e.g., 18.12±0.2), about 19.00 (e.g., 19.00±0.2), about 19.91(e.g., 19.91±0.2), about 20.39 (e.g., 20.39±0.2), about 20.86 (e.g., 20.86±0.2), about 21.89(e.g., 21.89±0.2), about 22.37 (e.g., 22.37±0.2), about 22.82 (e.g., 22.82±0.2), about 23.38(e.g., 23.38±0.2), about 24.29 (e.g., 24.29±0.2), about 24.90 (e.g., 24.90±0.2), about 26.24(e.g., 26.24±0.2), about 27.51 (e.g., 27.51±0.2), about 28.89 (e.g., 28.19±0.2), about 29.77(e.g., 29.77±0.2), about 30.52 (e.g., 30.52±0.2), about 31.67 (e.g., 31.67±0.2), and about 32.45 (e.g., 32.45±0.2). In some embodiments, Glucuronate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.72 (e.g., 4.72±0.2), about 7.42 (e.g., 7.42±0.2), about 7.86 (e.g., 7.86±0.2), about 9.87 (e.g., 9.87±0.2), about 13.86 (e.g., 13.86±0.2), about 15.17 (e.g., 15.17±0.2), about 15.43 (e.g., 15.43±0.2), about 16.05 (e.g., 16.05±0.2), about 16.83(e.g., 16.83±0.2), about 18.12 (e.g., 18.12±0.2), about 19.00 (e.g., 19.00±0.2), about 19.91(e.g., 19.91±0.2), about 20.39 (e.g., 20.39±0.2), about 20.86 (e.g., 20.86±0.2), about 21.89(e.g., 21.89±0.2), about 22.37 (e.g., 22.37±0.2), about 22.82 (e.g., 22.82±0.2), about 23.38(e.g., 23.38±0.2), about 24.29 (e.g., 24.29±0.2), about 24.90 (e.g., 24.90±0.2), about 26.24 (e.g., 26.24±0.2), about 27.51 (e.g., 27.51±0.2), about 28.89 (e.g., 28.89±0.2), about 29.77 (e.g., 29.77±0.2), about 30.52 (e.g., 30.52±0.2), about 31.67 (e.g., 31.67±0.2), and about 32.45 (e.g., 32.45±0.2). For example, Glucuronate Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.72 (e.g., 4.72±0.2), about 7.42 (e.g., 7.42±0.2), about 9.87 (e.g., 9.87±0.2), about 13.86 (e.g., 13.86±0.2), about 15.17 (e.g., 15.17±0.2), about 15.43 (e.g., 15.43±0.2), about 16.05 (e.g., 16.05±0.2), about 18.12 (e.g., 18.12±0.2), about 19.91 (e.g., 19.91±0.2), about 20.39 (e.g., 20.39±0.2), about20.86 (e.g., 20.86±0.2), about 21.19 (e.g., 21.19±0.2), and about 26.24 (e.g., 26.24±0.2). In some embodiments, Glucuronate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.72 (e.g., 4.72±0.2), about 7.42 (e.g., 7.42±0.2), about 9.87 (e.g., 9.87±0.2), about13.86 (e.g., 13.86±0.2), about 15.17 (e.g., 15.17±0.2), about 15.43 (e.g., 15.43±0.2), about16.05 (e.g., 16.05±0.2), about 18.12 (e.g., 18.12±0.2), about 19.91 (e.g., 19.91±0.2), about20.39 (e.g., 20.39±0.2), about 20.86 (e.g., 20.86±0.2), about 21.19 (e.g., 21.19±0.2), and about 26.24 (e.g., 26.24±0.2). For example, Glucuronate Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.72 (e.g., 4.72±0.2), about 7.42 (e.g., 7.42±0.2), about 13.86 (e.g., 13.86±0.2), about 15.17 (e.g., 15.17±0.2), about 19.91 (e.g., 19.91±0.2), about 21.19 (e.g., 21.19±0.2), and about 26.24 (e.g., 26.24±0.2). In some embodiments, Glucuronate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2- theta in degrees of about 4.72 (e.g., 4.72±0.2), about 7.42 (e.g., 7.42±0.2), about 13.86 (e.g., 13.86±0.2), about 15.17 (e.g., 15.17±0.2), about 19.91 (e.g., 19.91±0.2), about 21.19 (e.g., 21.19±0.2), and about 26.24 (e.g., 26.24±0.2). In some embodiments, Glucuronate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.72, about 19.91, and about 21.19. In some embodiments, Glucuronate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.72±0.2, 19.91±0.2, and 21.19±0.2. In some embodiments, Glucuronate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.72, and about 19.91. In some embodiments, Glucuronate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.72±0.2, and 19.91±0.2. In some embodiments, Glucuronate Form II has an XRPD pattern comprising peaks each assigned atan angle 2-theta in degrees of about 4.72. In some embodiments, Glucuronate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.72±0.2.

[0278] In some embodiments, Glucuronate Form II is characterized as having a TGA thermogram substantially as shown in FIG. 26B. In some embodiments, Glucuronate Form II is characterized as having a mass loss of about 1.4 % after heating from about 26.3 °C to about 125.0 °C, as determined by TGA. In some embodiments, Glucuronate Form II is characterized as having a further mass loss of about 8.4 % after heating from about 125.0 °C to about 209.4 °C, as determined by TGA.

[0279] In some embodiments, Glucuronate Form II is characterized as having a DSC thermogram substantially as shown in FIG. 26B. In some embodiments, Glucuronate Form II is characterized as having an endothermic event with an onset at about 141.4 °C. In some embodiments, Glucuronate Form II is characterized as having an endotherm peak at about 157.8 °C.

[0280] In some embodiments of Glucuronate Form II, at least one, at least two, at least three, at least four, at least five, at least six, or all of the following (a)-(g) apply: a. Glucuronate Form II has an XRPD pattern substantially as shown in FIG. 26A; b. Glucuronate Form II has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 18; and c. Glucuronate Form II has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 4.72±0.2, 19.91±0.2, and 21.19±0.2, ii. peaks at an angle 2-theta in degrees of about 4.72 (e.g., 4.72±0.2), about 7.42 (e.g., 7.42±0.2), about 13.86 (e.g., 13.86±0.2), about 15.17 (e.g., 15.17±0.2), about 19.91 (e.g., 19.91±0.2), about 21.19 (e.g., 21.19±0.2), and about 26.24 (e.g., 26.24±0.2), iii. peaks at an angle 2-theta in degrees of about 4.72 (e.g., 4.72±0.2), about 7.42 (e.g., 7.42±0.2), about 9.87 (e.g., 9.87±0.2), about 13.86 (e.g., 13.86±0.2), about 15.17 (e.g., 15.17±0.2), about 15.43 (e.g., 15.43±0.2), about 16.05 (e.g., 16.05±0.2), about 18.12 (e.g., 18.12±0.2), about 19.91 (e.g., 19.91±0.2), about 20.39 (e.g., 20.39±0.2), about 20.86 (e.g., 20.86±0.2), about 21.19 (e.g., 21.19±0.2), and about 26.24 (e.g., 26.24±0.2), oriv. peaks at an angle 2-theta in degrees of about 4.72 (e.g., 4.72±0.2), about 7.42 (e.g., 7.42±0.2), about 7.86 (e.g., 7.86±0.2), about 9.87 (e.g., 9.87±0.2), about 13.86 (e.g., 13.86±0.2), about 15.17 (e.g., 15.17±0.2), about 15.43 (e.g., 15.43±0.2), about 16.05 (e.g., 16.05±0.2), about 16.83 (e.g., 16.83±0.2), about 18.12 (e.g., 18.12±0.2), about 19.00 (e.g., 19.00±0.2), about 19.91 (e.g., 19.91±0.2), about 20.39 (e.g., 20.39±0.2), about 20.86 (e.g., 20.86±0.2), about21.89 (e.g., 21.89±0.2), about 22.37 (e.g., 22.37±0.2), about 22.82 (e.g., 22.82±0.2), about 23.38 (e.g., 23.38±0.2), about 24.29 (e.g., 24.29±0.2), about24.90 (e.g., 24.90±0.2), about 26.24 (e.g., 26.24±0.2), about 27.51 (e.g.,27.51±0.2), about 28.89 (e.g., 28.89±0.2), about 29.77 (e.g., 29.77±0.2), about 30.52 (e.g., 30.52±0.2), about 31.67 (e.g., 31.67±0.2), and about 32.45 (e.g., 32.45±0.2); d. Glucuronate Form II has a TGA thermogram substantially as shown in FIG. 26B; e. Glucuronate Form II is characterized as having a mass loss of about 1.4 % after heating from about 26.3 °C to about 125.0 °C and a further mass loss of about 8.4 % after heating from about 125.0 °C to about 209.4 °C; f. Glucuronate Form II has a DSC thermogram substantially as shown in FIG. 26B; and g. Glucuronate Form II is characterized as having an endothermic event with an onset at about 141.4 °C and peak at about 157.8 °C.Glucuronate Form III

[0281] In some embodiments, the crystalline form of the glucuronate salt of Compound A is Glucuronate Form III. In some embodiments, Glucuronate Form III is a mono glucuronate salt.

[0282] In some embodiments, Glucuronate Form III has an XRPD pattern substantially as shown in FIG. 27. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 19.Table 19.

[0283] In some embodiments, Glucuronate Form III has an XRPD pattern comprising peaks provided in Table 19. In some embodiments, Glucuronate Form III has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks atangles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG.26, or as provided in Table 19.

[0284] In some embodiments, Glucuronate Form III has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 19, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Glucuronate Form III may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.40 (e.g., 5.40±0.2), about 7.06 (e.g., 7.06±0.2), about 10.43 (e.g., 10.43±0.2), about 10.62 (e.g., 10.62±0.2), about 11.78 (e.g., 11.78±0.2), about14.19 (e.g., 14.19±0.2), about 15.06 (e.g., 15.06±0.2), about 16.70 (e.g., 16.70±0.2), about17.04 (e.g., 17.04±0.2), about 17.54 (e.g., 17.54±0.2), about 18.69 (e.g., 18.69±0.2), about19.41 (e.g., 19.41±0.2), about 19.81 (e.g., 19.81±0.2), about 20.14 (e.g., 20.14±0.2), about20.68 (e.g., 20.68±0.2), about 21.68 (e.g., 21.68±0.2), about 22.26 (e.g., 22.26±0.2), about23.69 (e.g., 23.69±0.2), about 24.19 (e.g., 24.19±0.2), about 24.92 (e.g., 24.92±0.2), about25.42 (e.g., 25.42±0.2), about 27.73 (e.g., 27.73±0.2), about 28.31 (e.g., 28.31±0.2), about29.29 (e.g., 29.29±0.2), and about 32.21 (e.g., 32.21±0.2). In some embodiments, Glucuronate Form III has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.40 (e.g., 5.40±0.2), about 7.06 (e.g., 7.06±0.2), about 10.43 (e.g., 10.43±0.2), about 10.62 (e.g., 10.62±0.2), about 11.78 (e.g., 11.78±0.2), about 14.19 (e.g., 14.19±0.2), about 15.06 (e.g., 15.06±0.2), about 16.70 (e.g., 16.70±0.2), about 17.04 (e.g., 17.04±0.2), about 17.54 (e.g., 17.54±0.2), about 18.69 (e.g., 18.69±0.2), about 19.41 (e.g., 19.41±0.2), about 19.81 (e.g., 19.81±0.2), about 20.14 (e.g., 20.14±0.2), about 20.68 (e.g., 20.68±0.2), about 21.68 (e.g., 21.68±0.2), about 22.26 (e.g., 22.26±0.2), about 23.69 (e.g., 23.69±0.2), about 24.19 (e.g., 24.19±0.2), about 24.92 (e.g., 24.92±0.2), about 25.42 (e.g., 25.42±0.2), about 27.73 (e.g., 27.73±0.2), about 28.31 (e.g., 28.31±0.2), about 29.29 (e.g., 29.29±0.2), and about 32.21 (e.g., 32.21±0.2). For example, Glucuronate Form III may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.40 (e.g., 5.40±0.2), about 10.62 (e.g., 10.62±0.2), about 11.78 (e.g., 11.78±0.2), about 14.19 (e.g., 14.19±0.2), about 15.06(e.g., 15.06±0.2), about 16.70 (e.g., 16.70±0.2), about 17.04 (e.g., 17.04±0.2), about 20.14(e.g., 20.14±0.2), about 20.68 (e.g., 20.68±0.2), about 22.26 (e.g., 22.26±0.2), about 23.69(e.g., 23.69±0.2), about 25.42 (e.g., 25.42±0.2), about 27.73 (e.g., 27.73±0.2), and about28.31 (e.g., 28.31±0.2). In some embodiments, Glucuronate Form III has an XRPD patterncomprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.40 (e.g., 5.40±0.2), about 10.62 (e.g., 10.62±0.2), about 11.78 (e.g., 11.78±0.2), about 14.19 (e.g., 14.19±0.2), about 15.06 (e.g., 15.06±0.2), about 16.70 (e.g., 16.70±0.2), about 17.04 (e.g., 17.04±0.2), about 20.14 (e.g., 20.14±0.2), about 20.68 (e.g., 20.68±0.2), about 22.26 (e.g., 22.26±0.2), about 23.69 (e.g., 23.69±0.2), about 25.42 (e.g., 25.42±0.2), about 27.73 (e.g., 27.73±0.2), and about 28.31 (e.g.,28.31±0.2). For example, Glucuronate Form III may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.40 (e.g., 5.40±0.2), about 14.19 (e.g., 14.19±0.2), about 15.06 (e.g., 15.06±0.2), about 17.04 (e.g., 17.04±0.2), about 20.68 (e.g., 20.68±0.2), about 23.69 (e.g., 23.69±0.2), about 27.73 (e.g., 27.73±0.2), and about 28.31 (e.g., 28.31±0.2). In some embodiments, Glucuronate Form III has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.40 (e.g., 5.40±0.2), about 14.19 (e.g., 14.19±0.2), about 15.06 (e.g., 15.06±0.2), about 17.04 (e.g., 17.04±0.2), about 20.68 (e.g., 20.68±0.2), about 23.69 (e.g., 23.69±0.2), about 27.73 (e.g., 27.73±0.2), and about 28.31 (e.g., 28.31±0.2). In some embodiments, Glucuronate Form III has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.40, about 14.19, and about 15.06. In some embodiments, Glucuronate Form III has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 5.40±0.2, 14.19±0.2, and 15.06±0.2. In some embodiments, Glucuronate Form III has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.40, and about 14.19. In some embodiments, Glucuronate Form III has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 5.40±0.2, and 14.19±0.2. In some embodiments, Glucuronate Form III has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.40. In some embodiments, Glucuronate Form III has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 5.40±0.2.

[0285] In some embodiments of Glucuronate Form III, at least one, at least two, or all of the following (a)-(c) apply: a. Glucuronate Form III has an XRPD pattern substantially as shown in FIG. 27; b. Glucuronate Form III has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 19; andc. Glucuronate Form III has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 5.40±0.2, 14.19±0.2, and 15.06±0.2, ii. peaks at an angle 2-theta in degrees of about 5.40 (e.g., 5.40±0.2), about 14.19 (e.g., 14.19±0.2), about 15.06 (e.g., 15.06±0.2), about 17.04 (e.g., 17.04±0.2), about 20.68 (e.g., 20.68±0.2), about 23.69 (e.g., 23.69±0.2), about 27.73 (e.g., 27.73±0.2), and about 28.31 (e.g., 28.31±0.2), iii. peaks at an angle 2-theta in degrees of about 5.40 (e.g., 5.40±0.2), about 10.62 (e.g., 10.62±0.2), about 11.78 (e.g., 11.78±0.2), about 14.19 (e.g., 14.19±0.2), about 15.06 (e.g., 15.06±0.2), about 16.70 (e.g., 16.70±0.2), about 17.04 (e.g., 17.04±0.2), about 20.14 (e.g., 20.14±0.2), about 20.68 (e.g., 20.68±0.2), about 22.26 (e.g., 22.26±0.2), about 23.69 (e.g., 23.69±0.2), about 25.42 (e.g., 25.42±0.2), about 27.73 (e.g., 27.73±0.2), and about 28.31 (e.g., 28.31±0.2), or iv. peaks at an angle 2-theta in degrees of about 5.40 (e.g., 5.40±0.2), about 7.06 (e.g., 7.06±0.2), about 10.43 (e.g., 10.43±0.2), about 10.62 (e.g., 10.62±0.2), about 11.78 (e.g., 11.78±0.2), about 14.19 (e.g., 14.19±0.2), about 15.06 (e.g., 15.06±0.2), about 16.70 (e.g., 16.70±0.2), about 17.04 (e.g., 17.04±0.2), about 17.54 (e.g., 17.54±0.2), about 18.69 (e.g., 18.69±0.2), about 19.41 (e.g., 19.41±0.2), about 19.81 (e.g., 19.81±0.2), about 20.14 (e.g., 20.14±0.2), about 20.68 (e.g., 20.68±0.2), about 21.68 (e.g., 21.68±0.2), about 22.26 (e.g., 22.26±0.2), about 23.69 (e.g., 23.69±0.2), about 24.19 (e.g., 24.19±0.2), about 24.92 (e.g., 24.92±0.2), about 25.42 (e.g., 25.42±0.2), about 27.73 (e.g., 27.73±0.2), about 28.31 (e.g., 28.31±0.2), about 29.29 (e.g., 29.29±0.2), and about 32.21 (e.g., 32.21±0.2).Glycolate Forms

[0286] In some embodiments, the crystalline form is a crystalline form of a glycolate salt. In some embodiments, the glycolate salt of Compound A is a mono glycolate salt.Glycolate Form I

[0287] In some embodiments, the crystalline form of the glycolate salt of Compound A is Glycolate Form I. In some embodiments, Glycolate Form I is a mono glycolate salt.

[0288] In some embodiments, Glycolate Form I has an XRPD pattern substantially as shown in FIG. 28A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 20.Table 20.

[0289] In some embodiments, Glycolate Form I has an XRPD pattern comprising peaks provided in Table 20. In some embodiments, Glycolate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 28A, or as provided in Table 20.

[0290] In some embodiments, Glycolate Form I has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 20, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Glycolate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.22 (e.g., 4.22±0.2), about 8.43 (e.g., 8.43±0.2), about12.66 (e.g., 12.66±0.2), about 12.90 (e.g., 12.90±0.2), about 13.60 (e.g., 13.60±0.2), about14.39 (e.g., 14.39±0.2), about 15.45 (e.g., 15.45±0.2), about 15.93 (e.g., 15.93±0.2), about16.37 (e.g., 16.37±0.2), about 16.74 (e.g., 16.74±0.2), about 16.98 (e.g., 16.98±0.2), about17.79 (e.g., 17.79±0.2), about 18.15 (e.g., 18.15±0.2), about 18.66 (e.g., 18.66±0.2), about19.06 (e.g., 19.06±0.2), about 19.74 (e.g., 19.74±0.2), about 20.31 (e.g., 20.31±0.2), about20.94 (e.g., 20.94±0.2), about 21.37 (e.g., 21.37±0.2), about 21.75 (e.g., 21.75±0.2), about22.32 (e.g., 22.32±0.2), about 23.08 (e.g., 23.08±0.2), about 23.70 (e.g., 23.70±0.2), about24.54 (e.g., 24.54±0.2), about 25.20 (e.g., 25.20±0.2), about 26.16 (e.g., 26.16±0.2), about26.77 (e.g., 26.77±0.2), about 26.99 (e.g., 26.99±0.2), about 27.39 (e.g., 27.39±0.2), about28.08 (e.g., 28.08±0.2), about 28.45 (e.g., 28.45±0.2), about 29.26 (e.g., 29.26±0.2), about29.50 (e.g., 29.50±0.2), about 30.06 (e.g., 30.06±0.2), about 30.59 (e.g., 30.59±0.2), about31.15 (e.g., 31.18±0.2), about 31.90 (e.g., 31.90±0.2), about 32.62 (e.g., 32.62±0.2), about33.61 (e.g., 33.61±0.2), about 34.21 (e.g., 34.21±0.2), and about 32.62 (e.g., 34.74±0.2). In some embodiments, Glycolate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.22 (e.g., 4.22±0.2), about 8.43 (e.g., 8.43±0.2), about 12.66 (e.g., 12.66±0.2), about12.90 (e.g., 12.90±0.2), about 13.60 (e.g., 13.60±0.2), about 14.39 (e.g., 14.39±0.2), about15.45 (e.g., 15.45±0.2), about 15.93 (e.g., 15.93±0.2), about 16.37 (e.g., 16.37±0.2), about16.74 (e.g., 16.74±0.2), about 16.98 (e.g., 16.98±0.2), about 17.79 (e.g., 17.79±0.2), about18.15 (e.g., 18.15±0.2), about 18.66 (e.g., 18.66±0.2), about 19.06 (e.g., 19.06±0.2), about19.74 (e.g., 19.74±0.2), about 20.31 (e.g., 20.31±0.2), about 20.94 (e.g., 20.94±0.2), about21.37 (e.g., 21.37±0.2), about 21.75 (e.g., 21.75±0.2), about 22.32 (e.g., 22.32±0.2), about23.08 (e.g., 23.08±0.2), about 23.70 (e.g., 23.70±0.2), about 24.54 (e.g., 24.54±0.2), about25.20 (e.g., 25.20±0.2), about 26.16 (e.g., 26.16±0.2), about 26.77 (e.g., 26.77±0.2), about26.99 (e.g., 26.99±0.2), about 27.39 (e.g., 27.39±0.2), about 28.08 (e.g., 28.08±0.2), about28.45 (e.g., 28.45±0.2), about 29.26 (e.g., 29.26±0.2), about 29.50 (e.g., 29.50±0.2), about30.06 (e.g., 30.06±0.2), about 30.59 (e.g., 30.59±0.2), about 31.15 (e.g., 31.18±0.2), about31.90 (e.g., 31.90±0.2), about 32.62 (e.g., 32.62±0.2), about 33.61 (e.g., 33.61±0.2), about34.21 (e.g., 34.21±0.2), and about 32.62 (e.g., 34.74±0.2). For example, Glycolate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.22 (e.g., 4.22±0.2), about 13.60 (e.g., 13.60±0.2), about 15.93 (e.g., 15.93±0.2), about 16.74 (e.g., 16.74±0.2), about 16.98 (e.g., 16.98±0.2), about 17.79 (e.g., 17.79±0.2), about 18.15 (e.g., 18.15±0.2), about 19.06 (e.g., 19.06±0.2), about 19.74 (e.g., 19.74±0.2),about 20.31 (e.g., 20.31±0.2), about 21.75 (e.g., 21.75±0.2), about 24.54 (e.g., 24.54±0.2), about 25.20 (e.g., 25.20±0.2), about 26.16 (e.g., 26.16±0.2), about 26.77 (e.g., 26.77±0.2), and about 28.45 (e.g., 28.45±0.2). In some embodiments, Glycolate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.22 (e.g., 4.22±0.2), about 13.60 (e.g., 13.60±0.2), about 15.93 (e.g., 15.93±0.2), about 16.74 (e.g., 16.74±0.2), about 16.98 (e.g.,16.98±0.2), about 17.79 (e.g., 17.79±0.2), about 18.15 (e.g., 18.15±0.2), about 19.06 (e.g.,19.06±0.2), about 19.74 (e.g., 19.74±0.2), about 20.31 (e.g., 20.31±0.2), about 21.75 (e.g.,21.75±0.2), about 24.54 (e.g., 24.54±0.2), about 25.20 (e.g., 25.20±0.2), about 26.16 (e.g.,26.16±0.2), about 26.77 (e.g., 26.77±0.2), and about 28.45 (e.g., 28.45±0.2). For example, Glycolate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2- theta in degrees of about 4.22 (e.g., 4.22±0.2), about 13.60 (e.g., 13.60±0.2), about 16.74 (e.g., 16.74±0.2), about 17.79 (e.g., 17.79±0.2), about 19.06 (e.g., 19.06±0.2), about 25.20 (e.g., 25.20±0.2), about 26.16 (e.g., 26.16±0). In some embodiments, Glycolate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.22 (e.g., 4.22±0.2), about 13.60 (e.g., 13.60±0.2), about 16.74 (e.g., 16.74±0.2), about 17.79 (e.g., 17.79±0.2), about 19.06 (e.g., 19.06±0.2), about 25.20 (e.g., 25.20±0.2), about 26.16 (e.g., 26.16±0). In some embodiments, Glycolate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.22, about 13.60, and about 16.74. In some embodiments, Glycolate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.22±0.2, 13.60±0.2 and 16.74±0.2. In some embodiments, Glycolate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 13.60, and about 16.74. In some embodiments, Glycolate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 13.60±0.2 and 16.74±0.2. In some embodiments, Glycolate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 16.74. In some embodiments, Glycolate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 16.74±0.2.

[0291] In some embodiments, Glycolate Form I is characterized as having a TGA thermogram substantially as shown in FIG. 28B. In some embodiments, Glycolate Form I ischaracterized as having a mass loss of about 4.6 % after heating from about 25.0 °C to about 87.5 °C, as determined by TGA. In some embodiments, Glycolate Form I is characterized as having a further mass loss of about 1.2 % after heating from about 87.5 °C to about 171.9 °C, as determined by TGA. In some embodiments, Glycolate Form I is characterized as having a further mass loss of about 12.0 % after heating from about 168.7 °C to about 300.0 °C, as determined by TGA.

[0292] In some embodiments, Glycolate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 28B. In some embodiments, Glycolate Form I is characterized as having an endothermic event with an onset at about 117.2 °C. In some embodiments, Glycolate Form I is characterized as having an endotherm peak at about 125.6 °C.

[0293] In some embodiments of Glycolate Form I, at least one, at least two, at least three, at least four, at least five, at least six, or all of the following (a)-(g) apply: a. Glycolate Form I has an XRPD pattern substantially as shown in FIG. 28A; b. Glycolate Form I has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 20; and c. Glycolate Form I has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 4.22±0.2, 13.60±0.2 and 16.74±0.2, ii. peaks at an angle 2-theta in degrees of about 4.22 (e.g., 4.22±0.2), about 13.60 (e.g., 13.60±0.2), about 16.74 (e.g., 16.74±0.2), about 17.79 (e.g., 17.79±0.2), about 19.06 (e.g., 19.06±0.2), about 25.20 (e.g., 25.20±0.2), about 26.16 (e.g., 26.16±0), iii. peaks at an angle 2-theta in degrees of about 4.22 (e.g., 4.22±0.2), about 13.60 (e.g., 13.60±0.2), about 15.93 (e.g., 15.93±0.2), about 16.74 (e.g., 16.74±0.2), about 16.98 (e.g., 16.98±0.2), about 17.79 (e.g., 17.79±0.2), about 18.15 (e.g., 18.15±0.2), about 19.06 (e.g., 19.06±0.2), about 19.74 (e.g., 19.74±0.2), about 20.31 (e.g., 20.31±0.2), about 21.75 (e.g., 21.75±0.2), about 24.54 (e.g., 24.54±0.2), about 25.20 (e.g., 25.20±0.2), about 26.16 (e.g., 26.16±0.2), about 26.77 (e.g., 26.77±0.2), and about 28.45 (e.g., 28.45±0.2), or iv. peaks at an angle 2-theta in degrees of about 4.22 (e.g., 4.22±0.2), about 8.43 (e.g., 8.43±0.2), about 12.66 (e.g., 12.66±0.2), about 12.90 (e.g., 12.90±0.2),about 13.60 (e.g., 13.60±0.2), about 14.39 (e.g., 14.39±0.2), about 15.45 (e.g., 15.45±0.2), about 15.93 (e.g., 15.93±0.2), about 16.37 (e.g., 16.37±0.2), about16.74 (e.g., 16.74±0.2), about 16.98 (e.g., 16.98±0.2), about 17.79 (e.g., 17.79±0.2), about 18.15 (e.g., 18.15±0.2), about 18.66 (e.g., 18.66±0.2), about 19.06 (e.g., 19.06±0.2), about 19.74 (e.g., 19.74±0.2), about 20.31 (e.g.,20.31±0.2), about 20.94 (e.g., 20.94±0.2), about 21.37 (e.g., 21.37±0.2), about21.75 (e.g., 21.75±0.2), about 22.32 (e.g., 22.32±0.2), about 23.08 (e.g., 23.08±0.2), about 23.70 (e.g., 23.70±0.2), about 24.54 (e.g., 24.54±0.2), about25.20 (e.g., 25.20±0.2), about 26.16 (e.g., 26.16±0.2), about 26.77 (e.g., 26.77±0.2), about 26.99 (e.g., 26.99±0.2), about 27.39 (e.g., 27.39±0.2), about 28.08 (e.g., 28.08±0.2), about 28.45 (e.g., 28.45±0.2), about 29.26 (e.g., 29.26±0.2), about 29.50 (e.g., 29.50±0.2), about 30.06 (e.g., 30.06±0.2), about 30.59 (e.g., 30.59±0.2), about 31.15 (e.g., 31.18±0.2), about 31.90 (e.g., 31.90±0.2), about 32.62 (e.g., 32.62±0.2), about 33.61 (e.g., 33.61±0.2), about34.21 (e.g., 34.21±0.2), and about 32.62 (e.g., 34.74±0.2) d. Glycolate Form I has a TGA thermogram substantially as shown in FIG. 28B; e. Glycolate Form I is characterized as having a mass loss of about 4.6 % after heating from about 25.0 °C to about 87.5 °C and about 1.2 % after heating from about 87.5 °C to about 171.9 °C, as determined by TGA, or about 12.0 % after heating from about 168.7 °C to about 300.0 °C, as determined by TGA; f. Glycolate Form I has a DSC thermogram substantially as shown in FIG. 28B; and g. Glycolate Form I is characterized as having endothermic event with an onset at about 117.2 °C and a peak at about 125.6 °C.Lactate Forms

[0294] In some embodiments, the crystalline form is a crystalline form of a lactate salt. In some embodiments, the glycolate salt of Compound A is a mono lactate salt. In some embodiments, the crystalline form of the lactate salt of Compound A is Lactate Form I, or Lactate Form II.Lactate Form I

[0295] In some embodiments, the crystalline form of the lactate salt of Compound A is Lactate Form I. In some embodiments, Lactate Form l is a mono lactate salt.

[0296] In some embodiments, Lactate Form I has an XRPD pattern substantially as shown in FIG. 29A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 21.Table 21.

[0297] In some embodiments, Lactate Form I has an XRPD pattern comprising peaks provided in Table 21. In some embodiments, Lactate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 29A, or as provided in Table 21.

[0298] In some embodiments, Lactate Form I has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 21, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Lactate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.27 (e.g., 5.27±0.2), about 6.98 (e.g., 6.98±0.2), about 10.17 (e.g., 10.17±0.2), about 11.50 (e.g., 11.50±0.2), about 14.60 (e.g., 14.60±0.2), about 16.80 (e.g., 16.80±0.2), about 19.75 (e.g., 19.75±0.2), about 21.16 (e.g., 21.16±0.2), about 24.02 (e.g., 24.02±0.2), and about 28.70 (e.g., 28.70±0.2). In some embodiments, LactateForm I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.27 (e.g., 5.27±0.2), about 6.98 (e.g., 6.98±0.2), about 10.17 (e.g., 10.17±0.2), about 11.50 (e.g., 11.50±0.2), about 14.60 (e.g., 14.60±0.2), about 16.80 (e.g., 16.80±0.2), about 19.75 (e.g., 19.75±0.2), about 21.16 (e.g., 21.16±0.2), about 24.02 (e.g., 24.02±0.2), and about 28.70 (e.g., 28.70±0.2). For example, Lactate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.27 (e.g., 5.27±0.2), about 11.50 (e.g., 11.50±0.2), aboutl6.80 (e.g., 16.80±0.2), about 24.02 (e.g., 24.02±0.2), and about 28.70 (e.g., 28.70±0.2). In some embodiments, Lactate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.27 (e.g., 5.27±0.2), about 11.50 (e.g., 11.50±0.2), aboutl6.80 (e.g., 16.80±0.2), about 24.02 (e.g., 24.02±0.2), and about 28.70 (e.g., 28.70±0.2). In some embodiments, Lactate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.27, about 11.50, and about 16.80. In some embodiments, Lactate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 5.27±0.2, 11.50±0.2 and 16.80±0.2. In some embodiments, Lactate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.27, and about 11.50. In some embodiments, Lactate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 5.27±0.2, and 11.50±0.2. In some embodiments, Lactate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.27. In some embodiments, Lactate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 5.27±0.2.

[0299] In some embodiments, Lactate Form I is characterized as having a TGA thermogram substantially as shown in FIG. 29B. In some embodiments, Lactate Form I is characterized as having a mass loss of about 2.9 % after heating from about 25.0 °C to about 72.1 °C, as determined by TGA. In some embodiments, Lactate Form I is characterized as having a further mass loss of about 8.3 % after heating from about 171.9 °C to about 250.0 °C, as determined by TGA.

[0300] In some embodiments, Lactate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 29B. In some embodiments, Lactate Form I is characterized as having no thermal events at a temperature selected from the range of about 25.0 °C to about 400.0 °C.

[0301] In some embodiments of Lactate Form I, at least one, at least two, at least three, at least four, at least five, or all of the following (a)-(f) apply: a. Lactate Form I has an XRPD pattern substantially as shown in FIG. 29A; b. Lactate Form I has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 21; and c. Lactate Form I has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 5.27±0.2, 11.50±0.2 and 16.80±0.2, ii. peaks at an angle 2-theta in degrees of about 5.27 (e.g., 5.27±0.2), about 11.50 (e.g., 11.50±0.2), aboutl6.80 (e.g., 16.80±0.2), about 24.02 (e.g., 24.02±0.2), and about 28.70 (e.g., 28.70±0.2), or iii. peaks at an angle 2-theta in degrees of about 5.27 (e.g., 5.27±0.2), about 6.98 (e.g., 6.98±0.2), about 10.17 (e.g., 10.17±0.2), about 11.50 (e.g., 11.50±0.2), about 14.60 (e.g., 14.60±0.2), about 16.80 (e.g., 16.80±0.2), about 19.75 (e.g., 19.75±0.2), about 21.16 (e.g., 21.16±0.2), about 24.02 (e.g., 24.02±0.2), and about 28.70 (e.g., 28.70±0.2); d. Lactate Form I has a TGA thermogram substantially as shown in FIG. 29B; e. Lactate Form I is characterized as having a mass loss of about 4.6 % after heating from about 2.9 % after heating from about 25.0 °C to about 72.1 °C and 8.3 % after heating from about 171.9 °C to about 250.0 °C, as determined by TGA; and f. Lactate Form I has a DSC thermogram substantially as shown in FIG. 29B.Lactate Form II

[0302] In some embodiments, the crystalline form of the lactate salt of Compound A is Lactate Form II. In some embodiments, Lactate Form II is a mono lactate salt.

[0303] In some embodiments, Lactate Form II has an XRPD pattern substantially as shown in FIG. 30A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 22.Table 22.

[0304] In some embodiments, Lactate Form II has an XRPD pattern comprising peaks provided in Table 22. In some embodiments, Lactate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 30A, or as provided in Table 22.

[0305] In some embodiments, Lactate Form II has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 22, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. Forexample, Lactate Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.06 (e.g., 4.06±0.2), about 13.31 (e.g., 13.31±0.2), about 14.10 (e.g., 14.10±0.2), about 14.86 (e.g., 14.86±0.2), about 15.90 (e.g., 15.90±0.2), about16.41 (e.g., 16.41±0.2), about 16.77 (e.g., 16.77±0.2), about 17.27 (e.g., 17.27±0.2), about17.91 (e.g., 17.91±0.2), about 18.77 (e.g., 18.77±0.2), about 20.13 (e.g., 20.13±0.2), about21.28 (e.g., 21.28±0.2), about 22.97 (e.g., 22.97±0.2), about 24.35 (e.g., 24.35±0.2), about25.20 (e.g., 25.20±0.2), about 26.13 (e.g., 26.13±0.2), about 26.61 (e.g., 26.61±0.2), and about 28.70 (e.g., 28.70±0.2). In some embodiments, Lactate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.06 (e.g., 4.06±0.2), about 13.31 (e.g., 13.31±0.2), about 14.10 (e.g., 14.10±0.2), about 14.86 (e.g., 14.86±0.2), about 15.90 (e.g., 15.90±0.2), about 16.41 (e.g., 16.41±0.2), about 16.77 (e.g., 16.77±0.2), about 17.27 (e.g., 17.27±0.2), about 17.91 (e.g., 17.91±0.2), about 18.77 (e.g., 18.77±0.2), about 20.13 (e.g., 20.13±0.2), about 21.28 (e.g., 21.28±0.2), about 22.97 (e.g., 22.97±0.2), about 24.35 (e.g., 24.35±0.2), about 25.20 (e.g., 25.20±0.2), about 26.13 (e.g., 26.13±0.2), about 26.61 (e.g., 26.61±0.2), and about 28.70 (e.g., 28.70±0.2). For example, Lactate Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.06 (e.g., 4.06±0.2), about 14.86 (e.g., 14.86±0.2), about 15.90 (e.g., 15.90±0.2), about 16.41 (e.g., 16.41±0.2), about 17.27 (e.g., 17.27±0.2), about 17.91 (e.g., 17.91±0.2), about 20.13 (e.g., 20.13±0.2), about 24.35 (e.g., 24.35±0.2), about 25.20 (e.g., 25.20±0.2), about 26.13 (e.g., 26.13±0.2), and about 26.61 (e.g., 26.61±0.2). In some embodiments, Lactate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 4.06 (e.g., 4.06±0.2), about 14.86 (e.g., 14.86±0.2), about 15.90 (e.g., 15.90±0.2), about 16.41 (e.g., 16.41±0.2), about 17.27 (e.g.,17.27±0.2), about 17.91 (e.g., 17.91±0.2), about 20.13 (e.g., 20.13±0.2), about 24.35 (e.g.,24.35±0.2), about 25.20 (e.g., 25.20±0.2), about 26.13 (e.g., 26.13±0.2), and about 26.61(e.g., 26.61±0.2). For example, Lactate Form II may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.06 (e.g., 4.06±0.2), about 15.90 (e.g., 15.90±0.2), about 17.27 (e.g., 17.27±0.2), about 25.20 (e.g., 25.20±0.2), about 26.13 (e.g., 26.13±0.2), and about 26.61 (e.g., 26.61±0.2). In some embodiments, Lactate Form II has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peakseach assigned at angles 2-theta in degrees of about 4.06 (e.g., 4.06±0.2), about 15.90 (e.g., 15.90±0.2), about 17.27 (e.g., 17.27±0.2), about 25.20 (e.g., 25.20±0.2), about 26.13 (e.g., 26.13±0.2), and about 26.61 (e.g., 26.61±0.2). In some embodiments, Lactate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.06, about 15.90, and about 25.20. In some embodiments, Lactate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.06±0.2, 15.90±0.2 and 25.20±0.2. In some embodiments, Lactate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.06, and about 25.20. In some embodiments, Lactate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 4.06±0.2, and 25.20±0.2. In some embodiments, Lactate Form II has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 25.20. In some embodiments, Lactate Form II has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 25.20±0.2.

[0306] In some embodiments, Lactate Form II is characterized as having a TGA thermogram substantially as shown in FIG. 30B. In some embodiments, Lactate Form II is characterized as having a mass loss of about 3.7 % after heating from about 25.0 °C to about 82.0 °C, as determined by TGA. In some embodiments, Lactate Form II is characterized as having a further mass loss of about 2.0 % after heating from about 88.9 °C to about 155.8 °C, as determined by TGA.

[0307] In some embodiments, Lactate Form II is characterized as having a DSC thermogram substantially as shown in FIG. 30B. In some embodiments, Lactate Form II is characterized as having no thermal events at a temperature selected from the range of about 25.0 °C to about 400.0 °C.

[0308] In some embodiments of Lactate Form II, at least one, at least two, at least three, at least four, at least five, or all of the following (a)-(f) apply: a. Lactate Form II has an XRPD pattern substantially as shown in FIG. 30A; b. Lactate Form II has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 22; and c. Lactate Form II has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 4.06±0.2, 15.90±0.2 and 25.20±0.2,ii. peaks at an angle 2-theta in degrees of about 4.06 (e.g., 4.06±0.2), about 15.90 (e.g., 15.90±0.2), about 17.27 (e.g., 17.27±0.2), about 25.20 (e.g., 25.20±0.2), about 26.13 (e.g., 26.13±0.2), and about 26.61 (e.g., 26.61±0.2), iii. peaks at an angle 2-theta in degrees of about 4.06 (e.g., 4.06±0.2), about 14.86 (e.g., 14.86±0.2), about 15.90 (e.g., 15.90±0.2), about 16.41 (e.g., 16.41±0.2), about 17.27 (e.g., 17.27±0.2), about 17.91 (e.g., 17.91±0.2), about 20.13 (e.g., 20.13±0.2), about 24.35 (e.g., 24.35±0.2), about 25.20 (e.g., 25.20±0.2), about 26.13 (e.g., 26.13±0.2), and about 26.61 (e.g., 26.61±0.2), or iv. peaks at an angle 2-theta in degrees of about 4.06 (e.g., 4.06±0.2), about 13.31 (e.g., 13.31±0.2), about 14.10 (e.g., 14.10±0.2), about 14.86 (e.g., 14.86±0.2), about 15.90 (e.g., 15.90±0.2), about 16.41 (e.g., 16.41±0.2), about 16.77 (e.g., 16.77±0.2), about 17.27 (e.g., 17.27±0.2), about 17.91 (e.g., 17.91±0.2), about 18.77 (e.g., 18.77±0.2), about 20.13 (e.g., 20.13±0.2), about 21.28 (e.g., 21.28±0.2), about 22.97 (e.g., 22.97±0.2), about 24.35 (e.g., 24.35±0.2), about 25.20 (e.g., 25.20±0.2), about 26.13 (e.g., 26.13±0.2), about 26.61 (e.g., 26.61±0.2), and about 28.70 (e.g., 28.70±0.2); d. Lactate Form II has a TGA thermogram substantially as shown in FIG. 30B; e. Lactate Form II is characterized as having a mass loss of about 3.7 % after heating from about 25.0 °C to about 82.0 °C and about 2.0 % after heating from about 88.9 °C to about 155.8 °C, as determined by TGA; and f. Lactate Form II has a DSC thermogram substantially as shown in FIG. 30B.Benzoate Forms

[0309] In some embodiments, the crystalline form is a crystalline form of a benzoate salt.Benzoate Form I

[0310] In some embodiments, the crystalline form of the benzoate salt of Compound A is Benzoate Form I.

[0311] In some embodiments, Benzoate Form I has an XRPD pattern substantially as shown in FIG. 31A. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 23.Table 23.

[0312] In some embodiments, Benzoate Form I has an XRPD pattern comprising peaks provided in Table 23. In some embodiments, Benzoate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 31A, or as provided in Table 23.

[0313] In some embodiments, Benzoate Form I has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 23, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Benzoate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 6.30 (e.g., 6.30±0.2), about 7.70 (e.g., 7.70±0.2), about 8.91 (e.g., 8.91±0.2), about 9.46 (e.g., 9.46±0.2), about 10.91 (e.g., 10.91±0.2), about 12.62 (e.g., 12.62±0.2), about 12.99 (e.g., 12.99±0.2), about 13.37 (e.g., 13.37±0.2), about 13.70 (e.g.,13.70±0.2), about 14.40 (e.g., 14.40±0.2), about 14.77 (e.g., 14.77±0.2), about 15.47 (e.g.,15.47±0.2), about 16.39 (e.g., 16.39±0.2), about 16.66 (e.g., 16.66±0.2), about 17.26 (e.g.,17.26±0.2), about 17.86 (e.g., 17.86±0.2), about 18.14 (e.g., 18.14±0.2), about 18.98 (e.g.,18.98±0.2), about 19.20 (e.g., 19.20±0.2), about 19.49 (e.g., 19.49±0.2), about 20.22 (e.g.,20.22±0.2), about 20.72 (e.g., 20.72±0.2), about 21.00 (e.g., 21.00±0.2), about 21.43 (e.g.,21.43±0.2), about 22.81 (e.g., 22.81±0.2), about 23.48 (e.g., 23.48±0.2), about 23.90 (e.g.,23.90±0.2), about 24.54 (e.g., 24.51±0.2), about 24.94 (e.g., 24.94±0.2), about 25.38 (e.g.,25.38±0.2), about 25.95 (e.g., 25.95±0.2), about 26.52 (e.g., 26.52±0.2), about 27.12 (e.g.,27.12±0.2), about 27.68 (e.g., 27.68±0.2), about 28.06 (e.g., 28.06±0.2), about 28.60 (e.g.,28.60±0.2), about 29.33 (e.g., 29.33±0.2), about 30.52 (e.g., 30.52±0.2), about 31.03 (e.g.,31.03±0.2), about 31.85 (e.g., 31.85±0.2), about 33.16 (e.g., 33.16±0.2), and about 33.73 (e.g., 33.73±0.2). In some embodiments, Benzoate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2- theta in degrees of about 6.30 (e.g., 6.30±0.2), about 7.70 (e.g., 7.70±0.2), about 8.91 (e.g., 8.91±0.2), about 9.46 (e.g., 9.46±0.2), about 10.91 (e.g., 10.91±0.2), about 12.62 (e.g., 12.62±0.2), about 12.99 (e.g., 12.99±0.2), about 13.37 (e.g., 13.37±0.2), about 13.70 (e.g.,13.70±0.2), about 14.40 (e.g., 14.40±0.2), about 14.77 (e.g., 14.77±0.2), about 15.47 (e.g.,15.47±0.2), about 16.39 (e.g., 16.39±0.2), about 16.66 (e.g., 16.66±0.2), about 17.26 (e.g.,17.26±0.2), about 17.86 (e.g., 17.86±0.2), about 18.14 (e.g., 18.14±0.2), about 18.98 (e.g.,18.98±0.2), about 19.20 (e.g., 19.20±0.2), about 19.49 (e.g., 19.49±0.2), about 20.22 (e.g.,20.22±0.2), about 20.72 (e.g., 20.72±0.2), about 21.00 (e.g., 21.00±0.2), about 21.43 (e.g.,21.43±0.2), about 22.81 (e.g., 22.81±0.2), about 23.48 (e.g., 23.48±0.2), about 23.90 (e.g.,23.90±0.2), about 24.54 (e.g., 24.51±0.2), about 24.94 (e.g., 24.94±0.2), about 25.38 (e.g.,25.38±0.2), about 25.95 (e.g., 25.95±0.2), about 26.52 (e.g., 26.52±0.2), about 27.12 (e.g.,27.12±0.2), about 27.68 (e.g., 27.68±0.2), about 28.06 (e.g., 28.06±0.2), about 28.60 (e.g.,28.60±0.2), about 29.33 (e.g., 29.33±0.2), about 30.52 (e.g., 30.52±0.2), about 31.03 (e.g.,31.03±0.2), about 31.85 (e.g., 31.85±0.2), about 33.16 (e.g., 33.16±0.2), and about 33.73 (e.g., 33.73±0.2). For example, Benzoate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 6.30 (e.g., 6.30±0.2), about 9.46 (e.g., 9.46±0.2), about 12.62 (e.g., 12.62±0.2), about 14.77 (e.g., 14.77±0.2), about 16.39 (e.g., 16.39±0.2), about 16.66 (e.g., 16.66±0.2), about 17.26 (e.g., 17.26±0.2), about 18.14(e.g., 18.14±0.2), about 19.20 (e.g., 19.20±0.2), about 21.43 (e.g., 21.43±0.2), about 22.81(e.g., 22.81±0.2), about 23.48 (e.g., 23.48±0.2), about 23.90 (e.g., 23.90±0.2), and about26.52 (e.g., 26.52±0.2). In some embodiments, Benzoate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 6.30 (e.g., 6.30±0.2), about 9.46 (e.g., 9.46±0.2), about 12.62 (e.g., 12.62±0.2), about 14.77 (e.g., 14.77±0.2), about 16.39 (e.g., 16.39±0.2), about16.66 (e.g., 16.66±0.2), about 17.26 (e.g., 17.26±0.2), about 18.14 (e.g., 18.14±0.2), about19.20 (e.g., 19.20±0.2), about 21.43 (e.g., 21.43±0.2), about 22.81 (e.g., 22.81±0.2), about23.48 (e.g., 23.48±0.2), about 23.90 (e.g., 23.90±0.2), and about 26.52 (e.g., 26.52±0.2). For example, Benzoate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 6.30 (e.g., 6.30±0.2), about 14.77 (e.g., 14.77±0.2), about 16.66 (e.g., 16.66±0.2), about 18.14 (e.g., 18.14±0.2), about 19.20 (e.g., 19.20±0.2), about 22.81 (e.g., 22.81±0.2), and about 26.52 (e.g., 26.52±0.2). In some embodiments, Benzoate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 6.30 (e.g., 6.30±0.2), about 14.77 (e.g., 14.77±0.2), about 16.66 (e.g., 16.66±0.2), about 18.14 (e.g., 18.14±0.2), about 19.20 (e.g., 19.20±0.2), about 22.81 (e.g., 22.81±0.2), and about 26.52 (e.g., 26.52±0.2). In some embodiments, Benzoate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 14.77, about 16.66, and about 18.14. In some embodiments, Benzoate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 14.77±0.2, 16.66±0.2 and 18.14±0.2. In some embodiments, Benzoate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 14.77, and about 18.14. In some embodiments, Benzoate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 14.77±0.2, and 18.14±0.2. In some embodiments, Benzoate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 14.77. In some embodiments, Benzoate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 14.77±0.2.

[0314] In some embodiments, Benzoate Form I is characterized as having a TGA thermogram substantially as shown in FIG. 31B. In some embodiments, Benzoate Form I is characterized as having an initial mass loss of 0.7 %. after heating from about 25.0 °C to about 137.5 °C, as determined by TGA. In some embodiments, Benzoate Form I ischaracterized as having a further mass loss of 12.7 %. after heating from about 137.5 °C to about 250.0 °C, as determined by TGA.

[0315] In some embodiments, Benzoate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 31B or 31C. In some embodiments, Benzoate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 31B. In some embodiments, Benzoate Form I is characterized as having an endothermic event with onset at about 173.4 °C. In some embodiments, Benzoate Form I is characterized as having an endotherm peak at about 182.2 °C. In some embodiments, Benzoate Form I is characterized as having a DSC thermogram substantially as shown in FIG. 31C. In some embodiments, Benzoate Form I is characterized as having an endothermic / exothermic event with onsets / peaks of 179.8 °C / 182.5 °C and 184.4 °C / 187.6 °C on heating to 200 °C.

[0316] In some embodiments, Benzoate Form I is characterized as having (a) a DVS isotherm pattern and (b) a DVS kinetic pattern substantially as shown in FIG. 31D.

[0317] In some embodiments of Benzoate Form I, at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or all of the following (a)-(h) apply: a. Benzoate Form I has an XRPD pattern substantially as shown in FIG. 31A; b. Benzoate Form I has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 23; and c. Benzoate Form I has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 14.77±0.2, 16.66±0.2 and 18.14±0.2, ii. peaks at an angle 2-theta in degrees of 6.30 (e.g., 6.30±0.2), about 14.77 (e.g., 14.77±0.2), about 16.66 (e.g., 16.66±0.2), about 18.14 (e.g., 18.14±0.2), about 19.20 (e.g., 19.20±0.2), about 22.81 (e.g., 22.81±0.2), and about 26.52 (e.g., 26.52±0.2), iii. peaks at an angle 2-theta in degrees of about 6.30 (e.g., 6.30±0.2), about 9.46 (e.g., 9.46±0.2), about 12.62 (e.g., 12.62±0.2), about 14.77 (e.g., 14.77±0.2), about 16.39 (e.g., 16.39±0.2), about 16.66 (e.g., 16.66±0.2), about 17.26 (e.g., 17.26±0.2), about 18.14 (e.g., 18.14±0.2), about 19.20 (e.g., 19.20±0.2), about 21.43 (e.g., 21.43±0.2), about 22.81 (e.g., 22.81±0.2), about 23.48 (e.g., 23.48±0.2), about 23.90 (e.g., 23.90±0.2), and about 26.52 (e.g., 26.52±0.2), oriv. peaks at an angle 2-theta in degrees of about 6.30 (e.g., 6.30±0.2), about 7.70 (e.g., 7.70±0.2), about 8.91 (e.g., 8.91±0.2), about 9.46 (e.g., 9.46±0.2), about 10.91 (e.g., 10.91±0.2), about 12.62 (e.g., 12.62±0.2), about 12.99 (e.g., 12.99±0.2), about 13.37 (e.g., 13.37±0.2), about 13.70 (e.g., 13.70±0.2), about 14.40 (e.g., 14.40±0.2), about 14.77 (e.g., 14.77±0.2), about 15.47 (e.g., 15.47±0.2), about 16.39 (e.g., 16.39±0.2), about 16.66 (e.g., 16.66±0.2), about 17.26 (e.g., 17.26±0.2), about 17.86 (e.g., 17.86±0.2), about 18.14 (e.g., 18.14±0.2), about 18.98 (e.g., 18.98±0.2), about 19.20 (e.g., 19.20±0.2), about 19.49 (e.g., 19.49±0.2), about 20.22 (e.g., 20.22±0.2), about 20.72 (e.g., 20.72±0.2), about 21.00 (e.g., 21.00±0.2), about 21.43 (e.g., 21.43±0.2), about 22.81 (e.g., 22.81±0.2), about 23.48 (e.g., 23.48±0.2), about 23.90 (e.g., 23.90±0.2), about 24.54 (e.g., 24.51±0.2), about 24.94 (e.g., 24.94±0.2), about 25.38 (e.g., 25.38±0.2), about 25.95 (e.g., 25.95±0.2), about 26.52 (e.g., 26.52±0.2), about 27.12 (e.g., 27.12±0.2), about 27.68 (e.g., 27.68±0.2), about 28.06 (e.g., 28.06±0.2), about 28.60 (e.g., 28.60±0.2), about 29.33 (e.g., 29.33±0.2), about 30.52 (e.g., 30.52±0.2), about 31.03 (e.g., 31.03±0.2), about 31.85 (e.g., 31.85±0.2), about 33.16 (e.g., 33.16±0.2), and about 33.73 (e.g., 33.73±0.2); d. Benzoate Form I has a TGA thermogram substantially as shown in FIG. 31B; e. Benzoate Form I is characterized as having a mass loss of about of 0.7 %. after heating from about 25.0 °C to about 137.5 °C and 12.7 %. after heating from about 137.5 °C to about 250.0 °C, as determined by TGA; f. Benzoate Form I has a DSC thermogram substantially as shown in FIG. 31B or FIG. 31C; g. Benzoate Form I is characterized as having an endothermic / exothermic event with onsets / peaks of 179.8 °C / 182.5 °C and 184.4 °C / 187.6 °C on heating to 200 °; and h. Benzoate Form I is characterized as having (a) a DVS isotherm pattern and (b) a DVS kinetic pattern substantially as shown in FIG. 31D.Succinate Forms

[0318] In some embodiments, the crystalline form is a crystalline form of a succinate salt.Succinate Form I

[0319] In some embodiments, the crystalline form of the succinate salt of Compound A is Succinate Form I.

[0320] In some embodiments, Succinate Form I has an XRPD pattern substantially as shown in FIG. 32. Positions of peaks and relative peak intensities that may be observed for the crystalline form using XRPD are shown in Table 24.Table 24.

[0321] In some embodiments, Succinate Form I has an XRPD pattern comprising peaks provided in Table 24. In some embodiments, Succinate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG. 32, or as provided in Table 24.

[0322] In some embodiments, Succinate Form I has an XRPD pattern comprising peaks as assigned at angles 2-theta in degrees as recited in Table 24, each peak of which can independently vary in assignment at angle 2-theta in degrees as described herein. For example, Succinate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.21 (e.g., 5.21±0.2), about 6.95 (e.g., 6.95±0.2), about 10.13 (e.g., 10.13±0.2), about 10.57 (e.g., 10.57±0.2), about 11.38 (e.g., 11.38±0.2), about12.90 (e.g., 12.90±0.2), about 13.83 (e.g., 13.83±0.2), about 14.55 (e.g., 14.55±0.2), about15.66 (e.g., 15.66±0.2), about 16.55 (e.g., 16.55±0.2), about 17.31 (e.g., 17.31±0.2), about18.64 (e.g., 18.64±0.2), about 19.57 (e.g., 19.57±0.2), about 20.55 (e.g., 20.55±0.2), about21.02 (e.g., 21.01±0.2), about 22.84 (e.g., 22.84±0.2), about 23.68 (e.g., 23.68±0.2), about24.50 (e.g., 24.50±0.2), about 25.41 (e.g., 25.41±0.2), about 27.81 (e.g., 27.81±0.2), and about 28.33 (e.g., 28.33±0.2). In some embodiments, Succinate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.21 (e.g., 5.21±0.2), about 6.95 (e.g., 6.95±0.2), about 10.13 (e.g., 10.13±0.2), about 10.57 (e.g., 10.57±0.2), about 11.38 (e.g., 11.38±0.2), about12.90 (e.g., 12.90±0.2), about 13.83 (e.g., 13.83±0.2), about 14.55 (e.g., 14.55±0.2), about15.66 (e.g., 15.66±0.2), about 16.55 (e.g., 16.55±0.2), about 17.31 (e.g., 17.31±0.2), about18.64 (e.g., 18.64±0.2), about 19.57 (e.g., 19.57±0.2), about 20.55 (e.g., 20.55±0.2), about21.02 (e.g., 21.01±0.2), about 22.84 (e.g., 22.84±0.2), about 23.68 (e.g., 23.68±0.2), about24.50 (e.g., 24.50±0.2), about 25.41 (e.g., 25.41±0.2), about 27.81 (e.g., 27.81±0.2), and about 28.33 (e.g., 28.33±0.2). For example, Succinate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of 5.21 (e.g., 5.21±0.2), about 6.95 (e.g., 6.95±0.2), about 10.13 (e.g., 10.13±0.2), about 10.57 (e.g., 10.57±0.2), about 11.38 (e.g., 11.38±0.2), about 16.55 (e.g., 16.55±0.2), about 19.57 (e.g., 19.57±0.2), about 21.02 (e.g., 21.01±0.2), about 23.68 (e.g., 23.68±0.2), and about 28.33 (e.g., 28.33±0.2). In some embodiments, Succinate Form I has an XRPD pattern comprising one or more (e.g., atleast one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.21 (e.g., 5.21±0.2), about 6.95 (e.g., 6.95±0.2), about 10.13 (e.g., 10.13±0.2), about10.57 (e.g., 10.57±0.2), about 11.38 (e.g., 11.38±0.2), about 16.55 (e.g., 16.55±0.2), about19.57 (e.g., 19.57±0.2), about 21.02 (e.g., 21.01±0.2), about 23.68 (e.g., 23.68±0.2), and about 28.33 (e.g., 28.33±0.2). For example, Succinate Form I may have an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.21 (e.g., 5.21±0.2), about 6.95 (e.g., 6.95±0.2), about 11.38 (e.g., 11.38±0.2), about 16.55 (e.g., 16.55±0.2), and about 23.68 (e.g., 23.68±0.2). In some embodiments, Succinate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks each assigned at angles 2-theta in degrees of about 5.21 (e.g., 5.21±0.2), about 6.95 (e.g., 6.95±0.2), about 11.38 (e.g., 11.38±0.2), about 16.55 (e.g., 16.55±0.2), and about 23.68 (e.g., 23.68±0.2). In some embodiments, Succinate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.21, about 6.95, and about 11.38. In some embodiments, Succinate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 5.21±0.2, 6.95±0.2 and 11.38±0.2. In some embodiments, Succinate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.21, and about 11.38. In some embodiments, Succinate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 5.21±0.2, and 11.38±0.2. In some embodiments, Succinate Form I has an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.21. In some embodiments, Succinate Form I has an XRPD pattern comprising peaks each assigned at angles 2-theta in degrees of about 5.21±0.2.

[0323] In some embodiments of Succinate Form I, at least one, at least two, or all of the following (a)-(c) apply: a. Succinate Form I has an XRPD pattern substantially as shown in FIG. 32; b. Succinate Form I has an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 24; and c. Succinate Form I has an XRPD pattern comprising: i. peaks at an angle 2-theta in degrees of about 5.21±0.2, 6.95±0.2 and 11.38±0.2,ii. peaks at an angle 2-theta in degrees of about 5.21 (e.g., 5.21±0.2), about 6.95 (e.g., 6.95±0.2), about 11.38 (e.g., 11.38±0.2), about 16.55 (e.g., 16.55±0.2), and about 23.68 (e.g., 23.68±0.2), iii. peaks at an angle 2-theta in degrees of about 5.21 (e.g., 5.21±0.2), about 6.95 (e.g., 6.95±0.2), about 10.13 (e.g., 10.13±0.2), about 10.57 (e.g., 10.57±0.2), about 11.38 (e.g., 11.38±0.2), about 16.55 (e.g., 16.55±0.2), about 19.57 (e.g., 19.57±0.2), about 21.02 (e.g., 21.01±0.2), about 23.68 (e.g., 23.68±0.2), and about 28.33 (e.g., 28.33±0.2), or iv. peaks at an angle 2-theta in degrees of about about 5.21 (e.g., 5.21±0.2), about 6.95 (e.g., 6.95±0.2), about 10.13 (e.g., 10.13±0.2), about 10.57 (e.g., 10.57±0.2), about 11.38 (e.g., 11.38±0.2), about 12.90 (e.g., 12.90±0.2), about 13.83 (e.g., 13.83±0.2), about 14.55 (e.g., 14.55±0.2), about 15.66 (e.g., 15.66±0.2), about 16.55 (e.g., 16.55±0.2), about 17.31 (e.g., 17.31±0.2), about 18.64 (e.g., 18.64±0.2), about 19.57 (e.g., 19.57±0.2), about 20.55 (e.g., 20.55±0.2), about 21.02 (e.g., 21.01±0.2), about 22.84 (e.g., 22.84±0.2), about 23.68 (e.g., 23.68±0.2), about 24.50 (e.g., 24.50±0.2), about 25.41 (e.g., 25.41±0.2), about 27.81 (e.g., 27.81±0.2), and about 28.33 (e.g., 28.33±0.2).Acetate Forms

[0324] In some embodiments, the crystalline form is a crystalline form of an acetate salt.Acetate Form I

[0325] In some embodiments, Acetate Form I has an XRPD pattern substantially as shown in FIG. 33A. In some embodiments, the crystalline form is a crystalline form of a succinate salt. In some embodiments, the crystalline form is characterized as having an X-ray powder diffraction (XRPD) pattern comprising a peak at an angle 2-theta of about 4.33 degrees. In some embodiments, the XRPD pattern further comprises a peak at an angle 2- theta of about 6.75 degrees. In some embodiments, Acetate Form I has an XRPD pattern comprising one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) of the peaks at angles 2-theta with the greatest intensity in the XRPD pattern substantially as shown in FIG.33A

[0326] In some embodiments, the crystalline form is characterized as having a TGA thermogram substantially as shown in FIG. 33B. In some embodiments, the crystalline form is characterized as having a mass loss of about 0.6 % after heating from about 25.0 °C to about 62.5 °C, as determined by TGA. In some embodiments, the crystalline form is characterized as having a further mass loss of about 2.35 % after heating from about 62.5 °C to about 187.5 °C, as determined by TGA. In some embodiments, the crystalline form is characterized as having a further mass loss of about 3.22 % after heating from about 187.5 °C to about 275.0 °C, as determined by TGA.

[0327] In some embodiments, the crystalline form is characterized as having a DSC thermogram substantially as shown in FIG. 33B. In some embodiments, the crystalline form is characterized as having an endothermic event with onset at about 157.8 °C. In some embodiments, the crystalline form is characterized as having an endotherm peak at about 168.7 °C. In some embodiments, the crystalline form is further characterized as having an endothermic event with onset at about 213.5 °C. In some embodiments, the endotherm peak is at about 221.4 °C.

[0328] It should be understood that relative intensities and peak assignments can vary depending on a number of factors, including sample preparation, mounting, the instrument and analytical procedure and settings used to obtain the spectrum, temperature effects on the unit cell, and extent of solvation, e.g., hydration, of the sample. For example, for HBr Form I, HBr Form II, HBr Form III, HC1 Form I, HC1 Form II, Sulfate Form I, Sulfate Form II, Sulfate Form III, Tosylate Form I, Mesylate Form I, Mesylate Form II, Napsylate Form I, Napsylate Form II, Napsylate Form III, Besylate Form I, Besylate Form II, Aspartate Form I, Aspartate Form II, Aspartate Form III, Maleate Form I, Maleate Form II, Esylate Form I, Esylate Form II, Malonate Form I, Malonate Form II, Glycyronate Form I, Glucuronate FormII, Glycolate Form I, Lactate Form I, Lactate Form II, Benzoate Form I, Succinate Form I, or Acetate Form I, relative peak intensities and peak assignments can vary within experimental error. In some embodiments, each peak assignment listed herein, can independently vary by ±0.6 degrees, ±0.4 degrees, ±0.2 degrees, or ±0.1 degrees 2-theta. In some embodiments, each peak assignment listed herein, including for HBr Form I, HBr Form II, HBr Form III, HC1 Form I, HC1 Form II, Sulfate Form I, Sulfate Form II, Sulfate Form III, Tosylate Form I, Mesylate Form I, Mesylate Form II, Napsylate Form I, Napsylate Form II, Napsylate FormIII, Besylate Form I, Besylate Form II, Aspartate Form I, Aspartate Form II, Aspartate FormIII, Maleate Form I, Maleate Form II, Esylate Form I, Esylate Form II, Malonate Form I, Malonate Form II, Glycyronate Form I, Glucuronate Form II, Glycolate Form I, Lactate FormI, Lactate Form II, Benzoate Form I, Succinate Form I, or Acetate Form I, can independently vary by ±0.2 degrees 2-theta.

[0329] In some embodiments of a crystalline form disclosed herein (e.g., HBr Form I, HBr Form II, HBr Form III, HC1 Form I, HC1 Form II, Sulfate Form I, Sulfate Form II, Sulfate Form III, Tosylate Form I, Mesylate Form I, Mesylate Form II, Napsylate Form I, Napsylate Form II, Napsylate Form III, Besylate Form I, Besylate Form II, Aspartate Form I, Aspartate Form II, Aspartate Form III, Maleate Form I, Maleate Form II, Esylate Form I, Esylate Form II, Malonate Form I, Malonate Form II, Glycyronate Form I, Glucuronate FormII, Glycolate Form I, Lactate Form I, Lactate Form II, Benzoate Form I, Succinate Form I, or Acetate Form I), the crystalline form is substantially anhydrous. For example, in some embodiments, the crystalline form has a water content of less than about 1%, about 0.5%, about 0.2%, or about 0.1% by weight. In some embodiments, the crystalline form has a water content in % by weight of one of about 0.1, 0.15, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1, or a range between any two of the preceding values. For example, the crystalline form can have a water content of about 0.1-1.0 wt %. In some embodiments, the water content is about 0.1-0.5 wt %. In some embodiments, the water content is about 0.15-0.5 wt %. The crystalline form can have a water content that varies in % by weight of ±1, ±0.75, ±0.5, ±0.25, or ±0.1 around a % by weight. For example, the crystalline form can have a water content of about 1 ±0.75 wt %. The water content can be about 1 ±0.5 wt %. The water content can be about 0.1 ±0.1 wt %. The water content can be about 0.15 ±0.1 wt %. The water content can be about 0.5 ±0.1 wt %. The water content can be about 0.5 ±0.25 wt %. The water content can be about 0.5 ±0.5 wt %.III, METHODS OF PREPARING

[0330] Provided herein are methods for preparing a crystalline form of a salt of Compound A.

[0331] In some embodiments, the method comprises preparing mixture Compound A in a solvent. In some embodiments, the method comprises preparing mixture of a salt of Compound A in a solvent.

[0332] In some embodiments, the method for preparing a crystalline form of a salt of Compound A comprises: a. contacting Compound A with a solvent; b. adding a salt forming reagent; and c. crystallizing a salt of Compound A.

[0333] In some embodiments of the method for preparing a crystalline form of a salt of Compound A, the solvent is selected from the group consisting of 1,2-Dichloroethene, 1,4- Dioxane, 1 -Butanol, 1 -Propanol, 2 -Ethoxy ethanol, 2-Methyl THF, 2 -Methyl- 1 -Propanol, 2- Propanol, 48 % Methanol : 52 % Water % v / v, 48 % Methanol : 52 % Water % v / v, 98.5 % Ethanol : 1.5 % Water % v / v, Acetone, Acetonitrile, Anisole, Butyl Acetate, Dichloromethane, Dimethylsulfoxide, Ethanol, Ethyl Acetate, Heptane, Isopropyl Acetate, Methanol, Methylethyl Ketone, Methylisobutyl Ketone, Nitromethane, N,N'- Dimethylacetamide, N,N'-Dimethylformamide, N-Methylpyrrolidone, tert-Butylmethyl Ether, Tetrahydrofuran, Toluene, Water, and Acetic Acid, or a mixture of any of the foregoing. In some embodiments, the solvent is selected from the group consisting of acetone, acetonitrile, ethanol, water, ethyl acetate, methanol, or tetrahydrofuran, or a mixture of any of the foregoing.

[0334] In some embodiments, the method for preparing a crystalline form of a salt of Compound A comprises adding a salt forming reagent. In some embodiments, the reagent is an acid or a base. In some embodiments, the reagent is an acid. In some embodiments, the reagent is selected from the group consisting of Hydrochloric acid, Hydrobromic acid, Sulfuric acid, Ethanesulfonic acid, p-Toluenesulfonic acid, Methanesulfonic acid, Naphthalene-2-sulfonic acid, Benzenesulfonic acid, Maleic acid, L- Aspartic acid, Phosphoric acid, Glutamic acid, Malonic acid, Fumaric acid, (+)-L-Tartaric acid, Citric acid, D- Glucuronic acid, Glycolic acid, L-Malic acid, L-Lactic acid, L-Ascorbic acid, Benzoic acid, Succinic acid, and Acetic acid. In some embodiments, the reagent is selected from the group consisting of HBr, HC1, sulfuric acid, p-toluene sulphonic acid, p-toluene sulphonic acid.H2O, methanesulphonic acid, naphthalenesulfonic acid, benzenesulfonic acid, aspartic acid, maleic acid, ethanesulphonic acid, malonic acid, glucuronic acid, glycolic acid, lactic acid, benzoic acid, succinic acid, or acetic acid. In some embodiments, the reagent is selected from the group consisting of HBr, HC1, p-toluene sulphonic acid.H2O, benzene sulphonic acid, maleic acid, or benzoic acid. In some embodiments, the reagent benzene sulphonic acid.

[0335] In some embodiments, the reagent is HBr and the solvent comprises acetone, ethyl acetate, THF, acetonitrile, ethanol: water, or ethanol. In some embodiments, the reagent is HBr and the solvent comprises ethanokwater (93:7% v / v). In some embodiments, the reagent is HC1 and the solvent comprises acetone, THF, acetonitrile, ethanol: water, ethyl acetate or ethanol. In some embodiments, the reagent is HC1 and the solvent comprises ethanokwater (93:7% v / v). In some embodiments, the reagent is sulfuric acid and the solvent comprises acetonitrile. In some embodiments, the reagent is p-toluenesulfonic acid and the solvent comprises acetone, or ethanol. In some embodiments, the reagent is / ?-toluenesulfonic acid and the solvent comprises ethanol. In some embodiments, the reagent is methanesulfonic acid and the solvent comprises acetone. In some embodiments, the reagent is benzenesulfonic acid and the solvent comprises ethanokwater (93:7% v / v). In some embodiments, the reagent is napthanesulfonic acid and the solvent comprises acetone, or THF. In some embodiments, the reagent is benzenesulfonic acid and the solvent comprises from acetone, acetonitrile, ethanokwater (93:7 %v / v) ethyl acetate or THF. In some embodiments, the reagent is aspartic acid and the solvent comprises acetonitrile, or THF. In some embodiments, the reagent is maleic acid and the solvent comprises acetone, acetonitrile, ethyl acetate, THF, or ethanol. In some embodiments, the reagent is ethanesulfonic acid and the solvent comprises acetone, acetonitrile, ethyl acetate or THF. In some embodiments, the reagent is malonic acid and the solvent comprises ethanol, THF, or acetonitrile. In some embodiments, the reagent is glucuronic acid and the solvent comprises ethanokwater (93:7 %v / v), or ethyl acetate. In some embodiments, the reagent is glycolic acid and the solvent comprises acetonitrile. In some embodiments, the reagent is lactic acid and the solvent comprises acetone, ethyl acetate, ethanol, THF, or acetonitrile. In some embodiments, the reagent is benzoic acid and the solvent comprises acetone, or acetonitrile. In some embodiments, the reagent is benzoic acid and the solvent comprises acetone. In some embodiments, the reagent is succinic acid and the solvent comprises ethanol. In some embodiments, the reagent is acetic acid and the solvent comprises ethyl acetate.

[0336] In some embodiments, the method for preparing a crystalline form of a salt of Compouund A, further comprises adding an anti-solvent.

[0337] In some embodiments, the method for preparing a crystalline form of a salt of Compound A comprises: a. contacting Compound A with a solvent;b. adding a salt forming reagent; c. optionally adding an anti-solvent; and d. crystallizing a salt of Compound A.

[0338] In some embodiments of the method for preparing a crystalline form of a salt of Compound A, the method is conducted under a temperature cycle. In some embodiments, the temperature is cycled between 5 and 40 °C. In some embodiments, the temperature is cycled between 5 and 40 °C with heating and cooling rates of 0.1 °C / min, and 1 hour holds at 5 °C and 40 °C. In some embodiments, the temperature is cycled for 3 days.

[0339] In some embodiments of the method for preparing a crystalline form of a salt of Compound A, the salt of Compound A is crystallized by evaporation, fast-cooling, solvent drop grinding, or reactive precipitation a solution thereof.

[0340] In some embodiments of the method for preparing a crystalline form of a salt of Compound A, the method comprises adding a salt forming reagent in a solvent. In some embodiments, the reagent is a liquid reagent. In some embodiments, the liquid reagent is prepared in a solvent. In some embodiments, the liquid reagent is prepared in ethanol. In some embodiments, the liquid reagent is dissolved in the same solvent as the Compound A. In some embodiments, the reagent is a solid reagent. In some embodiments, the solid reagent is dissolved in a solvent. In some embodiments, the solid reagent is dissolved in the same solvent as the Compound A. In some embodiments, the method is conducted under a temperature cycle. In some embodiments, the temperature is cycled between 5 and 40 °C. In some embodiments, the temperature is cycled between 5 and 40 °C with heating and cooling rates of 0.1 °C / min, and 1 hour holds at 5 °C and 40 °C. In some embodiments, the temperature is cycled for 2-3 days. In some embodiments, the temperature is cycled for 3 days. In some embodiments, anti-solvent is added to encourage precipitation. In some embodiments, slurries are separated via centrifugation. In some embodiments, the method further comprises allowing the solvent to evaporate at ambient temperature (ca. 20 °C) to recover solids. In some embodiments, the filtered product is dried under ambiant pressure. In some embodiments, the filtered product is dried under reduced pressure. In some embodiments, the filtered product is dried at an elevated temperature (e.g., about 40 °C). In some embodiments, the filtered product is dried under reduced pressure and at an elevated temperature. In some embodiments, the filtered product is dried under ambient pressure and ambient temperature.

[0341] In some embodiments of the method of preparing a crystalline form of a salt Compound A, the method comprises preparing a mixture of Compound A in a solvent. In some embodiments, the crystalline form is HBr Form I and the solvent comprises Acetone, Ethyl Acetate, or THF. In some embodiments, the crystalline form is HBr Form III and the solvent comprises Acetonitrile, Ethanol: Water (93:7 %v / v), or Ethanol. In some embodiments, the crystalline form is HC1 Form I and the solvent comprises acetonitrile. In some embodiments, the crystalline form is Sulfate Form I and the solvent comprises acetonitrile. In some embodiments, the crystalline form is Sulfate Form II and the solvent comprises EthanoFWater (93:7 %v / v). In some embodiments, the crystalline form is Tosylate Form I and the solvent comprises Acetone, or Ethanol. In some embodiments, the crystalline form is Maleate Form I and the solvent comprises Acetone, Acetonitrile, Ethyl Acetate, or THF. In some embodiments, the crystalline form is Maleate Form II and the solvent comprises ethanol. In some embodiments, the crystalline form is Esylate Form I and the solvent comprises Acetone, or Acetonitrile. In some embodiments, the crystalline form is Esylate Form II and the solvent comprises Ethyl Acetate, or THF. In some embodiments, the crystalline form is Malonate Form I and the solvent comprises ethanol. In some embodiments, the crystalline form is Malonate Form II and the solvent comprises acetonitrile. In some embodiments, the crystalline form is Glucuronate Form II and the solvent comprises Ethyl Acetate. In some embodiments, the crystalline form is Glucuronate Form III and the solvent comprises EthanoFWater (93:7 %v / v). In some embodiments, the crystalline form is Glycolate Form I and the solvent comprises acetonitrile. In some embodiments, the crystalline form is Lactate Form I and the solvent comprises Acetone, Ethyl Acetate, Ethanol, or THF. In some embodiments, the crystalline form is Lactate Form II and the solvent comprises acetonitrile. In some embodiments, the crystalline form is Benzoate Form I and the solvent comprises Acetone, or Acetonitrile. In some embodiments, the crystalline form is Acetate Form I and the solvent comprises ethyl acetate.

[0342] In some embodiments of the method of preparing a crystalline form of a salt Compound A, the method comprises preparing a mixture of amorphous Compound A in a solvent.

[0343] In some embodiments, the method for preparing a crystalline form of a salt of Compound A, comprises: a. contacting a salt of Compound A with a solvent; andb. crystallizing a salt of Compound A.HBr Form I:

[0344] In some embodiments, provided is a method of preparing HBr Form I. In some embodiments, the method comprises preparing a first mixture comprising Compound A in a first solvent. In some embodiments, the first solvent is acetone, ethyl acetate and THF. In some embodiments, the method further comprises preparing a second mixture comprising a salt forming reagent in a second solvent. In some embodiments, the salt forming reagent is HBr. In some embodiments, the second solvent is acetone, ethyl acetate and THF.. In some embodiments, the method further comprises adding the secondd mixture to the first mixture to form a third mixture. In some embodiments the method further comprises stirring the third mixture. In some embodiments, the third mixture is temperature cycled. In some embodiments, the temperature is cycled between 5 and 40 °C with heating and cooling rates of 0.1 °C / min, and 1 hour holds at 5 °C and 40 °C. In some embodiments, the third mixture forms a slurry. In some embodiments, the slurry is separated via centrifugation. In some embodiments, one or more anti-solvent is added. In some embodiments, the anti-solvent encourages precipitation. In some embodiments, addition of the antisolvent forms a slurry. In some embodiments the slurry is separated via centrifugation. In some embodiments, any of the aforementioned slurries is allowed to evaporate. In some embodiments the evaporation occurs at room temperature and pressure.HBr Form II:

[0345] In some embodiments, providedis a method of preparing HBr Form II. In some embodiments, the method comprises preparing a first mixture comprising Compound A in a first solvent. In some embodiments, the first solvent acetonitrile, ethanol :water (93:7 %v / v) or ethanol. In some embodiments, the method further comprises preparing a second mixture comprising a salt forming reagent in a second solvent. In some embodiments, the salt forming reagent is HBr. In some embodiments, the second solvent is acetonitrile, ethanokwater (93:7 %v / v) or ethanol. In some embodiments, the method further comprises adding the salt forming reagent mixture to the Compound A mixture to form a third mixture. In some embodiments the method further comprises stirring the third mixture. In some embodiments, the third mixture is temperature cycled. In some embodiments, the temperature is cycled between 5 and 40 °C with heating and cooling rates of 0.1 °C / min, and 1 hour holds at 5 °Cand 40 °C. In some embodiments, the third mixture forms a slurry. In some embodiments, the slurry is separated via centrifugation. In some embodiments, one or more anti-solvent is added. In some embodiments, the anti-solvent encourages precipitation. In some embodiments, addition of the antisolvent forms a slurry. In some embodiments the slurry is separated via centrifugation. In some embodiments, any of the aforementioned slurries is allowed to evaporate. In some embodiments the evaporation occurs at room temperature and pressure.HBr Form III:

[0346] In some embodiments, provided is a method of preparing HBr Form III. In some embodiments, the method comprises preparing a first mixture comprising Compound A in a first solvent. In some embodiments, the first solvent acetonitrile, ethanol: water (93:7 %v / v) and ethanol. In some embodiments, the first solvent ethanol :water (93:7 %v / v). In some embodiments, the method further comprises preparing a second mixture comprising a salt forming reagent in a second solvent. In some embodiments, the salt forming reagent is HBr. In some embodiments, the second solvent is acetonitrile, ethanol :water (93:7 %v / v) or ethanol. In some embodiments, the second solvent ethanokwater (93:7 %v / v)In some embodiments, the method further comprises adding the second mixture to the first mixture to form a third mixture. In some embodiments the method further comprises stirring the third mixture. In some embodiments, the third mixture is temperature cycled. In some embodiments, the temperature is cycled between 5 and 40 °C with heating and cooling rates of 0.1 °C / min, and 1 hour holds at 5 °C and 40 °C. In some embodiments, the third mixture forms a slurry. In some embodiments, the slurry is separated via centrifugation. In some embodiments, one or more anti-solvent is added. In some embodiments, the anti-solvent encourages precipitation. In some embodiments, addition of the antisolvent forms a slurry. In some embodiments the slurry is separated via centrifugation. In some embodiments, any of the aforementioned slurries is allowed to evaporate. In some embodiments the evaporation occurs at room temperature and pressure. In some embodiments, the method further comprises drying a precipitate of a previous step. In some embodiments the precipitate is dried overnight.

[0347] In some embodiments, provided is a method of preparing HBr Form III. In some embodiments, the method comprises drying HBr Form II.HCl Form I:

[0348] In some embodiments, providedis a method of preparing HC1 Form I. In some embodiments, the method comprises preparing a first mixture comprising Compound A in a first solvent. In some embodiments, the first solvent is acetone, THF, acetonitrile, ethanol: water (93:7 %v / v), or ethyl acetate. In some embodiments, the first solvent is acetone or THF. In some embodiments, the first solvent ethanol :water (93:7 %v / v). In some embodiments, the method further comprises preparing a second mixture comprising a salt forming reagent in a second solvent. In some embodiments, the salt forming reagent is HC1. In some embodiments, the second solvent is acetone, THF, acetonitrile, ethanobwater (93:7 %v / v), or ethyl acetate. In some embodiments, the second solvent is acetone or THF. In some embodiments, the first solvent ethanol: water (93:7 %v / v). In some embodiments, the method further comprises adding the second mixture to the first mixture to form a third mixture. In some embodiments the method further comprises stirring the third mixture. In some embodiments, the third mixture is temperature cycled. In some embodiments, the temperature is cycled between 5 and 40 °C with heating and cooling rates of 0.1 °C / min, and 1 hour holds at 5 °C and 40 °C. In some embodiments, the third mixture forms a slurry. In some embodiments, the slurry is separated via centrifugation. In some embodiments, one or more anti-solvent is added. In some embodiments, the anti-solvent encourages precipitation. In some embodiments, addition of the antisolvent forms a slurry. In some embodiments the slurry is separated via centrifugation. In some embodiments, any of the aforementioned slurries is allowed to evaporate. In some embodiments the evaporation occurs at room temperature and pressure. In some embodiments, when the first or second solvent is acetonitrile, ethanol :water (93:7 %v / v) ethyl acetate or ethanol, the method further comprises drying a precipitate of a previous step. In some embodiments the precipitate is dried at 40 °C under vacuum.

[0349] In some embodiments, provided is a method of preparing HC1 Form I. In some embodiments, the method comprises drying HC1 Form II. In some embodiments the HC1 Form II is dried at 40 °C under vacuum.HCl Form II:

[0350] In some embodiments, providedis a method of preparing HCl Form II. In some embodiments, the method comprises preparing a first mixture comprising Compound A in afirst solvent. In some embodiments, the first solvent is acetonitrile, ethanol: water (93:7 %v / v) ethyl acetate or ethanol. In some embodiments, the method further comprises preparing a second mixture comprising a salt forming reagent in a second solvent. In some embodiments, the salt forming reagent is HC1. In some embodiments, the second solvent is acetonitrile, ethanol: water (93:7 %v / v) ethyl acetate or ethanol. In some embodiments, the method further comprises adding the second mixture to the first mixture to form a third mixture. In some embodiments the method further comprises stirring the third mixture. In some embodiments, the third mixture is temperature cycled. In some embodiments, the temperature is cycled between 5 and 40 °C with heating and cooling rates of 0.1 °C / min, and 1 hour holds at 5 °C and 40 °C. In some embodiments, the third mixture forms a slurry. In some embodiments, the slurry is separated via centrifugation. In some embodiments, one or more anti-solvent is added. In some embodiments, the anti-solvent encourages precipitation. In some embodiments, addition of the antisolvent forms a slurry. In some embodiments the slurry is separated via centrifugation. In some embodiments, any of the aforementioned slurries is allowed to evaporate. In some embodiments the evaporation occurs at room temperature and pressure.Sulfate Form I:

[0351] In some embodiments, providedis a method of preparing Sulfate Form I. In some embodiments, the method comprises preparing a first mixture comprising Compound A in a first solvent. In some embodiments, the first solvent is acetonitrile. In some embodiments, the method further comprises preparing a second mixture comprising a salt forming reagent in a second solvent. In some embodiments, the salt forming reagent is sulfuric acid. In some embodiments, the second solvent is acetonitrile. In some embodiments, the method further comprises adding the second mixture to the first mixture to form a third mixture. In some embodiments the method further comprises stirring the third mixture. In some embodiments, the third mixture is temperature cycled. In some embodiments, the temperature is cycled between 5 and 40 °C with heating and cooling rates of 0.1 °C / min, and 1 hour holds at 5 °C and 40 °C. In some embodiments, the third mixture forms a slurry. In some embodiments, the slurry is separated via centrifugation. In some embodiments, one or more anti-solvent is added. In some embodiments, the anti-solvent encourages precipitation. In some embodiments, addition of the antisolvent forms a slurry. In some embodiments the slurry is separated via centrifugation. In some embodiments, any of the aforementioned slurries isallowed to evaporate. In some embodiments the evaporation occurs at room temperature and pressure.Sulfate Form II:

[0352] In some embodiments, providedis a method of preparing Sulfate Form II. In some embodiments, the method comprises preparing a first mixture comprising Compound A in a first solvent. In some embodiments, the first solvent is acetonitrile. In some embodiments, the method further comprises preparing a second mixture comprising a salt forming reagent in a second solvent. In some embodiments, the salt forming reagent is sulfuric acid. In some embodiments, the second solvent is acetonitrile. In some embodiments, the method further comprises adding the second mixture to the first mixture to form a third mixture. In some embodiments the method further comprises stirring the third mixture. In some embodiments, the third mixture is temperature cycled. In some embodiments, the temperature is cycled between 5 and 40 °C with heating and cooling rates of 0.1 °C / min, and 1 hour holds at 5 °C and 40 °C. In some embodiments, the third mixture forms a slurry. In some embodiments, the slurry is separated via centrifugation. In some embodiments, one or more anti-solvent is added. In some embodiments, the anti-solvent encourages precipitation. In some embodiments, addition of the antisolvent forms a slurry. In some embodiments the slurry is separated via centrifugation. In some embodiments, any of the aforementioned slurries is allowed to evaporate. In some embodiments the evaporation occurs at room temperature and pressure.Tosylate Form I:

[0353] In some embodiments, providedis a method of preparing Tosylate Form I. In some embodiments, the method comprises preparing a first mixture comprising Compound A in a first solvent. In some embodiments, the first solvent is acetone or ethanol. In some embodiments, the first solvent is ethanol. In some embodiments, the method further comprises preparing a second mixture comprising a salt forming reagent in a second solvent. In some embodiments, the salt forming reagent is p-toluenesulfonic acid. In some embodiments, the second solvent is acetone or ethanol. In some embodiments, the second solvent is ethanol In some embodiments, the method further comprises adding the second mixture to the first mixture to form a third mixture. In some embodiments the method further comprises stirring the third mixture. In some embodiments, the third mixture is temperaturecycled. In some embodiments, the temperature is cycled between 5 and 40 °C with heating and cooling rates of 0.1 °C / min, and 1 hour holds at 5 °C and 40 °C. In some embodiments, the third mixture forms a slurry. In some embodiments, the slurry is separated via centrifugation. In some embodiments, one or more anti-solvent is added. In some embodiments, the anti-solvent encourages precipitation. In some embodiments, addition of the antisolvent forms a slurry. In some embodiments the slurry is separated via centrifugation. In some embodiments, any of the aforementioned slurries is allowed to evaporate. In some embodiments the evaporation occurs at room temperature and pressure.Mesylate Form I:

[0354] In some embodiments, providedis a method of preparing Mesylate Form I. In some embodiments, the method comprises preparing a first mixture comprising Compound A in a first solvent. In some embodiments, the first solvent is acetone. In some embodiments, the method further comprises preparing a second mixture comprising a salt forming reagent in a second solvent. In some embodiments, the salt forming reagent is methanesulfonic acid. In some embodiments, the second solvent is acetone. In some embodiments, the method further comprises adding the second mixture to the first mixture to form a third mixture. In some embodiments the method further comprises stirring the third mixture. In some embodiments, the third mixture is temperature cycled. In some embodiments, the temperature is cycled between 5 and 40 °C with heating and cooling rates of 0.1 °C / m...

Claims

CLAIMSWhat is claimed is:

1. A crystalline form of a salt of the (E)-l-((10S)-4-((4-([l,2,4]triazolo[l,5-a]pyridin-7- yloxy)-2-fluoro-5-methylphenyl)amino)-7,8,10,l l-tetrahydro-9H-6,10- methanopyrimido[4',5':5,6]pyrido[3,2-b][l,4,7]oxadiazonin-9-yl)-4-(dimethylamino)but-2- en-l-one.

2. The crystalline form of claim 1, wherein the crystalline form is a crystalline form of a HBr, HC1, sulfate, tosylate, mesylate, napsylate, besylate, aspartate, maleate, esylate, malonate, glucuronate, glycolate, lactate, benzoate, succinate, or acetate salt.

3. The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline form of a HBr salt.

4. The crystalline form of claim 3, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 1A; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 1; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.59, about 18.47, and about 26.17; and / or d. a TGA / DSC thermogram substantially as shown in FIG. IB.

5. The crystalline form of claim 3, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 2; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 2; and / or c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.36, about 16.48, and about 25.97.

6. The crystalline form of claim 3, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 3A;b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 3; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of of about 4.41, about 15.56, about 16.48 and about 16.58; d. a TGA / DSC thermogram substantially as shown in FIG. 3B; e. a DSC thermogram substantially as shown in FIG. 3C; and / or f. a DVS isotherm pattern or DVS kinetic pattern substantially as shown in FIG. 3D.

7. The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline form of a HC1 salt.

8. The crystalline form of claim 7, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 4A; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 4; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.45, about 15.40, and about 16.53; d. a TGA / DSC thermogram substantially as shown in FIG. 4B; e. a DSC thermogram substantially as shown in FIG. 4C; and / or f. (a) a DVS isotherm pattern and (b) a DVS kinetic pattern as shown in FIG. 4D.

9. The crystalline form of claim 7, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 5; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 5; and / or c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.38, about 26.16, and about 26.24.

10. The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline form of a sulfate salt.

11. The crystalline form of claim 10, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 6A; and / orb. a TGA / DSC thermogram substantially as shown in FIG. 6B.

12. The crystalline form of claim 10, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 7A; and / or b. a TGA / DSC thermogram substantially as shown in FIG. 7B.

13. The crystalline form of claim 10, wherein the crystalline form is characterized as having an XRPD pattern substantially as shown in FIG. 8.

14. The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline form of a tosylate salt.

15. The crystalline form of claim 14, wherein the tosylate salt is a mono tosylate salt.

16. The crystalline form of claim 14 or 15, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 9A; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 6; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.19, about 16.11, and about 19.35; d. a TGA / DSC thermogram substantially as shown in FIG. 9B; and / or e. a DSC thermogram substantially as shown in FIG. 9C; and / or f. a) a DVS isotherm pattern and (b) a DVS kinetic pattern as shown in FIG. 9D.

17. The crystalline form of claim 1 or claim 2, wherein the crystalline form is a crystalline form of a mesylate salt.

18. The crystalline form of claim 17, wherein the mesylate salt is a mono mesylate salt.

19. The crystalline form of claim 17 or 18, wherein the crystalline form is characterized as having an XRPD pattern substantially as shown in FIG. 10.

20. The crystalline form of claim 17 or 18, wherein the crystalline form is characterized as having:a. an XRPD pattern substantially as shown in FIG. 11 A; and / or b. a TGA / DSC thermogram substantially as shown in FIG. 11B.

21. The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline form of a napsylate salt.

22. The crystalline form of claim 21, wherein the napsylate salt is a mono napsylate salt.

23. The crystalline form of claim 21 or 22, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 12A; and / or b. a TGA / DSC thermogram substantially as shown in FIG. 12B.

24. The crystalline form of claim 21 or 22, wherein the crystalline form is characterized as having an XRPD pattern substantially as shown in FIG. 13.

25. The crystalline form of claim 21 or 22, wherein the crystalline form is characterized as having an XRPD pattern substantially as shown in FIG. 14.

26. The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline form of a besylate salt.

27. The crystalline form of claim 26, wherein the besylate salt is a mono besylate salt.

28. The crystalline form of claim 26 or 27, wherein the crystalline form is characterized as having an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 7.

29. The crystalline form of any one of claims 26-28, wherein the crystalline form is characterized as having an X-ray powder diffraction (XRPD) pattern comprising a peak at an angle 2-theta of about 15.28 degrees.

30. The crystalline form of claim 29, wherein the XRPD pattern further comprises a peak at an angle 2-theta of about 4.30 degrees.

31. The crystalline form of claim 30, wherein the XRPD pattern further comprises a peak at an angle 2-theta of about 19.66 degrees.

32. The crystalline form of any one of claims 26-31, wherein the crystalline form is characterized as having an X-ray powder diffraction (XRPD) pattern comprising peaks each assigned at an angle 2-theta of about 4.30 (e.g., 4.30±0.2), about 12.71 (e.g., 12.71±0.2), about 14.11 (e.g., 14.11±0.2), about 15.28 (e.g., 15.28±0.2about 16.12 (e.g., 16.12±0.2), about 17.27 (e.g., 17.27±0.2), and about 19.66 (e.g., 19.66±0.2) degrees.

33. The crystalline form of any one of claims 26-32, wherein the crystalline form is characterized as having an XRPD pattern substantially as shown in FIG. 15A.

34. The crystalline form of any one of claims 26-33, wherein the crystalline form is characterized as having a TGA / DSC thermogram substantially as shown in FIG. 15B.

35. The crystalline form of claim 34, wherein the crystalline form is characterized as having having an initial mass loss of about 0.6 % after heating from about 25.0 °C to about 112.6 °C.

36. The crystalline form of claim 35, wherein the crystalline form is characterized as having having a further mass loss of about 3.7 % after heating from about 118.4 °C to about 247.1 °C, as determined by TGA.

37. The crystalline form of any one of claims 26-36, wherein the crystalline form is characterized as having a TGA / DSC thermogram substantially as shown in FIG. 15B, FIG. 15C, or FIG. 15D38. The crystalline form of claim 37, wherein the crystalline form is characterized as having an endothermic / exothermic event with onsets / peaks of about 201.7 °C / 226.7 °C and about 226.9 °C / 231.5 °C.

39. The crystalline form of any one of claims 26-38, wherein the crystalline form is characterized as having (a) a DVS isotherm pattern and / or (b) a DVS kinetic pattern substantially as shown in FIG. 15E.

40. The crystalline form of claim 26 or 27, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 16A; and / or b. a TGA / DSC thermogram substantially as shown in FIG. 16B.

41. The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline form of an aspartate salt.

42. The crystalline form of claim 41, wherein the aspartate salt is a hemi aspartate salt.

43. The crystalline form of claim 41 or 42, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 17; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 9; and / or c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.30, about 21.67, and about 23.33.

44. The crystalline form of claim 41 or 42, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 18A; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 10; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.22, about 21.73, and about 23.72; and / or d. a TGA / DSC thermogram substantially as shown in FIG. 18B.

45. The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline form of a maleate salt.

46. The crystalline form of claim 45, wherein the maleate salt is a mono maleate salt.

47. The crystalline form of claim 45 or 46, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 19A; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 11; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 9.69, about 11.64, and about 17.74; d. a TGA thermogram substantially as shown in FIG. 19B;e. a DSC thermogram substantially as shown in FIG. 19C; and / or f. (a) a DVS isotherm pattern and / or (b) a DVS kinetic pattern substantially as shown in FIG. 19D48. The crystalline form of claim 45, wherein the maleate salt is a hemi maleate salt.

49. The crystalline form of claim 45 or 48, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 20A; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 12; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.07, about 5.26, and about 23.74; and / or d. a TGA / DSC thermogram substantially as shown in FIG. 20B.

50. The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline form of an esylate salt.

51. The crystalline form of claim 50, wherein the esylate salt is a mono esylate salt.

52. The crystalline form of claim 50 or 51, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 21A; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 13; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.36, about 15.34, and about 18.23; and / or d. a TGA / DSC thermogram substantially as shown in FIG. 21B.

53. The crystalline form of claim 50 or 51, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 22A; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 14; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 15.56, about 16.77, and about 17.36; and / ord. a TGA / DSC thermogram substantially as shown in FIG. 22B.

54. The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline form of a malonate salt.

55. The crystalline form of claim 54, wherein the malonate salt is a mono malonate salt.

56. The crystalline form of claim 54 or 55, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 23A; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 15; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 11.82, about 17.65, and about 18.42; and / or d. a TGA / DSC thermogram substantially as shown in FIG. 23B.

57. The crystalline form of claim 54 or 55, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 24A; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 16; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.58, about 14.70, and about 24.50; and / or d. a TGA / DSC thermogram substantially as shown in FIG. 24B.

58. The crystalline form of claim 1 or claim 2, wherein the crystalline form is a crystalline form of a glucuronate salt.

59. The crystalline form of claim 58, wherein the malonate salt is a mono glucuronate salt.

60. The crystalline form of claim 58 or 59, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 25; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 17; and / orc. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 10.23, about 16.69, and about 22.92.

61. The crystalline form of claim 58 or 59, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 26A; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 18; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about about 4.72, about 19.91, and about 21.19; and / or d. a TGA / DSC thermogram substantially as shown in FIG. 26B.

62. The crystalline form of claim 58 or 59, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 27; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 19; and / or c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.40, about 14.19, and about 15.06.

63. The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline form of a glycolate salt.

64. The crystalline form of claim 63, wherein the glycolate salt is a mono glycolate salt.

65. The crystalline form of claim 63 or 64, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 28A; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 20; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.22, about 13.60, and about 16.74; and / or d. a TGA / DSC thermogram substantially as shown in FIG. 28B.

66. The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline form of a lactate salt.

67. The crystalline form of claim 66, wherein the lactate salt is a mono lactate salt.

68. The crystalline form of claim 66 or 67, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 29A; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 21; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.27, about 11.50, and about 16.80; and / or d. a TGA / DSC thermogram substantially as shown in FIG. 29B.

69. The crystalline form of claim 66 or 67, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 30A; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 22; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 4.06, about 15.90, and about 25.20; and / or d. a TGA / DSC thermogram substantially as shown in FIG. 30B.

70. The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline form of a benzoate salt.

71. The crystalline form of claim 66 or 67, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 31A; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 23; c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 14.77, about 16.66, and about 18.14; d. a TGA / DSC thermogram substantially as shown in FIG. 31B; e. a TGA / DSC thermogram substantially as shown in FIG. 31C; and / or f. (a) a DVS isotherm pattern and (b) a DVS kinetic pattern substantially as shown inFIG. 31D72. The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline form of a succinate salt.

73. The crystalline form of claim 72, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 32; b. an XRPD pattern comprising one or more peaks as assigned at angles 2-theta in degrees as recited in Table 24; and / or c. an XRPD pattern comprising peaks each assigned at an angle 2-theta in degrees of about 5.21, about 6.95, and about 11.38.

74. The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline form of an acetate salt.

75. The crystalline form of claim 74, wherein the crystalline form is characterized as having: a. an XRPD pattern substantially as shown in FIG. 33A; and / or b. a TGA / DSC thermogram substantially as shown in FIG. 33B.

76. A method for preparing the crystalline form of any one of claims 1-75, comprising: a. contacting (E)- 1 -(( 10S)-4-((4-([ 1 ,2,4]triazolo[ 1 ,5-a]pyridin-7-yloxy)-2-fluoro-5- methylphenyl)amino)-7,8, 10,11 -tetrahydro-9H-6, 10- methanopyrimido[4',5':5,6]pyrido[3,2-b][l,4,7]oxadiazonin-9-yl)-4- (dimethylamino)but-2-en-l-one with a solvent; b. adding a salt forming reagent; and c. crystallizing a salt of (E)-l-((10S)-4-((4-([l,2,4]triazolo[l,5-a]pyridin-7-yloxy)-2- fluoro-5-methylphenyl)amino)-7, 8, 10,11 -tetrahydro-9H-6, 10- methanopyrimido[4',5':5,6]pyrido[3,2-b][l,4,7]oxadiazonin-9-yl)-4- (dimethylamino)but-2-en- 1 -one.

77. The method of claim 76, wherein the solvent is selected from the group consisting of acetone, acetonitrile, ethanol, water, ethyl acetate, methanol, and tetrahydrofuran, and a mixture of any of the foregoing.

78. The method of claim 76 or 77, wherein the salt forming reagent is selected from the group consisting of HBr, HC1, sulfuric acid, p-toluene sulphonic acid, p-toluene sulphonic acid.JfcO, methanesulphonic acid, naphthalenesulfonic acid, benzenesulfonic acid, aspartic acid, maleic acid, ethanesulphonic acid, malonic acid, glucuronic acid, glycolic acid, lactic acid, benzoic acid, succinic acid, and acetic acid.

79. The method of claim 78, wherein the salt forming reagent is selected from the group consisting of HBr, HC1, / ?-toluene sulphonic acid.H?©, benzene sulphonic acid, maleic acid, and benzoic acid.

80. The method of claim 78, wherein: a. the salt forming reagent is HBr and the solvent comprises acetone, ethyl acetate, THF, acetonitrile, ethanol: water, or ethanol; b. the salt forming reagent is HC1 and the solvent comprises acetone, THF, acetonitrile, ethanol: water, ethyl acetate or ethanol; c. the salt forming reagent is sulfuric acid and the solvent comprises acetonitrile; d. the salt forming reagent is / ?-toluenesulfonic acid and the solvent comprises acetone, or ethanol; e. the salt forming reagent is methanesulfonic acid and the solvent comprises acetone; f. the salt forming reagent is benzenesulfonic acid and the solvent comprises ethanol: water (93:7% v / v); g. the salt forming reagent is napthanesulfonic acid and the solvent comprises acetone, or THF; h. the salt forming reagent is benzenesulfonic acid and the solvent comprises from acetone, acetonitrile, ethanol: water (93:7 %v / v) ethyl acetate or THF; i. the salt forming reagent is aspartic acid and the solvent comprises acetonitrile, or THF; j. the salt forming reagent is maleic acid and the solvent comprises acetone, acetonitrile, ethyl acetate, THF, or ethanol; k. the salt forming reagent is ethanesulfonic acid and the solvent comprises acetone, acetonitrile, ethyl acetate or THF;l. the salt forming reagent is malonic acid and the solvent comprises ethanol, THF, or acetonitrile; m. the salt forming reagent is glucuronic acid and the solvent comprises ethanobwater (93:7 %v / v), or ethyl acetate; n. the salt forming reagent is glycolic acid and the solvent comprises acetonitrile; o. the salt forming reagent is lactic acid and the solvent comprises acetone, ethyl acetate, ethanol, THF, or acetonitrile; p. the salt forming reagent is benzoic acid and the solvent comprises acetone, or acetonitrile; q. the salt forming reagent is succinic acid and the solvent comprises ethanol; or r. the salt forming reagent is acetic acid and the solvent comprises ethyl acetate.

81. The method of any one of claims 76-80, further comprising adding an anti-solvent.

82. The method of claim 81, wherein the anti-solvent is selected from the group consisting of heptane, acetonitrile, and water, and any mixture of any of the foregoing.

83. The method of any one of claims 76-80, wherein the salt forming reagent is benzenesulfonic acid.

84. A method for preparing a crystalline form of a besylate salt ofE)-l-((10S)-4-((4- ([l,2,4]triazolo[l,5-a]pyridin-7-yloxy)-2-fluoro-5-methylphenyl)amino)-7,8,10,l 1- tetrahydro-9H-6, 10-methanopyrimido[4', 5' : 5,6]pyrido[3 ,2-b] [ 1 ,4,7]oxadiazonin-9-yl)- 4-(dimethylamino)but-2-en-l -one with a solvent, comprising: a. contacting the besylate salt of (E)-l-((10S)-4-((4-([l,2,4]triazolo[l,5-a]pyridin-7- yloxy)-2-fluoro-5-methylphenyl)amino)-7,8,10,l l-tetrahydro-9H-6,10- methanopyrimido[4',5':5,6]pyrido[3,2-b][l,4,7]oxadiazonin-9-yl)-4- (dimethylamino)but-2-en-l-one with a solvent; and b. crystallizing the besylate salt of (E)-l-((10S)-4-((4-([l,2,4]triazolo[l,5-a]pyridin-7- yloxy)-2-fluoro-5-methylphenyl)amino)-7,8,10,l l-tetrahydro-9H-6,10- methanopyrimido[4',5':5,6]pyrido[3,2-b][l,4,7]oxadiazonin-9-yl)-4- (dimethylamino)but-2-en- 1 -one.

85. The method of claim 83 or 84, wherein the solvent comprises acetone, acetonitrile, ethanol: water, ethyl acetate or THF, or any mixture of the foregoing.

86. The method of claim 84, wherein the solvent comprises ethanokwater (93:7% v / v).

87. The method of any one of claims 83-86, wherein the crystalline form is Besylate Form I.

88. The method of any one of claims 83-87, wherein the method further comprises temperature cycling.

89. The method of any one of claims 76-88, wherein the salt of (E)-l-((10S)-4-((4- ([l,2,4]triazolo[l,5-a]pyridin-7-yloxy)-2-fluoro-5-methylphenyl)amino)-7,8,10,l 1- tetrahydro-9H-6, 10-methanopyrimido[4', 5' : 5,6]pyrido[3 ,2-b] [ 1 ,4,7]oxadiazonin-9-yl)-4- (dimethylamino)but-2-en-l-one is crystallized by evaporation, fast-cooling, solvent drop grinding, or reactive precipitation a solution thereof.

90. A crystalline form of a salt of (E)-l-((10S)-4-((4-([l,2,4]triazolo[l,5-a]pyridin-7- yloxy)-2-fluoro-5-methylphenyl)amino)-7,8,10,l l-tetrahydro-9H-6,10- methanopyrimido[4',5':5,6]pyrido[3,2-b][l,4,7]oxadiazonin-9-yl)-4-(dimethylamino)but-2- en-l-one, produced by the method of any one of claims 76-89.

91. A pharmaceutical composition comprising the crystalline form of any one of claims 1- 75, and 90, and a pharmaceutically acceptable excipient.

92. A kit comprising the crystalline form of any one of claims 1-75 and 90, or the pharmaceutical composition of claim 91.

93. The kit of claim 91, further comprising instructions for use in treating disease associated with point mutation in ErbB2 in an individual in need thereof.

94. A method of inhibiting kinase activity of a human receptor tyrosine kinase ErbB2 or a mutant form of human ErbB2 comprising contacting the ErbB2 or the mutant form with a therapeutically effective amount of the crystalline form of any one of claims 1-75 and 90, or a therapeutically effective amount of the pharmaceutical composition of claim 91.

95. The method of claim 94, wherein the mutant form of human ErbB2 comprises a mutation in Exon 20.

96. The method of claim 94 or 95, wherein the mutant form of human ErbB2 comprises one or more mutations that introduce amino acid deletions and / or insertions selected from thegroup consisting of: A775_A776insYVMA, G778_P780insGSP, G776delinsVC, P780_Y781insGSP, M774delinsWLV, A775_G776insSVMA, A775_G776insI, G776delinsLC, G778_S779InsCPG, and V777_G778insGSP.

97. The method of claim 94, wherein the mutant form of human ErbB2 comprises a disease-associated point mutation in ErbB2.

98. The method of claim 94 or 97, wherein the mutant form of human ErbB2 comprises one or more point mutations in ErbB2 that introduce:(a) an amino acid substitution selected from the group consisting of P122L, R217C, I263T, A293T, S305C, S310F / Y, H470Q, I655V, V659E, G660D, R678Q / C, L755R / S / P, I767M, D769H / N / Y, V777L / M, V842I, R868W, H878Y, E930K / D, E1021Q, F1030C, VI 1281, and N1219S; or(b) a frameshift at Al 232.

99. A method of treating a patient having a cancer, comprising administering to the patient a therapeutically effective amount of the crystalline form of any one of claims 1-75 and 90, or a therapeutically effective amount of the pharmaceutical composition of claim 91.

100. The method of claim 99, wherein the cancer comprises cells or tissue having increased ErbB2 kinase activity as compared to a control.

101. The method of claim 99 or claim 100, wherein the cancer comprises cells or tissue having one or more mutations in Exon 20 of the ErbB2.

102. The method of any one of claims 99-101, wherein the cancer comprises cells or tissue having one or more mutations in Exon 20 of the ErbB2 that introduce amino acid deletions and / or insertions selected from the group consisting of A775_A776insYVMA, G778_P780insGSP, G776delinsVC, P780_Y781insGSP, M774delinsWLV, A775_G776insSVMA, A775_G776insI, G776delinsLC, G778_S779InsCPG, and V777_G778insGSP.

103. The method of claim 99 or 100, wherein the cancer comprises cells or tissue having one or more disease-associated point mutations in ErbB2.

104. The method of any one of claims 99-100 and 103, wherein the cancer comprises cells or tissue having one or more point mutations that introduce:(a) an amino acid substitution selected from the group consisting of P122L, R217C, I263T, A293T, S305C, S310F / Y, H470Q, I655V, V659E, G660D, R678Q / C, L755R / S / P, I767M, D769H / N / Y, V777L / M, V842I, R868W, H878Y, E930K / D, E1021Q, F1030C, VI 1281, and N1219S; or(b) a frameshift at Al 232.

105. The method of any one of claims 99-104, wherein the cancer is lung, glioma, skin, head and neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.

106. The method of any one of claims 99-105, wherein the cancer is non-small cell lung cancer.

107. The method of any one of claims 99-106, wherein the patient has received at least one, at least two, or at least three prior therapies for the cancer.

108. The method of claim 107, wherein one or more of the prior therapies selected from the group consisting of lapatinib, neratinib, afatinib, pyrotinib, poziotinib, TAK-788, and tucatinib.

109. The method of any one of claims 99-108, wherein the method further comprises administering one or more additional anti-cancer agents.

110. The crystalline form of any one of claims 1-75 and 90, or the pharmaceutical composition of claim 91, for use in therapy.

Citation Information

Patent Citations

  • Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application

    US20200190091A1

  • [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors

    WO2021156180A1

  • Fused tetracyclic quinazoline derivatives as inhibitors of ERBB2

    WO2023081637A1